US 7,781,575 B2Grant

siRNA targeting tumor protein 53 (p53)

Issue Date:2010-08-24

•25 Claims

Abstract

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.

Metadata

Assignee

Dharmacon, Inc.

Inventors

Anastasia Khvorova
Angela Reynolds
Devin Leake
William Marshall
Steven Read
Stephen Scaringe

Application Information

Application Number:US 12/586,271

Filing Date:2009-09-18

Priority Date:2002-11-14

Art Unit:1635

Classifications

IPC:

A61K31/70C07H21/04

Patent Drawings

This patent does not have any drawings.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation-in-part of U.S. Ser. No. 10/714,333, filed Nov. 14, 2003, which claims the benefit of U.S. Provisional Application No. 60/426,137, filed Nov. 14, 2002, and also claims the benefit of U.S. Provisional Application No. 60/502,050, filed Sep. 10, 2003; this application is also a continuation-in-part of U.S. Ser. No. 10/940,892, filed Sep. 14, 2004, which is a continuation of PCT Application No. PCT/US 04/14885, international filing date May 12, 2004, The disclosures of the priority applications, including the sequence listings and tables submitted in electronic form in lieu of paper, are incorporated by reference into the instant specification.

SEQUENCE LISTING

[0002] The sequence listing for this application has been submitted in accordance with 37 CFR §1.52(e) and 37 CFR §1.821 on CD-ROM in lieu of paper on a disk containing the sequence listing file entitled “DHARMA_—2100-US126_CRF.txt” created Sep. 17, 2009, 100 kb. Applicants hereby incorporate by reference the sequence listing provided on CD-ROM in lieu of paper into the instant specification.

FIELD OF INVENTION

[0003] The present invention relates to RNA interference (“RNAi”).

BACKGROUND OF THE INVENTION

[0004] Relatively recently, researchers observed that double stranded RNA (“dsRNA”) could be used to inhibit protein expression. This ability to silence a gene has broad potential for treating human diseases, and many researchers and commercial entities are currently investing considerable resources in developing therapies based on this technology.

[0005] Double stranded RNA induced gene silencing can occur on at least three different levels: (i) transcription inactivation, which refers to RNA guided DNA or histone methylation; (ii) siRNA induced mRNA degradation; and (iii) mRNA induced transcriptional attenuation.

[0006] It is generally considered that the major mechanism of RNA induced silencing (RNA interference, or RNAi) in mammalian cells is mRNA degradation. Initial attempts to use RNAi in mammalian cells focused on the use of long strands of dsRNA. However, these attempts to induce RNAi met with limited success, due in part to the induction of the interferon response, which results in a general, as opposed to a target-specific, inhibition of protein synthesis. Thus, long dsRNA is not a viable option for RNAi in mammalian systems.

[0007] More recently it has been shown that when short (18-30 bp) RNA duplexes are introduced into mammalian cells in culture, sequence-specific inhibition of target mRNA can be realized without inducing an interferon response. Certain of these short dsRNAs, referred to as small inhibitory RNAs (“siRNAs”), can act catalytically at sub-molar concentrations to cleave greater than 95% of the target mRNA in the cell. A description of the mechanisms for siRNA activity, as well as some of its applications are described in Provost et al., Ribonuclease Activity and RNA Binding of Recombinant Human Dicer, E.M.B.O. J., 2002 Nov. 1; 21(21): 5864-5874; Tabara et al, The dsRNA Binding Protein RDE-4 Interacts with RDE-1, DCR-1 and a DexH-box Helicase to Direct RNAi in C. elegans, Cell 2002, June 28; 109(7):861-71; Ketting et al., Dicer Functions in RNA Interference and in Synthesis of Small RNA Involved in Developmental Timing in C. elegans; Martinez et al., Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi, Cell 2002, Sep. 6; 110(5):563; Hutvagner & Zamore, A microRNA in a multiple-turnover RNAi enzyme complex, Science 2002, 297:2056.

[0008] From a mechanistic perspective, introduction of long double stranded RNA into plants and invertebrate cells is broken down into siRNA by a Type III endonuclease known as Dicer. Sharp, RNA interference—2001, Genes Dev. 2001, 15:485. Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3′ overhangs. Bernstein, Caudy, Hammond, & Hannon (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference, Nature, 409:363. The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition. Nykanen, Haley, & Zamore (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway, Cell, 107:309. Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleaves the target to induce silencing. Elbashir, Lendeckel, & Tuschl (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs, Genes Dev., 15:188.

[0009] The interference effect can be long lasting and may be detectable after many cell divisions. Moreover, RNAi exhibits sequence specificity. Kisielow, M. et al. (2002) Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA, J. of Biochemistry, 363: 1-5. Thus, the RNAi machinery can specifically knock down one type of transcript, while not affecting closely related mRNA. These properties make siRNA a potentially valuable tool for inhibiting gene expression and studying gene function and drug target validation. Moreover, siRNAs are potentially useful as therapeutic agents against: (1) diseases that are caused by over-expression or misexpression of genes; and (2) diseases brought about by expression of genes that contain mutations.

[0010] Successful siRNA-dependent gene silencing depends on a number of factors. One of the most contentious issues in RNAi is the question of the necessity of siRNA design, i.e., considering the sequence of the siRNA used. Early work in C. elegans and plants circumvented the issue of design by introducing long dsRNA (see, for instance, Fire, A. et al. (1998) Nature 391:806-811). In this primitive organism, long dsRNA molecules are cleaved into siRNA by Dicer, thus generating a diverse population of duplexes that can potentially cover the entire transcript. While some fraction of these molecules are non-functional (i.e., induce little or no silencing) one or more have the potential to be highly functional, thereby silencing the gene of interest and alleviating the need for siRNA design. Unfortunately, due to the interferon response, this same approach is unavailable for mammalian systems. While this effect can be circumvented by bypassing the Dicer cleavage step and directly introducing siRNA, this tactic carries with it the risk that the chosen siRNA sequence may be non-functional or semi-functional.

[0011] A number of researches have expressed the view that siRNA design is not a crucial element of RNAi. On the other hand, others in the field have begun to explore the possibility that RNAi can be made more efficient by paying attention to the design of the siRNA. Unfortunately, none of the reported methods have provided a satisfactory scheme for reliably selecting siRNA with acceptable levels of functionality. Accordingly, there is a need to develop rational criteria by which to select siRNA with an acceptable level of functionality, and to identify siRNA that have this improved level of functionality, as well as to identify siRNAs that are hyperfunctional.

SUMMARY OF THE INVENTION

[0012] The present invention is directed to increasing the efficiency of RNAi, particularly in mammalian systems. Accordingly, the present invention provides kits, siRNAs and methods for increasing siRNA efficacy.

[0013] According to a first embodiment, the present invention provides a kit for gene silencing, wherein said kit is comprised of a pool of at least two siRNA duplexes, each of which is comprised of a sequence that is complementary to a portion of the sequence of one or more target messenger RNA, and each of which is selected using non-target specific criteria. Each of the at least two siRNA duplexes of the kit is complementary to a portion of the sequence of one or more target mRNAs and is preferably selected using Formula X.

[0014] According to a second embodiment, the present invention provides a method for selecting an siRNA, said method comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; and determining the relative functionality of the at least two siRNAs.

[0015] In one embodiment, the present invention also provides a method wherein said selection criteria are embodied in a formula comprising:
(−14)*G₁₃−13*A₁−12*U₇−11*U₂−10*A₁₁−10*U₄−10*C₃−10*C₅−10*C₆−9*A₁₀−9*U₉−9*C₁₈−8*G₁₀−7*U₁−7*U₁₆−7*C₁₇−7*C₁₉+7*U₁₇+8*A₂+8*A₄+8*A₅+8*C₄+9*G₈+10*A₇+10*U₁₈+11*A₁₉+11*C₉+15*G₁+18*A₃+19*U₁₀−Tm−3*(GC_total)−6*(GC_15-19)−30*X; or Formula VIII
(14.1)*A₃+(14.9)*A₆+(17.6)*A₁₃+(24.7)*A₁₉+(14.2)*U₁₀+(10.5)* C₉+(23.9)*G₁+(16.3)*G₂+(−12.3)*A₁₁+(−19.3)*U₁+(−12.1)*U₂+(−11)*U₃+(−15.2)*U₁₅+(−11.3)*U₁₆+(−11.8)*C₃+(−17.4)*C₆+(−10.5)*C₇+(−13.7)*G₁₃+(−25.9)*G₁₉−Tm−3*(GC_total)−6*(GC_15-19)−30*X; or Formula IX
(−8)*A₁+(−1)*A₂+(12)*A₃+(7)*A₄+(18)*A₅+(12)*A₆+(19)*A₇+(6)*A₈+(−4)*A₉+(−5)*A₁₀+(−2)*A₁₁+(−5)*A₁₂+(17)*A₁₃+(−3)*A₁₄+(4)*A₁₅+(2)*A₁₆+(8)*A₁₇+(11)*A₁₈+(30)*A₁₉+(−13)*U₁+(−10)*U₂+(2)*U₃+(−2)*U₄+(−5)*U₅+(5)*U₆+(−2)*U₇+(−10)*U₈+(−5)*U₉+(15)*U₁₀+(−1)*U₁₁+(0)*U₁₂+(10)*U₁₃+(−9)*U₁₄+(−13)*U₁₅+(−10)*U₁₆+(3)*U₁₇+(9)*U₁₈+(9)*U₁₉+(7)*C₁+(3)*C₁₂+(−21)*C₃+(5)*C₄+(−9)*C₅+(−20)*C₆+(−18)*C₇+(−5)*C₈+(5)*C₉+(1)*C₁₀+(2)*C₁₁+(−5)*C₁₂+(−3)*C₁₃+(−6)*C₁₄+(−2)*C₁₅+(−5)*C₁₆+(−3)*C₁₇+(−12)*C₈+(−18)*C₁₉+(14)*G₁+(8)*G₂+(7)*G₃+(−10)*G₄+(−4)*G₅+(2)*G₆+(1)*G₇+(9)*G₈+(5)*G₉+(−11)*G₁₀+(1)*G₁₁+(9)*G₁₂+(−24)*G₁₃+(18)*G₁₄+(11)*G₁₅+(13)*G₁₆+(−7)*G₁₇+(−9)*G₁₈+(−22)*G₁₉+6*(number of A+U in position 15-19)−3*(number of G+C in whole siRNA), Formula X

[0016] wherein position numbering begins at the 5′-most position of a sense strand, and

[0017] A₁=1 if A is the base at position 1 of the sense strand, otherwise its value is 0;
[0018] A₂=1 if A is the base at position 2 of the sense strand, otherwise its value is 0;
[0019] A₃=1 if A is the base at position 3 of the sense strand, otherwise its value is 0;
[0020] A₄=1 if A is the base at position 4 of the sense strand, otherwise its value is 0;
[0021] A₅=1 if A is the base at position 5 of the sense strand, otherwise its value is 0;
[0022] A₆=1 if A is the base at position 6 of the sense strand, otherwise its value is 0;
[0023] A₇=1 if A is the base at position 7 of the sense strand, otherwise its value is 0;
[0024] A₈=1 if A is the base at position 8 of the sense strand, otherwise its value is 0;
[0025] A₉=1 if A is the base at position 9 of the sense strand, otherwise its value is 0;
[0026] A₁₀=1 if A is the base at position 10 of the sense strand, otherwise its value is 0;
[0027] A₁₁=1 if A is the base at position 11 of the sense strand, otherwise its value is 0;
[0028] A₁₂=1 if A is the base at position 12 of the sense strand, otherwise its value is 0;
[0029] A₁₃=1 if A is the base at position 13 of the sense strand, otherwise its value is 0;
[0030] A₁₄=1 if A is the base at position 14 of the sense strand, otherwise its value is 0;
[0031] A₁₅=1 if A is the base at position 15 of the sense strand, otherwise its value is 0;
[0032] A₁₆=1 if A is the base at position 16 of the sense strand, otherwise its value is 0;
[0033] A₁₇=1 if A is the base at position 17 of the sense strand, otherwise its value is 0;
[0034] A₁₈=1 if A is the base at position 18 of the sense strand, otherwise its value is 0;
[0035] A₁₉=1 if A is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;

[0036] C₁=1 if C is the base at position 1 of the sense strand, otherwise its value is 0;

[0037] C₂=1 if C is the base at position 2 of the sense strand, otherwise its value is 0;
[0038] C₃=1 if C is the base at position 3 of the sense strand, otherwise its value is 0;
[0039] C₄=1 if C is the base at position 4 of the sense strand, otherwise its value is 0;
[0040] C₅=1 if C is the base at position 5 of the sense strand, otherwise its value is 0;
[0041] C₆=1 if C is the base at position 6 of the sense strand, otherwise its value is 0;
[0042] C₇=1 if C is the base at position 7 of the sense strand, otherwise its value is 0;
[0043] C₈=1 if C is the base at position 8 of the sense strand, otherwise its value is 0;
[0044] C₉=1 if C is the base at position 9 of the sense strand, otherwise its value is 0;
[0045] C₁₀=1 if C is the base at position 10 of the sense strand, otherwise its value is 0;
[0046] C₁₁=1 if C is the base at position 11 of the sense strand, otherwise its value is 0;
[0047] C₁₂=1 if C is the base at position 12 of the sense strand, otherwise its value is 0;
[0048] C₁₃=1 if C is the base at position 13 of the sense strand, otherwise its value is 0;
[0049] C₁₄=1 if C is the base at position 14 of the sense strand, otherwise its value is 0;
[0050] C₁₅=1 if C is the base at position 15 of the sense strand, otherwise its value is 0;
[0051] C₁₆=1 if C is the base at position 16 of the sense strand, otherwise its value is 0;
[0052] C₁₇=1 if C is the base at position 17 of the sense strand, otherwise its value is 0;
[0053] C₁₈=1 if C is the base at position 18 of the sense strand, otherwise its value is 0;
[0054] C₁₉=1 if C is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;

[0055] G₁=1 if G is the base at position 1 on the sense strand, otherwise its value is 0;

[0056] G₂=1 if G is the base at position 2 of the sense strand, otherwise its value is 0;
[0057] G₃=1 if G is the base at position 3 of the sense strand, otherwise its value is 0;
[0058] G₄=1 if G is the base at position 4 of the sense strand, otherwise its value is 0;
[0059] G₅=1 if G is the base at position 5 of the sense strand, otherwise its value is 0;
[0060] G₆=1 if G is the base at position 6 of the sense strand, otherwise its value is 0;
[0061] G₇=1 if G is the base at position 7 of the sense strand, otherwise its value is 0;
[0062] G₈=1 if G is the base at position 8 on the sense strand, otherwise its value is 0;
[0063] G₉=1 if G is the base at position 9 of the sense strand, otherwise its value is 0;
[0064] G₁₀=1 if G is the base at position 10 of the sense strand, otherwise its value is 0;
[0065] G₁₁=1 if G is the base at position 11 of the sense strand, otherwise its value is 0;
[0066] G₁₂=1 if G is the base at position 12 of the sense strand, otherwise its value is 0;
[0067] G₁₃=1 if G is the base at position 13 on the sense strand, otherwise its value is 0;
[0068] G₁₄=1 if G is the base at position 14 of the sense strand, otherwise its value is 0;
[0069] G₁₅=1 if G is the base at position 15 of the sense strand, otherwise its value is 0;
[0070] G₁₆=1 if G is the base at position 16 of the sense strand, otherwise its value is 0;
[0071] G₁₇=1 if G is the base at position 17 of the sense strand, otherwise its value is 0;
[0072] G₁₈=1 if G is the base at position 18 of the sense strand, otherwise its value is 0;
[0073] G₁₉=1 if G is the base at position 19 of the sense strand, otherwise if another base is present or the sense strand is only 18 base pairs in length, its value is 0;

[0074] U₁=1 if U is the base at position 1 on the sense strand, otherwise its value is 0;

[0075] U₂=1 if U is the base at position 2 on the sense strand, otherwise its value is 0;
[0076] U₃=1 if U is the base at position 3 on the sense strand, otherwise its value is 0;
[0077] U₄=1 if U is the base at position 4 on the sense strand, otherwise its value is 0;
[0078] U₅=1 if U is the base at position 5 on the sense strand, otherwise its value is 0;
[0079] U₆=1 if U is the base at position 6 on the sense strand, otherwise its value is 0;
[0080] U₇=1 if U is the base at position 7 on the sense strand, otherwise its value is 0;
[0081] U₈=1 if U is the base at position 8 on the sense strand, otherwise its value is 0;
[0082] U₉=1 if U is the base at position 9 on the sense strand, otherwise its value is 0;
[0083] U₁₀=1 if U is the base at position 10 on the sense strand, otherwise its value is 0;
[0084] U₁₁=1 if U is the base at position 11 on the sense strand, otherwise its value is 0;
[0085] U₁₂=1 if U is the base at position 12 on the sense strand, otherwise its value is 0;
[0086] U₁₃=1 if U is the base at position 13 on the sense strand, otherwise its value is 0;
[0087] U₁₄=1 if U is the base at position 14 on the sense strand, otherwise its value is 0;
[0088] U₁₅=1 if U is the base at position 15 on the sense strand, otherwise its value is 0;
[0089] U₁₆=1 if U is the base at position 16 on the sense strand, otherwise its value is 0;
[0090] U₁₇=1 if U is the base at position 17 on the sense strand, otherwise its value is 0;
[0091] U₁₈=1 if U is the base at position 18 on the sense strand, otherwise its value is 0.

[0092] GC_15-19=the number of G and C bases within positions 15-19 of the sense strand, or within positions 15-18 if the sense strand is only 18 base pairs in length;

[0093] GC_total=the number of G and C bases in the sense strand;

[0094] Tm=100 if the siRNA oligo has the internal repeat longer then 4 base pairs, otherwise its value is 0; and

[0095] X=the number of times that the same nucleotide repeats four or more times in a row.

[0096] According to a third embodiment, the invention provides a method for developing an algorithm for selecting siRNA, said method comprising: (a) selecting a set of siRNA; (b) measuring gene silencing ability of each siRNA from said set; (c) determining relative functionality of each siRNA; (d) determining improved functionality by the presence or absence of at least one variable selected from the group consisting of the presence or absence of a particular nucleotide at a particular position, the total number of As and Us in positions 15-19, the number of times that the same nucleotide repeats within a given sequence, and the total number of Gs and Cs; and (e) developing an algorithm using the information of step (d).

[0097] According to a fourth embodiment, the present invention provides a kit, wherein said kit is comprised of at least two siRNAs, wherein said at least two siRNAs comprise a first optimized siRNA and a second optimized siRNA, wherein said first optimized siRNA and said second optimized siRNA are optimized according a formula comprising Formula X.

[0098] According to a fifth embodiment, the present invention provides a method for identifying a hyperfunctional siRNA, comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; determining the relative functionality of the at least two siRNAs and assigning each of the at least two siRNAs a functionality score; and selecting siRNAs from the at least two siRNAs that have a functionality score that reflects greater than 80 percent silencing at a concentration in the picomolar range, wherein said greater than 80 percent silencing endures for greater than 120 hours.

[0099] According to a sixth embodiment, the present invention provides a method for developing an siRNA algorithm for selecting functional and hyperfunctional siRNAs for a given sequence. The method comprises: (i) selecting a set of siRNAs; (ii) measuring the gene silencing ability of each siRNA from said set; (iii) determining the relative functionality of each siRNA; (iv) determining the amount of improved functionality by the presence or absence of at least one variable selected from the group consisting of the total GC content, melting temperature of the siRNA, GC content at positions 15-19, the presence or absence of a particular nucleotide at a particular position, relative thermodynamic stability at particular positions in a duplex, and the number of times that the same nucleotide repeats within a given sequence; and (v) developing an algorithm using the information of step (d).

[0100] According to this embodiment, preferably the set of siRNAs comprises at least 90 siRNAs from at least one gene, more preferably at least 180 siRNAs from at least two different genes, and most preferably at least 270 and 360 siRNAs from at least three and four different genes, respectively. Additionally, in step (d) the determination is made with preferably at least two, more preferably at least three, even more preferably at least four, and most preferably all of the variables. The resulting algorithm is not target sequence specific.

[0101] In another embodiment, the present invention provides rationally designed siRNAs identified using the formulas above.

[0102] In yet another embodiment, the present invention is directed to hyperfunctional siRNA.

[0103] The ability to use the above algorithms, which are not sequence or species specific, allows for the cost-effective selection of optimized siRNAs for specific target sequences. Accordingly, there will be both greater efficiency and reliability in the use of siRNA technologies.

[0104] In various embodiments, siRNAs that target tumor protein 53 or protein 53 (p53), having sequences generated by the algorithms herein, are provided. In various embodiments, the siRNAs are rationally designed. In various embodiments, the siRNAs are functional or hyperfunctional.

[0105] In various embodiments, an siRNA that targets p53 is provided, wherein the siRNA is selected from the group consisting of various siRNA sequences targeting p53 that are disclosed herein.

[0106] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least substantially complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs or 19-30 base pairs, and said sense region comprises a sequence that is identical to, or in various embodiments at least substantially similar to, a sequence selected from the group consisting of various siRNAs that target p53 that are disclosed herein.

[0107] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least substantially complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs or 19-30 base pairs or 19-25 base pairs, and said sense region comprises a sequence that is identical to a contiguous stretch of at least 18 bases of a sequence selected from the group consisting of various siRNAs that target p53 that are disclosed herein.

[0108] In another embodiment, a pool of at least two siRNAs is provided, wherein said pool comprises a first siRNA and a second siRNA, said first siRNA comprises a duplex region of length 18-30 base pairs, or 19-30 base pairs, that has a first sense region that is at least substantially similar to, or is identical to, 18 bases of a first sequence and a second sequence, each sequence selected from the group consisting of various siRNA sequences targeting p53 that are disclosed herein.

[0109] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least substantially complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs, and said sense region comprises a sequence that is identical to a contiguous stretch of at least 18 bases of a sequence selected from the group consisting of various siRNAs that target p53 that are disclosed herein.

[0110] For a better understanding of the present invention together with other and further advantages and embodiments, reference is made to the following description taken in conjunction with the examples, the scope of which is set forth in the appended claims.

DETAILED DESCRIPTION

Definitions

[0111] Unless stated otherwise, the following terms and phrases have the meanings provided below:

[0112] Complementary

[0113] The term “complementary” refers to the ability of polynucleotides to form base pairs with one another. Base pairs are typically formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands. Complementary polynucleotide strands can base pair in the Watson-Crick manner (e.g., A to T, A to U, C to G), or in any other manner that allows for the formation of duplexes. As persons skilled in the art are aware, when using RNA as opposed to DNA, uracil rather than thymine is the base that is considered to be complementary to adenosine. However, when a U is denoted in the context of the present invention, the ability to substitute a T is implied, unless otherwise stated.

[0114] Perfect complementarity or 100% complementarity refers to the situation in which each nucleotide unit of one polynucleotide strand can hydrogen bond with a nucleotide unit of a second polynucleotide strand. Less than perfect complementarity refers to the situation in which some, but not all, nucleotide units of two strands can hydrogen bond with each other. For example, for two 20-mers, if only two base pairs on each strand can hydrogen bond with each other, the polynucleotide strands exhibit 10% complementarity. In the same example, if 18 base pairs on each strand can hydrogen bond with each other, the polynucleotide strands exhibit 90% complementarity.

[0115] Deoxynucleotide

[0116] The term “deoxynucleotide” refers to a nucleotide or polynucleotide lacking a hydroxyl group (OH group) at the 2′ and/or 3′ position of a sugar moiety. Instead, it has a hydrogen bonded to the 2′ and/or 3′ carbon. Within an RNA molecule that comprises one or more deoxynucleotides, “deoxynucleotide” refers to the lack of an OH group at the 2′ position of the sugar moiety, having instead a hydrogen bonded directly to the 2′ carbon.

[0117] Deoxyribonucleotide

[0118] The terms “deoxyribonucleotide” and “DNA” refer to a nucleotide or polynucleotide comprising at least one sugar moiety that has an H, rather than an OH, at its 2′ and/or 3′position.

[0119] Duplex Region

[0120] The phrase “duplex region” refers to the region in two complementary or substantially complementary polynucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a stabilized duplex between polynucleotide strands that are complementary or substantially complementary. For example, a polynucleotide strand having 21 nucleotide units can base pair with another polynucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the “duplex region” has 19 base pairs. The remaining bases may, for example, exist as 5′ and 3′ overhangs. Further, within the duplex region, 100% complementarity is not required; substantial complementarity is allowable within a duplex region. Substantial complementarity refers to 79% or greater complementarity. For example, a mismatch in a duplex region consisting of 19 base pairs results in 94.7% complementarity, rendering the duplex region substantially complementary.

[0121] Filters

[0122] The term “filter” refers to one or more procedures that are performed on sequences that are identified by the algorithm. In some instances, filtering includes in silico procedures where sequences identified by the algorithm can be screened to identify duplexes carrying desirable or undesirable motifs. Sequences carrying such motifs can be selected for, or selected against, to obtain a final set with the preferred properties. In other instances, filtering includes wet lab experiments. For instance, sequences identified by one or more versions of the algorithm can be screened using any one of a number of procedures to identify duplexes that have hyperfunctional traits (e.g., they exhibit a high degree of silencing at subnanomolar concentrations and/or exhibit high degrees of silencing longevity).

[0123] Gene Silencing

[0124] The phrase “gene silencing” refers to a process by which the expression of a specific gene product is lessened or attenuated. Gene silencing can take place by a variety of pathways. Unless specified otherwise, as used herein, gene silencing refers to decreases in gene product expression that results from RNA interference (RNAi), a defined, though partially characterized pathway whereby small inhibitory RNA (siRNA) act in concert with host proteins (e.g., the RNA induced silencing complex, RISC) to degrade messenger RNA (mRNA) in a sequence-dependent fashion. The level of gene silencing can be measured by a variety of means, including, but not limited to, measurement of transcript levels by Northern Blot Analysis, B-DNA techniques, transcription-sensitive reporter constructs, expression profiling (e.g., DNA chips), and related technologies. Alternatively, the level of silencing can be measured by assessing the level of the protein encoded by a specific gene. This can be accomplished by performing a number of studies including Western Analysis, measuring the levels of expression of a reporter protein that has e.g., fluorescent properties (e.g., GFP) or enzymatic activity (e.g., alkaline phosphatases), or several other procedures.

[0125] Nucleotide

[0126] The term “nucleotide” refers to a ribonucleotide or a deoxyribonucleotide or modified form thereof, as well as an analog thereof. Nucleotides include species that comprise purines, e.g., adenine, hypoxanthine, guanine, and their derivatives and analogs, as well as pyrimidines, e.g., cytosine, uracil, thymine, and their derivatives and analogs.

[0127] Nucleotide analogs include nucleotides having modifications in the chemical structure of the base, sugar and/or phosphate, including, but not limited to, 5-position pyrimidine modifications, 8-position purine modifications, modifications at cytosine exocyclic amines, and substitution of 5-bromo-uracil; and 2′-position sugar modifications, including but not limited to, sugar-modified ribonucleotides in which the 2′-OH is replaced by a group such as an H, OR, R, halo, SH, SR, NH₂, NHR, NR₂, or CN, wherein R is an alkyl moiety. Nucleotide analogs are also meant to include nucleotides with bases such as inosine, queuosine, xanthine, sugars such as 2′-methyl ribose, non-natural phosphodiester linkages such as methylphosphonates, phosphorothioates and peptides.

[0128] Modified bases refer to nucleotide bases such as, for example, adenine, guanine, cytosine, thymine, uracil, xanthine, inosine, and queuosine that have been modified by the replacement or addition of one or more atoms or groups. Some examples of types of modifications that can comprise nucleotides that are modified with respect to the base moieties include but are not limited to, alkylated, halogenated, thiolated, aminated, amidated, or acetylated bases, individually or in combination. More specific examples include, for example, 5-propynyluridine, 5-propynylcytidine, 6-methyladenine, 6-methylguanine, N,N,-dimethyladenine, 2-propyladenine, 2-propylguanine, 2-aminoadenine, 1-methylinosine, 3-methyluridine, 5-methylcytidine, 5-methyluridine and other nucleotides having a modification at the 5 position, 5-(2-amino)propyl uridine, 5-halocytidine, 5-halouridine, 4-acetylcytidine, 1-methyladenosine, 2-methyladenosine, 3-methylcytidine, 6-methyluridine, 2-methylguanosine, 7-methylguanosine, 2,2-dimethylguanosine, 5-methylaminoethyluridine, 5-methyloxyuridine, deazanucleotides such as 7-deaza-adenosine, 6-azouridine, 6-azocytidine, 6-azothymidine, 5-methyl-2-thiouridine, other thio bases such as 2-thiouridine and 4-thiouridine and 2-thiocytidine, dihydrouridine, pseudouridine, queuosine, archaeosine, naphthyl and substituted naphthyl groups, any O- and N-alkylated purines and pyrimidines such as N6-methyladenosine, 5-methylcarbonylmethyluridine, uridine 5-oxyacetic acid, pyridine-4-one, pyridine-2-one, phenyl and modified phenyl groups such as aminophenol or 2,4,6-trimethoxy benzene, modified cytosines that act as G-clamp nucleotides, 8-substituted adenines and guanines, 5-substituted uracils and thymines, azapyrimidines, carboxyhydroxyalkyl nucleotides, carboxyalkylaminoalkyl nucleotides, and alkylcarbonylalkylated nucleotides. Modified nucleotides also include those nucleotides that are modified with respect to the sugar moiety, as well as nucleotides having sugars or analogs thereof that are not ribosyl. For example, the sugar moieties may be, or be based on, mannoses, arabinoses, glucopyranoses, galactopyranoses, 4′-thioribose, and other sugars, heterocycles, or carbocycles.

[0129] The term nucleotide is also meant to include what are known in the art as universal bases. By way of example, universal bases include but are not limited to 3-nitropyrrole, 5-nitroindole, or nebularine. The term “nucleotide” is also meant to include the N3′ to P5′ phosphoramidate, resulting from the substitution of a ribosyl 3′ oxygen with an amine group.

[0130] Further, the term nucleotide also includes those species that have a detectable label, such as for example a radioactive or fluorescent moiety, or mass label attached to the nucleotide.

[0131] Polynucleotide

[0132] The term “polynucleotide” refers to polymers of nucleotides, and includes but is not limited to DNA, RNA, DNA/RNA hybrids including polynucleotide chains of regularly and/or irregularly alternating deoxyribosyl moieties and ribosyl moieties (i.e., wherein alternate nucleotide units have an —OH, then and —H, then an —OH, then an —H, and so on at the 2′ position of a sugar moiety), and modifications of these kinds of polynucleotides, wherein the attachment of various entities or moieties to the nucleotide units at any position are included.

[0133] Polyribonucleotide

[0134] The term “polyribonucleotide” refers to a polynucleotide comprising two or more modified or unmodified ribonucleotides and/or their analogs. The term “polyribonucleotide” is used interchangeably with the term “oligoribonucleotide.”

[0135] Ribonucleotide and Ribonucleic Acid

[0136] The term “ribonucleotide” and the phrase “ribonucleic acid” (RNA), refer to a modified or unmodified nucleotide or polynucleotide comprising at least one ribonucleotide unit. A ribonucleotide unit comprises an hydroxyl group attached to the 2′ position of a ribosyl moiety that has a nitrogenous base attached in N-glycosidic linkage at the 1′ position of a ribosyl moiety, and a moiety that either allows for linkage to another nucleotide or precludes linkage.

[0137] Off-Target Silencing and Off-Target Interference

[0138] The phrases “off-target silencing” and “off-target interference” are defined as degradation of mRNA other than the intended target mRNA due to overlapping and/or partial homology with secondary mRNA messages.

[0139] siRNA

[0140] The term “siRNA” refers to small inhibitory RNA duplexes that induce the RNA interference (RNAi) pathway. These molecules can vary in length (generally 18-30 base pairs) and contain varying degrees of complementarity to their target mRNA in the antisense strand. Some, but not all, siRNA have unpaired overhanging bases on the 5′ or 3′ end of the sense strand and/or the antisense strand. The term “siRNA” includes duplexes of two separate strands, as well as single strands that can form hairpin structures comprising a duplex region.

[0141] siRNA may be divided into five (5) groups (non-functional, semi-functional, functional, highly functional, and hyper-functional) based on the level or degree of silencing that they induce in cultured cell lines. As used herein, these definitions are based on a set of conditions where the siRNA is transfected into said cell line at a concentration of 100 nM and the level of silencing is tested at a time of roughly 24 hours after transfection, and not exceeding 72 hours after transfection. In this context, “non-functional siRNA” are defined as those siRNA that induce less than 50% (<50%) target silencing. “Semi-functional siRNA” induce 50-79% target silencing. “Functional siRNA” are molecules that induce 80-95% gene silencing. “Highly-functional siRNA” are molecules that induce greater than 95% gene silencing. “Hyperfunctional siRNA” are a special class of molecules. For purposes of this document, hyperfunctional siRNA are defined as those molecules that: (1) induce greater than 95% silencing of a specific target when they are transfected at subnanomolar concentrations (i.e., less than one nanomolar); and/or (2) induce functional (or better) levels of silencing for greater than 96 hours. These relative functionalities (though not intended to be absolutes) may be used to compare siRNAs to a particular target for applications such as functional genomics, target identification and therapeutics.

[0142] SMARTSCORE™, or siRNA Rank

[0143] The term “SMARTSCORE™”, or “siRNA rank” refers to a number determined by applying any of the formulas to a given siRNA sequence. The term “SMART-selected” or “rationally selected” or “rational selection” refers to siRNA that have been selected on the basis of their SMARTSCORES™, or siRNA ranking.

[0144] Target

[0145] The term “target” is used in a variety of different forms throughout this document and is defined by the context in which it is used. “Target mRNA” refers to a messenger RNA to which a given siRNA can be directed against. “Target sequence” and “target site” refer to a sequence within the mRNA to which the sense strand of an siRNA shows varying degrees of homology and the antisense strand exhibits varying degrees of complementarity. The phrase “siRNA target” can refer to the gene, mRNA, or protein against which an siRNA is directed. Similarly, “target silencing” can refer to the state of a gene, or the corresponding mRNA or protein.

[0146] Transfection

[0147] The term “transfection” refers to a process by which agents are introduced into a cell. The list of agents that can be transfected is large and includes, but is not limited to, siRNA, sense and/or anti-sense sequences, DNA encoding one or more genes and organized into an expression plasmid, proteins, protein fragments, and more. There are multiple methods for transfecting agents into a cell including, but not limited to, electroporation, calcium phosphate-based transfections, DEAE-dextran-based transfections, lipid-based transfections, molecular conjugate-based transfections (e.g., polylysine-DNA conjugates), microinjection and others.

[0148] The present invention is directed to improving the efficiency of gene silencing by siRNA. Through the inclusion of multiple siRNA sequences that are targeted to a particular gene and/or selecting an siRNA sequence based on certain defined criteria, improved efficiency may be achieved.

[0149] The present invention will now be described in connection with preferred embodiments. These embodiments are presented in order to aid in an understanding of the present invention and are not intended, and should not be construed, to limit the invention in any way. All alternatives, modifications and equivalents that may become apparent to those of ordinary skill upon reading this disclosure are included within the spirit and scope of the present invention. Furthermore, this disclosure is not a primer on RNA interference. Basic concepts known to persons skilled in the art have not been set forth in detail.

[0150] The present invention is directed to increasing the efficiency of RNAi, particularly in mammalian systems. Accordingly, the present invention provides kits, siRNAs and methods for increasing siRNA efficacy.

[0151] According to a first embodiment, the present invention provides a kit for gene silencing, wherein said kit is comprised of a pool of at least two siRNA duplexes, each of which is comprised of a sequence that is complementary to a portion of the sequence of one or more target messenger RNA, and each of which is selected using non-target specific criteria.

[0152] According to a second embodiment, the present invention provides a method for selecting an siRNA, said method comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; and determining the relative functionality of the at least two siRNAs. The selection criteria may for example, be embodied in a formula comprising Formula VIII or Formula X.

[0153] Any of the methods of selecting siRNA in accordance with the invention can further comprise comparing the internal stability profiles of the siRNAs to be selected, and selecting those siRNAs with the most favorable internal stability profiles. Any of the methods of selecting siRNA can further comprise selecting either for or against sequences that contain motifs that induce cellular stress. Such motifs include, for example, toxicity motifs. Any of the methods of selecting siRNA can further comprise either selecting for or selecting against sequences that comprise stability motifs.

[0154] In another embodiment, the present invention provides a method of gene silencing, comprising introducing into a cell at least one siRNA selected according to any of the methods of the present invention. The siRNA can be introduced by allowing passive uptake of siRNA, or through the use of a vector.

[0155] According to a third embodiment, the invention provides a method for developing an algorithm for selecting siRNA, said method comprising: (a) selecting a set of siRNA; (b) measuring gene silencing ability of each siRNA from said set; (c) determining relative functionality of each siRNA; (d) determining improved functionality by the presence or absence of at least one variable selected from the group consisting of the presence or absence of a particular nucleotide at a particular position, the total number of As and Us in positions 15-19, the number of times that the same nucleotide repeats within a given sequence, and the total number of Gs and Cs; and (e) developing an algorithm using the information of step (d).

[0156] In another embodiment, the invention provides a method for selecting an siRNA with improved functionality, comprising using the above-mentioned algorithm to identify an siRNA of improved functionality.

[0157] According to a fourth embodiment, the present invention provides a kit, wherein said kit is comprised of at least two siRNAs, wherein said at least two siRNAs comprise a first optimized siRNA and a second optimized siRNA, wherein said first optimized siRNA and said second optimized siRNA are optimized according a formula comprising Formula X.

[0158] According to a fifth embodiment, the present invention provides a method for identifying a hyperfunctional siRNA, comprising applying selection criteria to a set of potential siRNA that comprise 18-30 base pairs, wherein said selection criteria are non-target specific criteria, and said set comprises at least two siRNAs and each of said at least two siRNAs contains a sequence that is at least substantially complementary to a target gene; determining the relative functionality of the at least two siRNAs and assigning each of the at least two siRNAs a functionality score; and selecting siRNAs from the at least two siRNAs that have a functionality score that reflects greater than 80 percent silencing at a concentration in the picomolar range, wherein said greater than 80 percent silencing endures for greater than 120 hours.

[0159] In other embodiments, the invention provides kits and/or methods wherein the siRNA are comprised of two separate polynucleotide strands; wherein the siRNA are comprised of a single contiguous molecule such as, for example, a unimolecular siRNA (comprising, for example, either a nucleotide or non-nucleotide loop); wherein the siRNA are expressed from one or more vectors; and wherein two or more genes are silenced by a single administration of siRNA.

[0160] According to a sixth embodiment, the present invention provides a method for developing an siRNA algorithm for selecting functional and hyperfunctional siRNAs for a given sequence. The method comprises: (i) selecting a set of siRNAs; (ii) measuring the gene silencing ability of each siRNA from said set; (iii) determining the relative functionality of each siRNA; (iv) determining the amount of improved functionality by the presence or absence of at least one variable selected from the group consisting of the total GC content, melting temperature of the siRNA, GC content at positions 15-19, the presence or absence of a particular nucleotide at a particular position, relative thermodynamic stability at particular positions in a duplex, and the number of times that the same nucleotide repeats within a given sequence; and (v) developing an algorithm using the information of step (d).

[0161] According to this embodiment, preferably the set of siRNAs comprises at least 90 siRNAs from at least one gene, more preferably at least 180 siRNAs from at least two different genes, and most preferably at least 270 and 360 siRNAs from at least three and four different genes, respectively. Additionally, in step (d) the determination is made with preferably at least two, more preferably at least three, even more preferably at least four, and most preferably all of the variables. The resulting algorithm is not target sequence specific.

[0162] The ability to use the above algorithms, which are not sequence or species specific, allows for the cost-effective selection of optimized siRNAs for specific target sequences. Accordingly, there will be both greater efficiency and reliability in the use of siRNA technologies.

[0163] The methods disclosed herein can be used in conjunction with comparing internal stability profiles of selected siRNAs, and designing an siRNA with a desirable internal stability profile; and/or in conjunction with a selection either for or against sequences that contain motifs that induce cellular stress, for example, cellular toxicity.

[0164] Any of the methods disclosed herein can be used to silence one or more genes by introducing an siRNA selected, or designed, in accordance with any of the methods disclosed herein. The siRNA(s) can be introduced into the cell by any method known in the art, including passive uptake or through the use of one or more vectors.

[0165] Any of the methods and kits disclosed herein can employ either unimolecular siRNAs, siRNAs comprised of two separate polynucleotide strands, or combinations thereof. Any of the methods disclosed herein can be used in gene silencing, where two or more genes are silenced by a single administration of siRNA(s). The siRNA(s) can be directed against two or more target genes, and administered in a single dose or single transfection, as the case may be.

[0166] Optimizing siRNA

[0167] According to one embodiment, the present invention provides a method for improving the effectiveness of gene silencing for use to silence a particular gene through the selection of an optimal siRNA. An siRNA selected according to this method may be used individually, or in conjunction with the first embodiment, i.e., with one or more other siRNAs, each of which may or may not be selected by this criteria in order to maximize their efficiency.

[0168] The degree to which it is possible to select an siRNA for a given mRNA that maximizes these criteria will depend on the sequence of the mRNA itself. However, the selection criteria will be independent of the target sequence. According to this method, an siRNA is selected for a given gene by using a rational design. That said, rational design can be described in a variety of ways. Rational design is, in simplest terms, the application of a proven set of criteria that enhance the probability of identifying a functional or hyperfunctional siRNA. In one method, rationally designed siRNA can be identified by maximizing one or more of the following criteria:

[0169] A low GC content, preferably between about 30-52%.

[0170] At least 2, preferably at least 3 A or U bases at positions 15-19 of the siRNA on the sense strand.

[0171] An A base at position 19 of the sense strand.

[0172] An A base at position 3 of the sense strand.

[0173] A U base at position 10 of the sense strand.

[0174] An A base at position 14 of the sense strand.

[0175] A base other than C at position 19 of the sense strand.

[0176] A base other than G at position 13 of the sense strand.

[0177] A Tm, which refers to the character of the internal repeat that results in inter- or intramolecular structures for one strand of the duplex, that is preferably not stable at greater than 50° C., more preferably not stable at greater than 37° C., even more preferably not stable at greater than 30° C. and most preferably not stable at greater than 20° C.

[0178] A base other than U at position 5 of the sense strand.

[0179] A base other than A at position 11 of the sense strand.

[0180] A base other than an A at position 1 of the sense strand.

[0181] A base other than an A at position 2 of the sense strand.

[0182] An A base at position 4 of the sense strand.

[0183] An A base at position 5 of the sense strand.

[0184] An A base at position 6 of the sense strand.

[0185] An A base at position 7 of the sense strand.

[0186] An A base at position 8 of the sense strand.

[0187] A base other than an A at position 9 of the sense strand.

[0188] A base other than an A at position 10 of the sense strand.

[0189] A base other than an A at position 11 of the sense strand.

[0190] A base other than an A at position 12 of the sense strand.

[0191] An A base at position 13 of the sense strand.

[0192] A base other than an A at position 14 of the sense strand.

[0193] An A base at position 15 of the sense strand

[0194] An A base at position 16 of the sense strand.

[0195] An A base at position 17 of the sense strand.

[0196] An A base at position 18 of the sense strand.

[0197] A base other than a U at position 1 of the sense strand.

[0198] A base other than a U at position 2 of the sense strand.

[0199] A U base at position 3 of the sense strand.

[0200] A base other than a U at position 4 of the sense strand.

[0201] A base other than a U at position 5 of the sense strand.

[0202] A U base at position 6 of the sense strand.

[0203] A base other than a U at position 7 of the sense strand.

[0204] A base other than a U at position 8 of the sense strand.

[0205] A base other than a U at position 9 of the sense strand.

[0206] A base other than a U at position 11 of the sense strand.

[0207] A U base at position 13 of the sense strand.

[0208] A base other than a U at position 14 of the sense strand.

[0209] A base other than a U at position 15 of the sense strand.

[0210] A base other than a U at position 16 of the sense strand.

[0211] A U base at position 17 of the sense strand.

[0212] A U base at position 18 of the sense strand.

[0213] A U base at position 19 of the sense strand.

[0214] A C base at position 1 of the sense strand.

[0215] A C base at position 2 of the sense strand.

[0216] A base other than a C at position 3 of the sense strand.

[0217] A C base at position 4 of the sense strand.

[0218] A base other than a C at position 5 of the sense strand.

[0219] A base other than a C at position 6 of the sense strand.

[0220] A base other than a C at position 7 of the sense strand.

[0221] A base other than a C at position 8 of the sense strand.

[0222] A C base at position 9 of the sense strand.

[0223] A C base at position 10 of the sense strand.

[0224] A C base at position 11 of the sense strand.

[0225] A base other than a C at position 12 of the sense strand.

[0226] A base other than a C at position 13 of the sense strand.

[0227] A base other than a C at position 14 of the sense strand.

[0228] A base other than a C at position 15 of the sense strand.

[0229] A base other than a C at position 16 of the sense strand.

[0230] A base other than a C at position 17 of the sense strand.

[0231] A base other than a C at position 18 of the sense strand.

[0232] A G base at position 1 of the sense strand.

[0233] A G base at position 2 of the sense strand.

[0234] A G base at position 3 of the sense strand.

[0235] A base other than a G at position 4 of the sense strand.

[0236] A base other than a G at position 5 of the sense strand.

[0237] A G base at position 6 of the sense strand.

[0238] A G base at position 7 of the sense strand.

[0239] A G base at position 8 of the sense strand.

[0240] A G base at position 9 of the sense strand.

[0241] A base other than a G at position 10 of the sense strand.

[0242] A G base at position 11 of the sense strand.

[0243] A G base at position 12 of the sense strand.

[0244] A G base at position 14 of the sense strand.

[0245] A G base at position 15 of the sense strand.

[0246] A G base at position 16 of the sense strand.

[0247] A base other than a G at position 17 of the sense strand.

[0248] A base other than a G at position 18 of the sense strand.

[0249] A base other than a G at position 19 of the sense strand.

[0250] The importance of various criteria can vary greatly. For instance, a C base at position 10 of the sense strand makes a minor contribution to duplex functionality. In contrast, the absence of a C at position 3 of the sense strand is very important. Accordingly, preferably an siRNA will satisfy as many of the aforementioned criteria as possible.

[0251] With respect to the criteria, GC content, as well as a high number of AU in positions 15-19 of the sense strand, may be important for easement of the unwinding of double stranded siRNA duplex. Duplex unwinding has been shown to be crucial for siRNA functionality in vivo.

[0252] With respect to criterion 9, the internal structure is measured in terms of the melting temperature of the single strand of siRNA, which is the temperature at which 50% of the molecules will become denatured. With respect to criteria 2-8 and 10-11, the positions refer to sequence positions on the sense strand, which is the strand that is identical to the mRNA.

[0253] In one preferred embodiment, at least criteria 1 and 8 are satisfied. In another preferred embodiment, at least criteria 7 and 8 are satisfied. In still another preferred embodiment, at least criteria 1, 8 and 9 are satisfied.

[0254] It should be noted that all of the aforementioned criteria regarding sequence position specifics are with respect to the 5′ end of the sense strand. Reference is made to the sense strand, because most databases contain information that describes the information of the mRNA. Because according to the present invention a chain can be from 18 to 30 bases in length, and the aforementioned criteria assumes a chain 19 base pairs in length, it is important to keep the aforementioned criteria applicable to the correct bases.

[0255] When there are only 18 bases, the base pair that is not present is the base pair that is located at the 3′ of the sense strand. When there are twenty to thirty bases present, then additional bases are added at the 5′ end of the sense chain and occupy positions ⁻1 to ⁻11. Accordingly, with respect to SEQ. ID NO. 0001 NNANANNNNUCNAANNNNA and SEQ. ID NO. 0028 GUCNNANANNNNUCNAANNNNA, both would have A at position 3, A at position 5, U at position 10, C at position 11, A and position 13, A and position 14 and A at position 19. However, SEQ. ID NO. 0028 would also have C at position −1, U at position −2 and G at position −3.

[0256] For a 19 base pair siRNA, an optimal sequence of one of the strands may be represented below, where N is any base, A, C, G, or U:

[0257]

	SEQ. ID NO. 0001.	NNANANNNNU CNAANNNNA

	SEQ. ID NO. 0002.	NNANANNNNU GNAANNNNA

	SEQ. ID NO. 0003.	NNANANNNNU UNAANNNNA

	SEQ. ID NO. 0004.	NNANANNNNU CNCANNNNA

	SEQ. ID NO. 0005.	NNANANNNNU GNCANNNNA

	SEQ. ID NO. 0006.	NNANANNNNU UNCANNNNA

	SEQ. ID NO. 0007.	NNANANNNNU CNUANNNNA

	SEQ. ID NO. 0008.	NNANANNNNU GNUANNNNA

	SEQ. ID NO. 0009.	NNANANNNNU UNUANNNNA

	SEQ. ID NO. 0010.	NNANCNNNNU CNAANNNNA

	SEQ. ID NO. 0011.	NNANCNNNNU GNAANNNNA

	SEQ. ID NO. 0012.	NNANCNNNNU UNAANNNNA

	SEQ. ID NO. 0013.	NNANCNNNNU CNCANNNNA

	SEQ. ID NO. 0014.	NNANCNNNNU GNCANNNNA

	SEQ. ID NO. 0015.	NNANCNNNNU UNCANNNNA

	SEQ. ID NO. 0016.	NANCNNNNUC CNUANNNNA

	SEQ. ID NO. 0017.	NNANCNNNNU GNUANNNNA

	SEQ. ID NO. 0018.	NNANCNNNNU UNUANNNNA

	SEQ. ID NO. 0019.	NNANGNNNNU CNAANNNNA

	SEQ. ID NO. 0020.	NNANGNNNNU GNAANNNNA

	SEQ. ID NO. 0021.	NNANGNNNNU UNAANNNNA

	SEQ. ID NO. 0022.	NNANGNNNNU CNCANNNNA

	SEQ. ID NO. 0023.	NNANGNNNNU GNCANNNNA

	SEQ. ID NO. 0024.	NNANGNNNNU UNCANNNNA

	SEQ. ID NO. 0025.	NNANGNNNNU CNUANNNNA

	SEQ. ID NO. 0026.	NNNANGNNNU GNUANNNNA

	SEQ. ID NO. 0027.	NNANGNNNNN UNUANNNNA

[0258] In one embodiment, the sequence used as an siRNA is selected by choosing the siRNA that score highest according to one of the following seven algorithms that are represented by Formulas I-VII:
Relative functionality of siRNA=−(GC/3)+(AU_15-19)−(Tm_{20° C.})*3−(G₁₃)*3−(C₁₉)+(A₁₉)*2+(A₃)+(U₁₀)+(A₁₄)−(U₅)−(A₁₁) Formula I
Relative functionality of siRNA=−(GC/3)−(AU_15-19)*3−(G₁₃)*3−(C₁₉)+(A₁₉)*2+(A₃) Formula II
Relative functionality of siRNA=−(GC/3)+(AU_15-19)−(Tm_{20° C.})*3 Formula III
Relative functionality of siRNA=−(GC/2+(AU_15-19)/2−(Tm_{20° C.})*2−(G₁₃)*3−(C₁₉)+(A₁₉)*2+(A₃)+(U₁₀)+(A₁₄)−(U₅)−(A₁₁) Formula IV
Relative functionality of siRNA=−(G₁₃)*3−(C₁₉)+(A₁₉)*2+(A₃)+(U₁₀)+(A₁₄)−(U₅)−(A₁₁) Formula V
Relative functionality of siRNA=−(G₁₃)*3−(C₁₉)+(A₁₉)*2+(A₃) Formula VI
Relative functionality of siRNA=−(GC/2)+(AU_15-19)/2−(Tm_{20° C.})*1−(G₁₃)*3−(C₁₉)+(A₁₉)*3+(A₃)*3+(U₁₀)/2+(A₁₄)/2−(U₅)/2−(A₁₁)/2 Formula VII

[0259] In Formulas I-VII:

[0260] wherein A₁₉=1 if A is the base at position 19 on the sense strand, otherwise its value is 0,

[0261] AU_15-19=0-5 depending on the number of A or U bases on the sense strand at positions 15-19;

[0262] G₁₃=1 if G is the base at position 13 on the sense strand, otherwise its value is 0;

[0263] C₁₉=1 if C is the base at position 19 of the sense strand, otherwise its value is 0;

[0264] GC=the number of G and C bases in the entire sense strand;

[0265] Tm_{20° C.}=1 if the Tm is greater than 20° C.;

[0266] A₃=1 if A is the base at position 3 on the sense strand, otherwise its value is 0;

[0267] U₁₀=1 if U is the base at position 10 on the sense strand, otherwise its value is 0;

[0268] A₁₄=1 if A is the base at position 14 on the sense strand, otherwise its value is 0;

[0269] U₅=1 if U is the base at position 5 on the sense strand, otherwise its value is 0; and

[0270] A₁₁=1 if A is the base at position 11 of the sense strand, otherwise its value is 0.

[0271] Formulas I-VII provide relative information regarding functionality. When the values for two sequences are compared for a given formula, the relative functionality is ascertained; a higher positive number indicates a greater functionality. For example, in many applications a value of 5 or greater is beneficial.

[0272] Additionally, in many applications, more than one of these formulas would provide useful information as to the relative functionality of potential siRNA sequences. However, it is beneficial to have more than one type of formula, because not every formula will be able to help to differentiate among potential siRNA sequences. For example, in particularly high GC mRNAs, formulas that take that parameter into account would not be useful and application of formulas that lack GC elements (e.g., formulas V and VI) might provide greater insights into duplex functionality. Similarly, formula II might by used in situations where hairpin structures are not observed in duplexes, and formula IV might be applicable for sequences that have higher AU content. Thus, one may consider a particular sequence in light of more than one or even all of these algorithms to obtain the best differentiation among sequences. In some instances, application of a given algorithm may identify an unusually large number of potential siRNA sequences, and in those cases, it may be appropriate to re-analyze that sequence with a second algorithm that is, for instance, more stringent. Alternatively, it is conceivable that analysis of a sequence with a given formula yields no acceptable siRNA sequences (i.e. low SMARTSCORES™, or siRNA ranking). In this instance, it may be appropriate to re-analyze that sequences with a second algorithm that is, for instance, less stringent. In still other instances, analysis of a single sequence with two separate formulas may give rise to conflicting results (i.e. one formula generates a set of siRNA with high SMARTSCORES™, or siRNA ranking, while the other formula identifies a set of siRNA with low SMARTSCORES™, or siRNA ranking). In these instances, it may be necessary to determine which weighted factor(s) (e.g. GC content) are contributing to the discrepancy and assessing the sequence to decide whether these factors should or should not be included. Alternatively, the sequence could be analyzed by a third, fourth, or fifth algorithm to identify a set of rationally designed siRNA.

[0273] The above-referenced criteria are particularly advantageous when used in combination with pooling techniques as depicted in Table I:

[0274]

TABLE I

FUNCTIONAL PROBABILITY
	438.1.1OLIGOS	438.1.2POOLS

438.1.3CRITERIA	>95%	>80%	<70%	>95%	>80%	<70%
438.1.4CURRENT	33.0	50.0	23.0	79.5	97.3	0.3
NEW	50.0	88.5	8.0	93.8	99.98	0.005
(GC)	28.0	58.9	36.0	72.8	97.1	1.6

[0275] The term “current” used in Table I refers to Tuschl's conventional siRNA parameters (Elbashir, S. M. et al. (2002) “Analysis of gene function in somatic mammalian cells using small interfering RNAs” Methods 26: 199-213). “New” refers to the design parameters described in Formulas I-VII. “GC” refers to criteria that select siRNA solely on the basis of GC content.

[0276] As Table I indicates, when more functional siRNA duplexes are chosen, siRNAs that produce <70% silencing drops from 23% to 8% and the number of siRNA duplexes that produce >80% silencing rises from 50% to 88.5%. Further, of the siRNA duplexes with >80% silencing, a larger portion of these siRNAs actually silence >95% of the target expression (the new criteria increases the portion from 33% to 50%). Using this new criteria in pooled siRNAs, shows that, with pooling, the amount of silencing >95% increases from 79.5% to 93.8% and essentially eliminates any siRNA pool from silencing less than 70%.

[0277] Table II similarly shows the particularly beneficial results of pooling in combination with the aforementioned criteria. However, Table II, which takes into account each of the aforementioned variables, demonstrates even a greater degree of improvement in functionality.

[0278]

TABLE II

FUNCTIONAL PROBABILITY
	OLIGOS	POOLS
			NON-			NON-
	FUNCTIONAL	AVERAGE	FUNCTIONAL	FUNCTIONAL	AVERAGE	FUNCTIONAL

RANDOM	20	40	50	67	97	3
CRITERIA 1	52	99	0.1	97	93	0.0040
CRITERIA 4	89	99	0.1	99	99	0.0000

[0279] The terms “functional,” “Average,” and “Non-functional” used in Table II, refer to siRNA that exhibit >80%, >50%, and <50% functionality, respectively. Criteria 1 and 4 refer to specific criteria described above.

[0280] The above-described algorithms may be used with or without a computer program that allows for the inputting of the sequence of the mRNA and automatically outputs the optimal siRNA. The computer program may, for example, be accessible from a local terminal or personal computer, over an internal network or over the Internet.

[0281] In addition to the formulas above, more detailed algorithms may be used for selecting siRNA. Preferably, at least one RNA duplex of 18-30 base pairs is selected such that it is optimized according a formula selected from: Formula VIII, Formula IX and Formula X.

[0282] Formulas VIII, IX, and X, as well as formulas I-VII, provide methods for selecting siRNA in order to increase the efficiency of gene silencing. A subset of variables of any of the formulas may be used, though when fewer variables are used, the optimization hierarchy becomes less reliable.

[0283] With respect to the variables of the above-referenced formulas, a single letter of A or C or G or U followed by a subscript refers to a binary condition. The binary condition is that either the particular base is present at that particular position (wherein the value is “1”) or the base is not present (wherein the value is “0”). Because position 19 is optional, i.e., there might be only 18 base pairs, when there are only 18 base pairs, any base with a subscript of 19 in the formulas above would have a zero value for that parameter. Before or after each variable is a number followed by *, which indicates that the value of the variable is to be multiplied or weighed by that number.

[0284] The numbers preceding the variables A, or G, or C, or U in Formulas VIII, IX, and X (or after the variables in Formula I-VII) were determined by comparing the difference in the frequency of individual bases at different positions in functional siRNA and total siRNA. Specifically, the frequency in which a given base was observed at a particular position in functional groups was compared with the frequency that that same base was observed in the total, randomly selected siRNA set. If the absolute value of the difference between the functional and total values was found to be greater than 6%, that parameter was included in the equation. Thus, for instance, if the frequency of finding a “G” at position 13 (G₁₃) is found to be 6% in a given functional group, and the frequency of G₁₃in the total population of siRNAs is 20%, the difference between the two values is 6%-20%=−14%. As the absolute value is greater than six (6), this factor (−14) is included in the equation. Thus, in Formula VIII, in cases where the siRNA under study has a G in position 13, the accrued value is (−14)*(1)=−14. In contrast, when a base other than G is found at position 13, the accrued value is (−14)*(0)=0.

[0285] When developing a means to optimize siRNAs, the inventors observed that a bias toward low internal thermodynamic stability of the duplex at the 5′-antisense (AS) end is characteristic of naturally occurring miRNA precursors. The inventors extended this observation to siRNAs for which functionality had been assessed in tissue culture.

[0286] With respect to the parameter GC_15-19, a value of 0-5 will be ascribed depending on the number of G or C bases at positions 15 to 19. If there are only 18 base pairs, the value is between 0 and 4.

[0287] With respect to the criterion GC_totalcontent, a number from 0-30 will be ascribed, which correlates to the total number of G and C nucleotides on the sense strand, excluding overhangs. Without wishing to be bound by any one theory, it is postulated that the significance of the GC content (as well as AU content at positions 15-19, which is a parameter for formulas III-VII) relates to the easement of the unwinding of a double-stranded siRNA duplex. Duplex unwinding is believed to be crucial for siRNA functionality in vivo and overall low internal stability, especially low internal stability of the first unwound base pair is believed to be important to maintain sufficient processivity of RISC complex-induced duplex unwinding. If the duplex has 19 base pairs, those at positions 15-19 on the sense strand will unwind first if the molecule exhibits a sufficiently low internal stability at that position. As persons skilled in the art are aware, RISC is a complex of approximately twelve proteins; Dicer is one, but not the only, helicase within this complex. Accordingly, although the GC parameters are believed to relate to activity with Dicer, they are also important for activity with other RISC proteins.

[0288] The value of the parameter Tm is 0 when there are no internal repeats longer than (or equal to) four base pairs present in the siRNA duplex; otherwise the value is 1. Thus for example, if the sequence ACGUACGU, or any other four nucleotide (or more) palindrome exists within the structure, the value will be one (1). Alternatively if the structure ACGGACG, or any other 3 nucleotide (or less) palindrome exists, the value will be zero (0).

[0289] The variable “X” refers to the number of times that the same nucleotide occurs contiguously in a stretch of four or more units. If there are, for example, four contiguous As in one part of the sequence and elsewhere in the sequence four contiguous Cs, X=2. Further, if there are two separate contiguous stretches of four of the same nucleotides or eight or more of the same nucleotides in a row, then X=2. However, X does not increase for five, six or seven contiguous nucleotides.

[0290] Again, when applying Formula VIII, Formula IX, or Formula X, to a given mRNA, (the “target RNA” or “target molecule”), one may use a computer program to evaluate the criteria for every sequence of 18-30 base pairs or only sequences of a fixed length, e.g., 19 base pairs. Preferably the computer program is designed such that it provides a report ranking of all of the potential siRNAs 18-30 base pairs, ranked according to which sequences generate the highest value. A higher value refers to a more efficient siRNA for a particular target gene. The computer program that may be used may be developed in any computer language that is known to be useful for scoring nucleotide sequences, or it may be developed with the assistance of commercially available product such as Microsoft's product.net. Additionally, rather than run every sequence through one and/or another formula, one may compare a subset of the sequences, which may be desirable if for example only a subset are available. For instance, it may be desirable to first perform a BLAST (Basic Local Alignment Search Tool) search and to identify sequences that have no homology to other targets. Alternatively, it may be desirable to scan the sequence and to identify regions of moderate GC context, then perform relevant calculations using one of the above-described formulas on these regions. These calculations can be done manually or with the aid of a computer.

[0291] As with Formulas I-VII, either Formula VIII, Formula IX, or Formula X may be used for a given mRNA target sequence. However, it is possible that according to one or the other formula more than one siRNA will have the same value. Accordingly, it is beneficial to have a second formula by which to differentiate sequences. Formulas IX and X were derived in a similar fashion as Formula VIII, yet used a larger data set and thus yields sequences with higher statistical correlations to highly functional duplexes. The sequence that has the highest value ascribed to it may be referred to as a “first optimized duplex.” The sequence that has the second highest value ascribed to it may be referred to as a “second optimized duplex.” Similarly, the sequences that have the third and fourth highest values ascribed to them may be referred to as a third optimized duplex and a fourth optimized duplex, respectively. When more than one sequence has the same value, each of them may, for example, be referred to as first optimized duplex sequences or co-first optimized duplexes. Formula X is similar to Formula IX, yet uses a greater number of variables and for that reason, identifies sequences on the basis of slightly different criteria.

[0292] It should also be noted that the output of a particular algorithm will depend on several of variables including: (1) the size of the data base(s) being analyzed by the algorithm, and (2) the number and stringency of the parameters being applied to screen each sequence. Thus, for example, in U.S. patent application Ser. No. 10/714,333, entitled “Functional and Hyperfunctional siRNA,” filed Nov. 14, 2003, Formula VIII was applied to the known human genome (NCBI REFSEQ database) through ENTREZ (EFETCH). As a result of these procedures, roughly 1.6 million siRNA sequences were identified. Application of Formula VIII to the same database in March of 2004 yielded roughly 2.2 million sequences, a difference of approximately 600,000 sequences resulting from the growth of the database over the course of the months that span this period of time. Application of other formulas (e.g., Formula X) that change the emphasis of, include, or eliminate different variables can yield unequal numbers of siRNAs. Alternatively, in cases where application of one formula to one or more genes fails to yield sufficient numbers of siRNAs with scores that would be indicative of strong silencing, said genes can be reassessed with a second algorithm that is, for instance, less stringent.

[0293] siRNA sequences identified using Formula VIII and Formula X (minus sequences generated by Formula VIII) are contained within the enclosed compact disks. The data included on the enclosed compact disks is described more fully below. The sequences identified by Formula VIII and Formula X that are disclosed in the compacts disks may be used in gene silencing applications.

[0294] It should be noted that for Formulas VIII, IX, and X all of the aforementioned criteria are identified as positions on the sense strand when oriented in the 5′ to 3′ direction as they are identified in connection with Formulas I-VII unless otherwise specified.

[0295] Formulas I-X, may be used to select or to evaluate one, or more than one, siRNA in order to optimize silencing. Preferably, at least two optimized siRNAs that have been selected according to at least one of these formulas are used to silence a gene, more preferably at least three and most preferably at least four. The siRNAs may be used individually or together in a pool or kit. Further, they may be applied to a cell simultaneously or separately. Preferably, the at least two siRNAs are applied simultaneously. Pools are particularly beneficial for many research applications. However, for therapeutics, it may be more desirable to employ a single hyperfunctional siRNA as described elsewhere in this application.

[0296] When planning to conduct gene silencing, and it is necessary to choose between two or more siRNAs, one should do so by comparing the relative values when the siRNA are subjected to one of the formulas above. In general a higher scored siRNA should be used.

[0297] Useful applications include, but are not limited to, target validation, gene functional analysis, research and drug discovery, gene therapy and therapeutics. Methods for using siRNA in these applications are well known to persons of skill in the art.

[0298] Because the ability of siRNA to function is dependent on the sequence of the RNA and not the species into which it is introduced, the present invention is applicable across a broad range of species, including but not limited to all mammalian species, such as humans, dogs, horses, cats, cows, mice, hamsters, chimpanzees and gorillas, as well as other species and organisms such as bacteria, viruses, insects, plants and C. elegans.

[0299] The present invention is also applicable for use for silencing a broad range of genes, including but not limited to the roughly 45,000 genes of a human genome, and has particular relevance in cases where those genes are associated with diseases such as diabetes, Alzheimer's, cancer, as well as all genes in the genomes of the aforementioned organisms.

[0300] The siRNA selected according to the aforementioned criteria or one of the aforementioned algorithms are also, for example, useful in the simultaneous screening and functional analysis of multiple genes and gene families using high throughput strategies, as well as in direct gene suppression or silencing.

[0301] Development of the Algorithms

[0302] To identify siRNA sequence features that promote functionality and to quantify the importance of certain currently accepted conventional factors—such as G/C content and target site accessibility—the inventors synthesized an siRNA panel consisting of 270 siRNAs targeting three genes, Human Cyclophilin, Firefly Luciferase, and Human DBI. In all three cases, siRNAs were directed against specific regions of each gene. For Human Cyclophilin and Firefly Luciferase, ninety siRNAs were directed against a 199 bp segment of each respective mRNA. For DBI, 90 siRNAs were directed against a smaller, 109 base pair region of the mRNA. The sequences to which the siRNAs were directed are provided below.

[0303] It should be noted that in certain sequences, “t” is present. This is because many databases contain information in this manner. However, the t denotes a uracil residue in mRNA and siRNA. Any algorithm will, unless otherwise specified, process at in a sequence as a u.

[0304]

	Human cyclophilin: 193-390, M60857
	SEQ. ID NO. 0029:
	gttccaaaaa cagtggataa ttttgtggcc ttagctacag

	gagagaaagg atttggctac aaaaacagca aattccatcg

	tgtaatcaag gacttcatga tccagggcgg agacttcacc

	aggggagatg gcacaggagg aaagagcatc tacggtgagc

	gcttccccga tgagaacttc aaactgaagc actacgggcc

	tggctggg

	Firefly luciferase: 1434-1631, U47298 (pGL3,
	Promega)
	SEQ. ID NO. 0030:
	tgaacttccc gccgccgttg ttgttttgga gcacggaaag

	acgatgacgg aaaaagagat cgtggattac gtcgccagtc

	aagtaacaac cgcgaaaaag ttgcgcggag gagttgtgtt

	tgtggacgaa gtaccgaaag gtcttaccgg aaaactcgac

	gcaagaaaaa tcagagagat cctcataaag gccaagaagg

	DBI, NM_020548 (202-310) (every position)
	SEQ. ID NO. 0031:
	acgggcaagg ccaagtggga tgcctggaat gagctgaaag

	ggacttccaa ggaagatgcc atgaaagctt acatcaacaa

	agtagaagag ctaaagaaaa aatacggg

[0305] A list of the siRNAs appears in Table IV (see Examples Section, Example I).

[0306] The set of duplexes was analyzed to identify correlations between siRNA functionality and other biophysical or thermodynamic properties. When the siRNA panel was analyzed in functional and non-functional subgroups, certain nucleotides were much more abundant at certain positions in functional or non-functional groups. More specifically, the frequency of each nucleotide at each position in highly functional siRNA duplexes was compared with that of nonfunctional duplexes in order to assess the preference for or against any given nucleotide at every position. These analyses were used to determine important criteria to be included in the siRNA algorithms (Formulas VIII, IX, and X).

[0307] The data set was also analyzed for distinguishing biophysical properties of siRNAs in the functional group, such as optimal percent of GC content, propensity for internal structures and regional thermodynamic stability. Of the presented criteria, several are involved in duplex recognition, RISC activation/duplex unwinding, and target cleavage catalysis. Random selection yields siRNA duplexes with unpredictable and widely varying silencing potencies as measured in tissue culture using HEK293 cells.

[0308] siRNA identified and optimized in this document work equally well in a wide range of cell types. Each DBI siRNA displays very similar functionality in HEK293 (ATCC, CRL-1573, human embryonic kidney), HeLa (ATCC, CCL-2, cervical epithelial adenocarcinoma) and DU145 (HTB-81, prostate) cells as determined by the B-DNA assay. Thus, siRNA functionality is determined by the primary sequence of the siRNA and not by the intracellular environment. Additionally, it should be noted that although the present invention provides for a determination of the functionality of siRNA for a given target, the same siRNA may silence more than one gene. For example, the complementary sequence of the silencing siRNA may be present in more than one gene. Accordingly, in these circumstances, it may be desirable not to use the siRNA with highest SMARTSCORE™, or siRNA ranking. In such circumstances, it may be desirable to use the siRNA with the next highest SMARTSCORE™, or siRNA ranking.

[0309] To determine the relevance of G/C content in siRNA function, the G/C content of each duplex in the panel was calculated and the functional classes of siRNAs (<F50, ≧F50, ≧F80, ≧F95 where F refers to the percent gene silencing) were sorted accordingly. The majority of the highly functional siRNAs (≧F95) fell within the G/C content range of 36%-52%. Twice as many non-functional (<F50) duplexes fell within the high G/C content groups (>57% GC content) compared to the 36%-52% group. The group with extremely low GC content (26% or less) contained a higher proportion of non-functional siRNAs and no highly functional siRNAs. The G/C content range of 30%-52% was therefore selected as Criterion I for siRNA functionality, consistent with the observation that a G/C range 30%-70% promotes efficient RNAi targeting. Application of this criterion alone provided only a marginal increase in the probability of selecting functional siRNAs from the panel: selection of F50 and F95 siRNAs was improved by 3.6% and 2.2%, respectively. The siRNA panel permitted a more systematic analysis and quantification of the importance of this criterion than that used previously.

[0310] A relative measure of local internal stability is the A/U base pair (bp) content; therefore, the frequency of A/U bp was determined for each of the five terminal positions of the duplex (5′ sense (S)/5′ antisense (AS)) of all siRNAs in the panel. Duplexes were then categorized by the number of A/U bp in positions 1-5 and 15-19 of the sense strand. The thermodynamic flexibility of the duplex 5′-end (positions 1-5; S) did not appear to correlate appreciably with silencing potency, while that of the 3′-end (positions 15-19; S) correlated with efficient silencing. No duplexes lacking A/U bp in positions 15-19 were functional. The presence of one A/U bp in this region conferred some degree of functionality, but the presence of three or more A/Us was preferable and therefore defined as Criterion II. When applied to the test panel, only a marginal increase in the probability of functional siRNA selection was achieved: a 1.8% and 2.3% increase for F50 and F95 duplexes, respectively (Table III).

[0311] The complementary strands of siRNAs that contain internal repeats or palindromes may form internal fold-back structures. These hairpin-like structures exist in equilibrium with the duplexed form effectively reducing the concentration of functional duplexes. The propensity to form internal hairpins and their relative stability can be estimated by predicted melting temperatures. High Tm reflects a tendency to form hairpin structures. Lower Tm values indicate a lesser tendency to form hairpins. When the functional classes of siRNAs were sorted by T_m, the following trends were identified: duplexes lacking stable internal repeats were the most potent silencers (no F95 duplex with predicted hairpin structure T_m>60° C.). In contrast, about 60% of the duplexes in the groups having internal hairpins with calculated T_mvalues less than 20° C. were F80. Thus, the stability of internal repeats is inversely proportional to the silencing effect and defines Criterion III (predicted hairpin structure T_m≧20° C.).

[0312] Sequence-Based Determinants of siRNA Functionality

[0313] When the siRNA panel was sorted into functional and non-functional groups, the frequency of a specific nucleotide at each position in a functional siRNA duplex was compared with that of a nonfunctional duplex in order to assess the preference for or against a certain nucleotide. The data may be separated into two sets: those duplexes that meet the criteria, a specific nucleotide in a certain position—(Selected) and those that do not—(Eliminated). The duplexes were further sorted from most functional to least functional. Statistical analysis revealed correlations between silencing and several sequence-related properties of siRNAs. Table III shows quantitative analysis for the following five sequence-related properties of siRNA: (A) an A at position 19 of the sense strand; (B) an A at position 3 of the sense strand; (C) a U at position 10 of the sense strand; (D) a base other than G at position 13 of the sense strand; and (E) a base other than C at position 19 of the sense strand.

[0314] When the siRNAs in the panel were evaluated for the presence of an A at position 19 of the sense strand, the percentage of non-functional duplexes decreased from 20% to 11.8%, and the percentage of F95 duplexes increased from 21.7% to 29.4% (Table III). Thus, the presence of an A in this position defined Criterion IV.

[0315] Another sequence-related property correlated with silencing was the presence of an A in position 3 of the sense strand. Of the siRNAs with A₃, 34.4% were F95, compared with 21.7% randomly selected siRNAs. The presence of a U base in position 10 of the sense strand exhibited an even greater impact. Of the duplexes in this group, 41.7% were F95. These properties became criteria V and VI, respectively.

[0316] Two negative sequence-related criteria that were identified were the absence of a G at position 13 of the sense strand, which conferred a marginal increase in selecting functional duplexes and lack of a C at position 19 of the sense strand, which also correlated with functionality. Thus, among functional duplexes, position 19 was most likely occupied by A, and rarely occupied by C. These rules were defined as criteria VII and VIII, respectively.

[0317] Application of each criterion individually provided marginal but statistically significant increases in the probability of selecting a potent siRNA. Although the results were informative, the inventors sought to maximize potency and therefore consider multiple criteria or parameters. Optimization is particularly important when developing therapeutics. Interestingly, the probability of selecting a functional siRNA based on each thermodynamic criteria was 2%-4% higher than random, but 4%-8% higher for the sequence-related determinates. Presumably, these sequence-related increases reflect the complexity of the RNAi mechanism and the multitude of protein-RNA interactions that are involved in RNAi-mediated silencing.

[0318]

TABLE III

	PERCENT	IMPROVEMENT
CRITERION	FUNCTIONAL	OVER RANDOM (%)


I. 30%-52% G/C Content	<F50	16.4	−3.6
	≧F50	83.6	3.6
	≧F80	60.4	4.3
	≧F95	23.9	2.2
II. At least 3 A/U bases at	<F50	18.2	−1.8
positions 15-19 of the sense	≧F50	81.8	1.8
strand	≧F80	59.7	3.6
	≧F95	24.0	2.3
III. Absence of internal	<F50	16.7	−3.3
repeats, as measured by Tm of	≧F50	83.3	3.3
secondary structure ≦20° C.	≧F80	61.1	5.0
	≧F95	24.6	2.9
IV. An A base at position 19	<F50	11.8	−8.2
of the sense strand	≧F50	88.2	8.2
	≧F80	75.0	18.9
	≧F95	29.4	7.7
V. An A base at position 3 of	<F50	17.2	−2.8
the sense strand	≧F50	82.8	2.8
	≧F80	62.5	6.4
	≧F95	34.4	12.7
VI. A U base at position 10	<F50	13.9	−6.1
of the sense strand	≧F50	86.1	6.1
	≧F80	69.4	13.3
	≧F95	41.7	20
VII. A base other than C at	<F50	18.8	−1.2
position 19 of the sense strand	≧F50	81.2	1.2
	≧F80	59.7	3.6
	≧F95	24.2	2.5
VIII. A base other than G at	<F50	15.2	−4.8
position 13 of the sense strand	≧F50	84.8	4.8
	≧F80	61.4	5.3
	≧F95	26.5	4.8

[0319] The siRNA Selection Algorithm

[0320] In an effort to improve selection further, all identified criteria, including but not limited to those listed in Table III were combined into the algorithms embodied in Formula VIII, Formula IX, and Formula X. Each siRNA was then assigned a score (referred to as a SMARTSCORE™, or siRNA ranking) according to the values derived from the formulas. Duplexes that scored higher than 0 or −20 (unadjusted), for Formulas VIII and IX, respectively, effectively selected a set of functional siRNAs and excluded all non-functional siRNAs. Conversely, all duplexes scoring lower than 0 and −20 (minus 20) according to formulas VIII and IX, respectively, contained some functional siRNAs but included all non-functional siRNAs. It should be noted that the scores derived from the algorithm can also be provided as “adjusted” scores. To convert Formula VIII unadjusted scores into adjusted scores it is necessary to use the following equation:
(160+unadjusted score)/2.25

[0321] When this takes place, an unadjusted score of “0” (zero) is converted to 75. Similarly, unadjusted scores for Formula X can be converted to adjusted scores. In this instance, the following equation is applied:
(228+unadjusted score)/3.56

[0322] When these manipulations take place, an unadjusted score of 38 is converted to an adjusted score of 75.

[0323] The methods for obtaining the seven criteria embodied in Table III are illustrative of the results of the process used to develop the information for Formulas VIII, IX, and X. Thus similar techniques were used to establish the other variables and their multipliers. As described above, basic statistical methods were use to determine the relative values for these multipliers.

[0324] To determine the value for “Improvement over Random” the difference in the frequency of a given attribute (e.g., GC content, base preference) at a particular position is determined between individual functional groups (e.g., <F50) and the total siRNA population studied (e.g., 270 siRNA molecules selected randomly). Thus, for instance, in Criterion I (30%-52% GC content) members of the <F50 group were observed to have GC contents between 30-52% in 16.4% of the cases. In contrast, the total group of 270 siRNAs had GC contents in this range, 20% of the time. Thus for this particular attribute, there is a small negative correlation between 30%-52% GC content and this functional group (i.e., 16.4%-20%=−3.6%). Similarly, for Criterion VI, (a “U” at position 10 of the sense strand), the >F95 group contained a “U” at this position 41.7% of the time. In contrast, the total group of 270 siRNAs had a “U” at this position 21.7% of the time, thus the improvement over random is calculated to be 20% (or 41.7%-21.7%).

[0325] Identifying The Average Internal Stability Profile of Strong siRNA

[0326] In order to identify an internal stability profile that is characteristic of strong siRNA, 270 different siRNAs derived from the cyclophilin B, the diazepam binding inhibitor (DBI), and the luciferase gene were individually transfected into HEK293 cells and tested for their ability to induce RNAi of the respective gene. Based on their performance in the in vivo assay, the sequences were then subdivided into three groups, (i)>95% silencing; (ii) 80-95% silencing; and (iii) less than 50% silencing. Sequences exhibiting 51-84% silencing were eliminated from further consideration to reduce the difficulties in identifying relevant thermodynamic patterns.

[0327] Following the division of siRNA into three groups, a statistical analysis was performed on each member of each group to determine the average internal stability profile (AISP) of the siRNA. To accomplish this the Oligo 5.0 Primer Analysis Software and other related statistical packages (e.g., Excel) were exploited to determine the internal stability of pentamers using the nearest neighbor method described by Freier et al., (1986) Improved free-energy parameters for predictions of RNA duplex stability, Proc Natl. Acad. Sci. U.S.A. 83(24): 9373-7. Values for each group at each position were then averaged, and the resulting data were graphed on a linear coordinate system with the Y-axis expressing the ΔG (free energy) values in kcal/mole and the X-axis identifying the position of the base relative to the 5′ end.

[0328] The results of the analysis identified multiple key regions in siRNA molecules that were critical for successful gene silencing. At the 3′-most end of the sense strand (5′antisense), highly functional siRNA (>95% gene silencing) have a low internal stability (AISP of position 19=˜−7.6 kcal/mol). In contrast low-efficiency siRNA (i.e., those exhibiting less than 50% silencing, <F50) display a distinctly different profile, having high ΔG values (˜−8.4 kcal/mol) for the same position. Moving in a 5′ (sense strand) direction, the internal stability of highly efficient siRNA rises (position 12 =˜−8.3 kcal/mole) and then drops again (position 7=˜−7.7 kcal/mol) before leveling off at a value of approximately −8.1 kcal/mol for the 5′ terminus. siRNA with poor silencing capabilities show a distinctly different profile. While the AISP value at position 12 is nearly identical with that of strong siRNAs, the values at positions 7 and 8 rise considerably, peaking at a high of ˜−9.0 kcal/mol. In addition, at the 5′ end of the molecule the AISP profile of strong and weak siRNA differ dramatically. Unlike the relatively strong values exhibited by siRNA in the >95% silencing group, siRNAs that exhibit poor silencing activity have weak AISP values (−7.6, −7.5, and −7.5 kcal/mol for positions 1, 2 and 3 respectively).

[0329] Overall the profiles of both strong and weak siRNAs form distinct sinusoidal shapes that are roughly 180° out-of-phase with each other. While these thermodynamic descriptions define the archetypal profile of a strong siRNA, it will likely be the case that neither the ΔG values given for key positions in the profile or the absolute position of the profile along the Y-axis (i.e., the ΔG-axis) are absolutes. Profiles that are shifted upward or downward (i.e., having on an average, higher or lower values at every position) but retain the relative shape and position of the profile along the X-axis can be foreseen as being equally effective as the model profile described here. Moreover, it is likely that siRNA that have strong or even stronger gene-specific silencing effects might have exaggerated ΔG values (either higher or lower) at key positions. Thus, for instance, it is possible that the 5′-most position of the sense strand (position 19) could have ΔG values of 7.4 kcal/mol or lower and still be a strong siRNA if, for instance, a G-C→G-T/U mismatch were substituted at position 19 and altered duplex stability. Similarly, position 12 and position 7 could have values above 8.3 kcal/mol and below 7.7 kcal/mole, respectively, without abating the silencing effectiveness of the molecule. Thus, for instance, at position 12, a stabilizing chemical modification (e.g., a chemical modification of the 2′ position of the sugar backbone) could be added that increases the average internal stability at that position. Similarly, at position 7, mismatches similar to those described previously could be introduced that would lower the ΔG values at that position.

[0330] Lastly, it is important to note that while functional and non-functional siRNA were originally defined as those molecules having specific silencing properties, both broader or more limiting parameters can be used to define these molecules. As used herein, unless otherwise specified, “non-functional siRNA” are defined as those siRNA that induce less than 50% (<50%) target silencing, “semi-functional siRNA” induce 50-79% target silencing, “functional siRNA” are molecules that induce 80-95% gene silencing, and “highly-functional siRNA” are molecules that induce great than 95% gene silencing. These definitions are not intended to be rigid and can vary depending upon the design and needs of the application. For instance, it is possible that a researcher attempting to map a gene to a chromosome using a functional assay, may identify an siRNA that reduces gene activity by only 30%. While this level of gene silencing may be “non-functional” for, e.g., therapeutic needs, it is sufficient for gene mapping purposes and is, under these uses and conditions, “functional.” For these reasons, functional siRNA can be defined as those molecules having greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% silencing capabilities at 100 nM transfection conditions. Similarly, depending upon the needs of the study and/or application, non-functional and semi-functional siRNA can be defined as having different parameters. For instance, semi-functional siRNA can be defined as being those molecules that induce 20%, 30%, 40%, 50%, 60%, or 70% silencing at 100 nM transfection conditions. Similarly, non-functional siRNA can be defined as being those molecules that silence gene expression by less than 70%, 60%, 50%, 40%, 30%, or less. Nonetheless, unless otherwise stated, the descriptions stated in the “Definitions” section of this text should be applied.

[0331] Functional attributes can be assigned to each of the key positions in the AISP of strong siRNA. The low 5′ (sense strand) AISP values of strong siRNAs may be necessary for determining which end of the molecule enters the RISC complex. In contrast, the high and low AISP values observed in the central regions of the molecule may be critical for siRNA-target mRNA interactions and product release, respectively.

[0332] If the AISP values described above accurately define the thermodynamic parameters of strong siRNA, it would be expected that similar patterns would be observed in strong siRNA isolated from nature. Natural siRNAs exist in a harsh, RNase-rich environment and it can be hypothesized that only those siRNA that exhibit heightened affinity for RISC (i.e., siRNA that exhibit an average internal stability profile similar to those observed in strong siRNA) would survive in an intracellular environment. This hypothesis was tested using GFP-specific siRNA isolated from N. benthamiana. Llave et al. (2002) Endogenous and Silencing-Associated Small RNAs in Plants, The Plant Cell 14, 1605-1619, introduced long double-stranded GFP-encoding RNA into plants and subsequently re-isolated GFP-specific siRNA from the tissues. The AISP of fifty-nine of these GFP-siRNA were determined, averaged, and subsequently plotted alongside the AISP profile obtained from the cyclophilin B/DBI/luciferase siRNA having >90% silencing properties. Comparison of the two groups shows that profiles are nearly identical. This finding validates the information provided by the internal stability profiles and demonstrates that: (1) the profile identified by analysis of the cyclophilin B/DBI/luciferase siRNAs are not gene specific; and (2) AISP values can be used to search for strong siRNAs in a variety of species.

[0333] Both chemical modifications and base-pair mismatches can be incorporated into siRNA to alter the duplex's AISP and functionality. For instance, introduction of mismatches at positions 1 or 2 of the sense strand destabilized the 5′ end of the sense strand and increases the functionality of the molecule. Similarly, addition of 2′-O-methyl groups to positions 1 and 2 of the sense strand can also alter the AISP and (as a result) increase both the functionality of the molecule and eliminate off-target effects that results from sense strand homology with the unrelated targets.

[0334] Rationale for Criteria in a Biological Context

[0335] The fate of siRNA in the RNAi pathway may be described in 5 major steps: (1) duplex recognition and pre-RISC complex formation; (2) ATP-dependent duplex unwinding/strand selection and RISC activation; (3) mRNA target identification; (4) mRNA cleavage, and (5) product release. Given the level of nucleic acid-protein interactions at each step, siRNA functionality is likely influenced by specific biophysical and molecular properties that promote efficient interactions within the context of the multi-component complexes. Indeed, the systematic analysis of the siRNA test set identified multiple factors that correlate well with functionality. When combined into a single algorithm, they proved to be very effective in selecting active siRNAs.

[0336] The factors described here may also be predictive of key functional associations important for each step in RNAi. For example, the potential formation of internal hairpin structures correlated negatively with siRNA functionality. Complementary strands with stable internal repeats are more likely to exist as stable hairpins thus decreasing the effective concentration of the functional duplex form. This suggests that the duplex is the preferred conformation for initial pre-RISC association. Indeed, although single complementary strands can induce gene silencing, the effective concentration required is at least two orders of magnitude higher than that of the duplex form.

[0337] siRNA-pre-RISC complex formation is followed by an ATP-dependent duplex unwinding step and “activation” of the RISC. The siRNA functionality was shown to correlate with overall low internal stability of the duplex and low internal stability of the 3′ sense end (or differential internal stability of the 3′ sense compare to the 5′ sense strand), which may reflect strand selection and entry into the RISC. Overall duplex stability and low internal stability at the 3′ end of the sense strand were also correlated with siRNA functionality. Interestingly, siRNAs with very high and very low overall stability profiles correlate strongly with non-functional duplexes. One interpretation is that high internal stability prevents efficient unwinding while very low stability reduces siRNA target affinity and subsequent mRNA cleavage by the RISC.

[0338] Several criteria describe base preferences at specific positions of the sense strand and are even more intriguing when considering their potential mechanistic roles in target recognition and mRNA cleavage. Base preferences for A at position 19 of the sense strand but not C, are particularly interesting because they reflect the same base preferences observed for naturally occurring miRNA precursors. That is, among the reported miRNA precursor sequences 75% contain a U at position 1 which corresponds to an A in position 19 of the sense strand of siRNAs, while G was under-represented in this same position for miRNA precursors. These observations support the hypothesis that both miRNA precursors and siRNA duplexes are processed by very similar if not identical protein machinery. The functional interpretation of the predominance of a U/A base pair is that it promotes flexibility at the 5′antisense ends of both siRNA duplexes and miRNA precursors and facilitates efficient unwinding and selective strand entrance into an activated RISC.

[0339] Among the criteria associated with base preferences that are likely to influence mRNA cleavage or possibly product release, the preference for U at position 10 of the sense strand exhibited the greatest impact, enhancing the probability of selecting an F80 sequence by 13.3%. Activated RISC preferentially cleaves target mRNA between nucleotides 10 and 11 relative to the 5′ end of the complementary targeting strand. Therefore, it may be that U, the preferred base for most endoribonucleases, at this position supports more efficient cleavage. Alternatively, a U/A bp between the targeting siRNA strand and its cognate target mRNA may create an optimal conformation for the RISC-associated “slicing” activity.

[0340] Post Algorithm Filters

[0341] According to another embodiment, the output of any one of the formulas previously listed can be filtered to remove or select for siRNAs containing undesirable or desirable motifs or properties, respectively. In one example, sequences identified by any of the formulas can be filtered to remove any and all sequences that induce toxicity or cellular stress. Introduction of an siRNA containing a toxic motif into a cell can induce cellular stress and/or cell death (apoptosis) which in turn can mislead researchers into associating a particular (e.g., nonessential) gene with, e.g., an essential function. Alternatively, sequences generated by any of the before mentioned formulas can be filtered to identify and retain duplexes that contain toxic motifs. Such duplexes may be valuable from a variety of perspectives including, for instance, uses as therapeutic molecules. A variety of toxic motifs exist and can exert their influence on the cell through RNAi and non-RNAi pathways. Examples of toxic motifs are explained more fully in commonly assigned U.S. Provisional Patent Application Ser. No. 60/538,874, entitled “Identification of Toxic Sequences,” filed Jan. 23, 2004. Briefly, toxic motifs include A/G UUU A/G/U, G/C AAA G/C, and GCCA, or a complement of any of the foregoing.

[0342] In another instance, sequences identified by any of the before mentioned formulas can be filtered to identify duplexes that contain motifs (or general properties) that provide serum stability or induce serum instability. In one envisioned application of siRNA as therapeutic molecules, duplexes targeting disease-associated genes will be introduced into patients intravenously. As the half-life of single and double stranded RNA in serum is short, post-algorithm filters designed to select molecules that contain motifs that enhance duplex stability in the presence of serum and/or (conversely) eliminate duplexes that contain motifs that destabilize siRNA in the presence of serum, would be beneficial.

[0343] In another instance, sequences identified by any of the before mentioned formulas can be filtered to identify duplexes that are hyperfunctional. Hyperfunctional sequences are defined as those sequences that (1) induce greater than 95% silencing of a specific target when they are transfected at subnanomolar concentrations (i.e., less than one nanomolar); and/or (2) induce functional (or better) levels of silencing for greater than 96 hours. Filters that identify hyperfunctional molecules can vary widely. In one example, the top ten, twenty, thirty, or forty siRNA can be assessed for the ability to silence a given target at, e.g., concentrations of 1 nM and 0.5 nM to identify hyperfunctional molecules.

[0344] Pooling

[0345] According to another embodiment, the present invention provides a pool of at least two siRNAs, preferably in the form of a kit or therapeutic reagent, wherein one strand of each of the siRNAs, the sense strand comprises a sequence that is substantially similar to a sequence within a target mRNA. The opposite strand, the antisense strand, will preferably comprise a sequence that is substantially complementary to that of the target mRNA. More preferably, one strand of each siRNA will comprise a sequence that is identical to a sequence that is contained in the target mRNA. Most preferably, each siRNA will be 19 base pairs in length, and one strand of each of the siRNAs will be 100% complementary to a portion of the target mRNA.

[0346] By increasing the number of siRNAs directed to a particular target using a pool or kit, one is able both to increase the likelihood that at least one siRNA with satisfactory functionality will be included, as well as to benefit from additive or synergistic effects. Further, when two or more siRNAs directed against a single gene do not have satisfactory levels of functionality alone, if combined, they may satisfactorily promote degradation of the target messenger RNA and successfully inhibit translation. By including multiple siRNAs in the system, not only is the probability of silencing increased, but the economics of operation are also improved when compared to adding different siRNAs sequentially. This effect is contrary to the conventional wisdom that the concurrent use of multiple siRNA will negatively impact gene silencing (e.g., Holen, T. et al. (2003) “Similar behavior of single strand and double strand siRNAs suggests they act through a common RNAi pathway.” NAR 31: 2401-21407).

[0347] In fact, when two siRNAs were pooled together, 54% of the pools of two siRNAs induced more than 95% gene silencing. Thus, a 2.5-fold increase in the percentage of functionality was achieved by randomly combining two siRNAs. Further, over 84% of pools containing two siRNAs induced more than 80% gene silencing.

[0348] More preferably, the kit is comprised of at least three siRNAs, wherein one strand of each siRNA comprises a sequence that is substantially similar to a sequence of the target mRNA and the other strand comprises a sequence that is substantially complementary to the region of the target mRNA. As with the kit that comprises at least two siRNAs, more preferably one strand will comprise a sequence that is identical to a sequence that is contained in the mRNA and another strand that is 100% complementary to a sequence that is contained in the mRNA. During experiments, when three siRNAs were combined together, 60% of the pools induced more than 95% gene silencing and 92% of the pools induced more than 80% gene silencing.

[0349] Further, even more preferably, the kit is comprised of at least four siRNAs, wherein one strand of each siRNA comprises a sequence that is substantially similar to a region of the sequence of the target mRNA, and the other strand comprises a sequence that is substantially complementary to the region of the target mRNA. As with the kit or pool that comprises at least two siRNAs, more preferably one strand of each of the siRNA duplexes will comprise a sequence that is identical to a sequence that is contained in the mRNA, and another strand that is 100% complementary to a sequence that is contained in the mRNA.

[0350] Additionally, kits and pools with at least five, at least six, and at least seven siRNAs may also be useful with the present invention. For example, pools of five siRNA induced 95% gene silencing with 77% probability and 80% silencing with 98.8% probability. Thus, pooling of siRNAs together can result in the creation of a target-specific silencing reagent with almost a 99% probability of being functional. The fact that such high levels of success are achievable using such pools of siRNA, enables one to dispense with costly and time-consuming target-specific validation procedures.

[0351] For this embodiment, as well as the other aforementioned embodiments, each of the siRNAs within a pool will preferably comprise 18-30 base pairs, more preferably 18-25 base pairs, and most preferably 19 base pairs. Within each siRNA, preferably at least 18 contiguous bases of the antisense strand will be 100% complementary to the target mRNA. More preferably, at least 19 contiguous bases of the antisense strand will be 100% complementary to the target mRNA. Additionally, there may be overhangs on either the sense strand or the antisense strand, and these overhangs may be at either the 5′ end or the 3′ end of either of the strands, for example there may be one or more overhangs of 1-6 bases. When overhangs are present, they are not included in the calculation of the number of base pairs. The two nucleotide 3′ overhangs mimic natural siRNAs and are commonly used but are not essential. Preferably, the overhangs should consist of two nucleotides, most often dTdT or UU at the 3′ end of the sense and antisense strand that are not complementary to the target sequence. The siRNAs may be produced by any method that is now known or that comes to be known for synthesizing double stranded RNA that one skilled in the art would appreciate would be useful in the present invention. Preferably, the siRNAs will be produced by Dharmacon's proprietary ACE® technology. However, other methods for synthesizing siRNAs are well known to persons skilled in the art and include, but are not limited to, any chemical synthesis of RNA oligonucleotides, ligation of shorter oligonucleotides, in vitro transcription of RNA oligonucleotides, the use of vectors for expression within cells, recombinant Dicer products and PCR products.

[0352] The siRNA duplexes within the aforementioned pools of siRNAs may correspond to overlapping sequences within a particular mRNA, or non-overlapping sequences of the mRNA. However, preferably they correspond to non-overlapping sequences. Further, each siRNA may be selected randomly, or one or more of the siRNA may be selected according to the criteria discussed above for maximizing the effectiveness of siRNA.

[0353] Included in the definition of siRNAs are siRNAs that contain substituted and/or labeled nucleotides that may, for example, be labeled by radioactivity, fluorescence or mass. The most common substitutions are at the 2′ position of the ribose sugar, where moieties such as H (hydrogen) F, NH₃, OCH₃and other O— alkyl, alkenyl, alkynyl, and orthoesters, may be substituted, or in the phosphorous backbone, where sulfur, amines or hydrocarbons may be substituted for the bridging of non-bridging atoms in the phosphodiester bond. Examples of modified siRNAs are explained more fully in commonly assigned U.S. patent application Ser. No. 10/613,077, filed Jul. 1, 2003.

[0354] Additionally, as noted above, the cell type into which the siRNA is introduced may affect the ability of the siRNA to enter the cell; however, it does not appear to affect the ability of the siRNA to function once it enters the cell. Methods for introducing double-stranded RNA into various cell types are well known to persons skilled in the art.

[0355] As persons skilled in the art are aware, in certain species, the presence of proteins such as RdRP, the RNA-dependent RNA polymerase, may catalytically enhance the activity of the siRNA. For example, RdRP propagates the RNAi effect in C. elegans and other non-mammalian organisms. In fact, in organisms that contain these proteins, the siRNA may be inherited. Two other proteins that are well studied and known to be a part of the machinery are members of the Argonaute family and Dicer, as well as their homologues. There is also initial evidence that the RISC complex might be associated with the ribosome so the more efficiently translated mRNAs will be more susceptible to silencing than others.

[0356] Another very important factor in the efficacy of siRNA is mRNA localization. In general, only cytoplasmic mRNAs are considered to be accessible to RNAi to any appreciable degree. However, appropriately designed siRNAs, for example, siRNAs modified with internucleotide linkages or 2′-O-methyl groups, may be able to cause silencing by acting in the nucleus. Examples of these types of modifications are described in commonly assigned U.S. patent application Ser. Nos. 10/431,027 and 10/613,077.

[0357] As described above, even when one selects at least two siRNAs at random, the effectiveness of the two may be greater than one would predict based on the effectiveness of two individual siRNAs. This additive or synergistic effect is particularly noticeable as one increases to at least three siRNAs, and even more noticeable as one moves to at least four siRNAs. Surprisingly, the pooling of the non-functional and semi-functional siRNAs, particularly more than five siRNAs, can lead to a silencing mixture that is as effective if not more effective than any one particular functional siRNA.

[0358] Within the kits of the present invention, preferably each siRNA will be present in a concentration of between 0.001 and 200 μM, more preferably between 0.01 and 200 nM, and most preferably between 0.1 and 10 nM.

[0359] In addition to preferably comprising at least four or five siRNAs, the kits of the present invention will also preferably comprise a buffer to keep the siRNA duplex stable. Persons skilled in the art are aware of buffers suitable for keeping siRNA stable. For example, the buffer may be comprised of 100 mM KCl, 30 mM HEPES-pH 7.5, and 1 mM MgCl₂. Alternatively, kits might contain complementary strands that contain any one of a number of chemical modifications (e.g., a 2′-O-ACE) that protect the agents from degradation by nucleases. In this instance, the user may (or may not) remove the modifying protective group (e.g., deprotect) before annealing the two complementary strands together.

[0360] By way of example, the kits may be organized such that pools of siRNA duplexes are provided on an array or microarray of wells or drops for a particular gene set or for unrelated genes. The array may, for example, be in 96 wells, 384 wells or 1284 wells arrayed in a plastic plate or on a glass slide using techniques now known or that come to be known to persons skilled in the art. Within an array, preferably there will be controls such as functional anti-lamin A/C, cyclophilin and two siRNA duplexes that are not specific to the gene of interest.

[0361] In order to ensure stability of the siRNA pools prior to usage, they may be retained in lyophilized form at minus twenty degrees (−20° C.) until they are ready for use. Prior to usage, they should be resuspended; however, even once resuspended, for example, in the aforementioned buffer, they should be kept at minus twenty degrees, (−20° C.) until used. The aforementioned buffer, prior to use, may be stored at approximately 4° C. or room temperature. Effective temperatures at which to conduct transfections are well known to persons skilled in the art and include for example, room temperature.

[0362] The kits may be applied either in vivo or in vitro. Preferably, the siRNA of the pools or kits is applied to a cell through transfection, employing standard transfection protocols. These methods are well known to persons skilled in the art and include the use of lipid-based carriers, electroporation, cationic carriers, and microinjection. Further, one could apply the present invention by synthesizing equivalent DNA sequences (either as two separate, complementary strands, or as hairpin molecules) instead of siRNA sequences and introducing them into cells through vectors. Once in the cells, the cloned DNA could be transcribed, thereby forcing the cells to generate the siRNA. Examples of vectors suitable for use with the present application include but are not limited to the standard transient expression vectors, adenoviruses, retroviruses, lentivirus-based vectors, as well as other traditional expression vectors. Any vector that has an adequate siRNA expression and procession module may be used. Furthermore, certain chemical modifications to siRNAs, including but not limited to conjugations to other molecules, may be used to facilitate delivery. For certain applications it may be preferable to deliver molecules without transfection by simply formulating in a physiological acceptable solution.

[0363] This embodiment may be used in connection with any of the aforementioned embodiments. Accordingly, the sequences within any pool may be selected by rational design.

[0364] Multigene Silencing

[0365] In addition to developing kits that contain multiple siRNA directed against a single gene, another embodiment includes the use of multiple siRNA targeting multiple genes. Multiple genes may be targeted through the use of high- or hyper-functional siRNA. High- or hyper-functional siRNA that exhibit increased potency, require lower concentrations to induce desired phenotypic (and thus therapeutic) effects. This circumvents RISC saturation. It therefore reasons that if lower concentrations of a single siRNA are needed for knockout or knockdown expression of one gene, then the remaining (uncomplexed) RISC will be free and available to interact with siRNA directed against two, three, four, or more, genes. Thus in this embodiment, the authors describe the use of highly functional or hyper-functional siRNA to knock out three separate genes. More preferably, such reagents could be combined to knockout four distinct genes. Even more preferably, highly functional or hyperfunctional siRNA could be used to knock out five distinct genes. Most preferably, siRNA of this type could be used to knockout or knockdown the expression of six or more genes.

[0366] Hyperfunctional siRNA

[0367] The term hyperfunctional siRNA (hf-siRNA) describes a subset of the siRNA population that induces RNAi in cells at low- or sub-nanomolar concentrations for extended periods of time. These traits, heightened potency and extended longevity of the RNAi phenotype, are highly attractive from a therapeutic standpoint. Agents having higher potency require lesser amounts of the molecule to achieve the desired physiological response, thus reducing the probability of side effects due to “off-target” interference. In addition to the potential therapeutic benefits associated with hyperfunctional siRNA, hf-siRNA are also desirable from an economic perspective. Hyperfunctional siRNA may cost less on a per-treatment basis, thus reducing overall expenditures to both the manufacturer and the consumer.

[0368] Identification of hyperfunctional siRNA involves multiple steps that are designed to examine an individual siRNA agent's concentration- and/or longevity-profiles. In one non-limiting example, a population of siRNA directed against a single gene are first analyzed using the previously described algorithm (Formula VIII). Individual siRNA are then introduced into a test cell line and assessed for the ability to degrade the target mRNA. It is important to note that when performing this step it is not necessary to test all of the siRNA. Instead, it is sufficient to test only those siRNA having the highest SMARTSCORES™, or siRNA ranking (i.e., SMARTSCORES™, or siRNA ranking >−10). Subsequently, the gene silencing data was plotted against the SMARTSCORES™, or siRNA rankings. siRNA that (1) induce a high degree of gene silencing (i.e., they induce greater than 80% gene knockdown) and (2) have superior SMARTSCORES™ (i.e., a SMARTSCORE™, or siRNA ranking, of >−10, suggesting a desirable average internal stability profile) are selected for further investigations designed to better understand the molecule's potency and longevity. In one, non-limiting study dedicated to understanding a molecule's potency, an siRNA is introduced into one (or more) cell types in increasingly diminishing concentrations (e.g., 3.0→0.3 nM). Subsequently, the level of gene silencing induced by each concentration is examined and siRNA that exhibit hyperfunctional potency (i.e., those that induce 80% silencing or greater at, e.g., picomolar concentrations) are identified. In a second study, the longevity profiles of siRNA having high (>−10) SMARTSCORES™, or siRNA rankings and greater than 80% silencing are examined. In one non-limiting example of how this is achieved, siRNA are introduced into a test cell line and the levels of RNAi are measured over an extended period of time (e.g., 24-168 hrs). siRNAs that exhibit strong RNA interference patterns (i.e., >80% interference) for periods of time greater than, e.g., 120 hours, are thus identified. Studies similar to those described above can be performed on any and all of the >10⁶siRNA included in this document to further define the most functional molecule for any given gene. Molecules possessing one or both properties (extended longevity and heightened potency) are labeled “hyperfunctional siRNA,” and earmarked as candidates for future therapeutic studies.

[0369] While the example(s) given above describe one means by which hyperfunctional siRNA can be isolated, neither the assays themselves nor the selection parameters used are rigid and can vary with each family of siRNA. Families of siRNA include siRNAs directed against a single gene, or directed against a related family of genes.

[0370] The highest quality siRNA achievable for any given gene may vary considerably. Thus, for example, in the case of one gene (gene X), rigorous studies such as those described above may enable the identification of an siRNA that, at picomolar concentrations, induces 99⁺% silencing for a period of 10 days. Yet identical studies of a second gene (gene Y) may yield an siRNA that at high nanomolar concentrations (e.g., 100 nM) induces only 75% silencing for a period of 2 days. Both molecules represent the very optimum siRNA for their respective gene targets and therefore are designated “hyperfunctional.” Yet due to a variety of factors including but not limited to target concentration, siRNA stability, cell type, off-target interference, and others, equivalent levels of potency and longevity are not achievable. Thus, for these reasons, the parameters described in the before mentioned assays can vary. While the initial screen selected siRNA that had SMARTSCORES™, or siRNA rankings above −10 and a gene silencing capability of greater than 80%, selections that have stronger (or weaker) parameters can be implemented. Similarly, in the subsequent studies designed to identify molecules with high potency and longevity, the desired cutoff criteria (i.e., the lowest concentration that induces a desirable level of interference, or the longest period of time that interference can be observed) can vary. The experimentation subsequent to application of the rational criteria of this application is significantly reduced where one is trying to obtain a suitable hyperfunctional siRNA for, for example, therapeutic use. When, for example, the additional experimentation of the type described herein is applied by one skilled in the art with this disclosure in hand, a hyperfunctional siRNA is readily identified.

[0371] The siRNA may be introduced into a cell by any method that is now known or that comes to be known and that from reading this disclosure, persons skilled in the art would determine would be useful in connection with the present invention in enabling siRNA to cross the cellular membrane. These methods include, but are not limited to, any manner of transfection, such as, for example, transfection employing DEAE-Dextran, calcium phosphate, cationic lipids/liposomes, micelles, manipulation of pressure, microinjection, electroporation, immunoporation, use of vectors such as viruses, plasmids, cosmids, bacteriophages, cell fusions, and coupling of the polynucleotides to specific conjugates or ligands such as antibodies, antigens, or receptors, passive introduction, adding moieties to the siRNA that facilitate its uptake, and the like.

[0372] Having described the invention with a degree of particularity, examples will now be provided. These examples are not intended to and should not be construed to limit the scope of the claims in any way.

EXAMPLES

General Techniques and Nomenclatures

[0373] siRNA nomenclature. All siRNA duplexes are referred to by sense strand. The first nucleotide of the 5′-end of the sense strand is position 1, which corresponds to position 19 of the antisense strand for a 19-mer. In most cases, to compare results from different experiments, silencing was determined by measuring specific transcript mRNA levels or enzymatic activity associated with specific transcript levels, 24 hours post-transfection, with siRNA concentrations held constant at 100 nM. For all experiments, unless otherwise specified, transfection efficiency was ensured to be over 95%, and no detectable cellular toxicity was observed. The following system of nomenclature was used to compare and report siRNA-silencing functionality: “F” followed by the degree of minimal knockdown. For example, F50 signifies at least 50% knockdown, F80 means at least 80%, and so forth. For this study, all sub-F50 siRNAs were considered non-functional.

[0374] Cell culture and transfection. 96-well plates are coated with 50 μl of 50 mg/ml poly-L-lysine (Sigma) for 1 hr, and then washed 3× with distilled water before being dried for 20 min. HEK293 cells or HEK293Lucs or any other cell type of interest are released from their solid support by trypsinization, diluted to 3.5×10⁵cells/ml, followed by the addition of 100 μL of cells/well. Plates are then incubated overnight at 37° C., 5% CO₂. Transfection procedures can vary widely depending on the cell type and transfection reagents. In one non-limiting example, a transfection mixture consisting of 2 mL Opti-MEM I (Gibco-BRL), 80 μl Lipofectamine 2000 (Invitrogen), 15 μL SUPERNasin at 20 U/μl (Ambion), and 1.5 μl of reporter gene plasmid at 1 μg/μl is prepared in 5-ml polystyrene round bottom tubes. One hundred μl of transfection reagent is then combined with 100 μl of siRNAs in polystyrene deep-well titer plates (Beckman) and incubated for 20 to 30 min at room temperature. Five hundred and fifty microliters of Opti-MEM is then added to each well to bring the final siRNA concentration to 100 nM. Plates are then sealed with parafilm and mixed. Media is removed from HEK293 cells and replaced with 95 μl of transfection mixture. Cells are incubated overnight at 37° C., 5% CO₂.

[0375] Quantification of gene knockdown. A variety of quantification procedures can be used to measure the level of silencing induced by siRNA or siRNA pools. In one non-limiting example: to measure mRNA levels 24 hrs post-transfection, QuantiGene branched-DNA (bDNA) kits (Bayer) (Wang, et al, Regulation of insulin preRNA splicing by glucose. Proc. Natl. Acad. Sci. USA 1997, 94:4360.) are used according to manufacturer instructions. To measure luciferase activity, media is removed from HEK293 cells 24 hrs post-transfection, and 50 μl of Steady-GLO reagent (Promega) is added. After 5 minutes, plates are analyzed on a plate reader.

Example I

Sequences Used to Develop the Algorithm

[0376] Anti-Firefly and anti-Cyclophilin siRNAs panels sorted according to using Formula VIII predicted values. All siRNAs scoring more than 0 (formula VIII) and more then 20 (formula IX) are fully functional. All ninety sequences for each gene (and DBI) appear below in Table IV.

[0377]

TABLE IV

Cyclo	1	SEQ ID 0032	GUUCCAAAAACAGUGGAUA

Cyclo	2	SEQ ID 0033	UCCAAAAACAGUGGAUAAU

Cyclo	3	SEQ ID 0034	CAAAAACAGUGGAUAAUUU

Cyclo	4	SEQ ID 0035	AAAACAGUGGAUAAUUUUG

Cyclo	5	SEQ ID 0036	AACAGUGGAUAAUUUUGUG

Cyclo	6	SEQ ID 0037	CAGUGGAUAAUUUUGUGGC

Cyclo	7	SEQ ID 0038	GUGGAUAAUUUUGUGGCCU

Cyclo	8	SEQ ID 0039	GGAUAAUUUUGUGGCCUUA

Cyclo	9	SEQ ID 0040	AUAAUUUUGUGGCCUUAGC

Cyclo	10	SEQ ID 0041	AAUUUUGUGGCCUUAGCUA

Cyclo	11	SEQ ID 0042	UUUUGUGGCCUUAGCUACA

Cyclo	12	SEQ ID 0043	UUGUGGCCUUAGCUACAGG

Cyclo	13	SEQ ID 0044	GUGGCCUUAGCUACAGGAG

Cyclo	14	SEQ ID 0045	GGCCUUAGCUACAGGAGAG

Cyclo	15	SEQ ID 0046	CCUUAGCUACAGGAGAGAA

Cyclo	16	SEQ ID 0047	UUAGCUACAGGAGAGAAAG

Cyclo	17	SEQ ID 0048	AGCUACAGGAGAGAAAGGA

Cyclo	18	SEQ ID 0049	CUACAGGAGAGAAAGGAUU

Cyclo	19	SEQ ID 0050	ACAGGAGAGAAAGGAUUUG

Cyclo	20	SEQ ID 0051	AGGAGAGAAAGGAUUUGGC

Cyclo	21	SEQ ID 0052	GAGAGAAAGGAUUUGGCUA

Cyclo	22	SEQ ID 0053	GAGAAAGGAUUUGGCUACA

Cyclo	23	SEQ ID 0054	GAAAGGAUUUGGCUACAAA

Cyclo	24	SEQ ID 0055	AAGGAUUUGGCUACAAAAA

Cyclo	25	SEQ ID 0056	GGAUUUGGCUACAAAAACA

Cyclo	26	SEQ ID 0057	AUUUGGCUACAAAAACAGC

Cyclo	27	SEQ ID 0058	UUGGCUACAAAAACAGCAA

Cyclo	28	SEQ ID 0059	GGCUACAAAAACAGCAAAU

Cyclo	29	SEQ ID 0060	CUACAAAAACAGCAAAUUC

Cyclo	30	SEQ ID 0061	ACAAAAACAGCAAAUUCCA

Cyclo	31	SEQ ID 0062	AAAAACAGCAAAUUCCAUC

Cyclo	32	SEQ ID 0063	AAACAGCAAAUUCCAUCGU

Cyclo	33	SEQ ID 0064	ACAGCAAAUUCCAUCGUGU

Cyclo	34	SEQ ID 0065	AGCAAAUUCCAUCGUGUAA

Cyclo	35	SEQ ID 0066	CAAAUUCCAUCGUGUAAUC

Cyclo	36	SEQ ID 0067	AAUUCCAUCGUGUAAUCAA

Cyclo	37	SEQ ID 0068	UUCCAUCGUGUAAUCAAGG

Cyclo	38	SEQ ID 0069	CCAUCGUGUAAUCAAGGAC

Cyclo	39	SEQ ID 0070	AUCGUGUAAUCAAGGACUU

Cyclo	40	SEQ ID 0071	CGUGUAAUCAAGGACUUCA

Cyclo	41	SEQ ID 0072	UGUAAUCAAGGACUUCAUG

Cyclo	42	SEQ ID 0073	UAAUCAAGGACUUCAUGAU

Cyclo	43	SEQ ID 0074	AUCAAGGACUUCAUGAUCC

Cyclo	44	SEQ ID 0075	CAAGGACUUCAUGAUCCAG

Cyclo	45	SEQ ID 0076	AGGACUUCAUGAUCCAGGG

Cyclo	46	SEQ ID 0077	GACUUCAUGAUCCAGGGCG

Cyclo	47	SEQ ID 0078	CUUCAUGAUCCAGGGCGGA

Cyclo	48	SEQ ID 0079	UCAUGAUCCAGGGCGGAGA

Cyclo	49	SEQ ID 0080	AUGAUCCAGGGCGGAGACU

Cyclo	50	SEQ ID 0081	CAUCCAGGGCGGAGACUUC

Cyclo	51	SEQ ID 0082	UCCAGGGCGGAGACUUCAC

Cyclo	52	SEQ ID 0083	CAGGGCGGAGACUUCACCA

Cyclo	53	SEQ ID 0084	GGGCGGAGACUUCACCAGG

Cyclo	54	SEQ ID 0085	GCGGAGACUUCACCAGGGG

Cyclo	55	SEQ ID 0086	GGAGACUUCACCAGGGGAG

Cyclo	56	SEQ ID 0087	AGACUUCACCAGGGGAGAU

Cyclo	57	SEQ ID 0088	ACUUCACCAGGGGAGAUGG

Cyclo	58	SEQ ID 0089	UUCACCAGGGGAGAUGGCA

Cyclo	59	SEQ ID 0090	CACCAGGGGAGAUGGCACA

Cyclo	60	SEQ ID 0091	CCAGGGGAGAUGGCACAGG

Cyclo	61	SEQ ID 0092	AGGGGAGAUGGCACAGGAG

Cyclo	62	SEQ ID 0093	GGGAGAUGGCACAGGAGGA

Cyclo	63	SEQ ID 0427	GAGAUGGCACAGGAGGAAA

Cyclo	64	SEQ ID 0095	GAUGGCACAGGAGGAAAGA

Cyclo	65	SEQ ID 0094	UGGCACAGGAGGAAAGAGC

Cyclo	66	SEQ ID 0096	GCACAGGAGGAAAGAGCAU

Cyclo	67	SEQ ID 0097	ACAGGAGGAAAGAGCAUCU

Cyclo	68	SEQ ID 0098	AGGAGGAAAGAGCAUCUAC

Cyclo	69	SEQ ID 0099	GAGGAAAGAGCAUCUACGG

Cyclo	70	SEQ ID 0100	GGAAAGAGCAUCUACGGUG

Cyclo	71	SEQ ID 0101	AAAGAGCAUCUACGGUGAG

Cyclo	72	SEQ ID 0102	AGAGCAUCUACGGUGAGCG

Cyclo	73	SEQ ID 0103	AGCAUCUACGGUGAGCGCU

Cyclo	74	SEQ ID 0104	CAUCUACGGUGAGCGCUUC

Cyclo	75	SEQ ID 0105	UCUACGGUGAGCGCUUCCC

Cyclo	76	SEQ ID 0106	UACGGUGAGCGCUUCCCCG

Cyclo	77	SEQ ID 0107	CGGUGAGCGCUUCCCCGAU

Cyclo	78	SEQ ID 0108	GUGAGCGCUUCCCCGAUGA

Cyclo	79	SEQ ID 0109	GAGCGCUUCCCCGAUGAGA

Cyclo	80	SEQ ID 0110	GCGCUUCCCCGAUGAGAAC

Cyclo	81	SEQ ID 0111	GCUUCCCCGAUGAGAACUU

Cyclo	82	SEQ ID 0112	UUCCCCGAUGAGAACUUCA

Cyclo	83	SEQ ID 0113	CCCCGAUGAGAACUUCAAA

Cyclo	84	SEQ ID 0114	CCGAUCAGAACUUCAAACU

Cyclo	85	SEQ ID 0115	GAUGAGAACUUCAAACUGA

Cyclo	86	SEQ ID 0116	UGAGAACUUCAAACUGAAG

Cyclo	87	SEQ ID 0117	AGAACUUCAAACUGAAGCA

Cyclo	88	SEQ ID 0118	AACUUCAAACUGAAGCACU

Cyclo	89	SEQ ID 0119	CUUCAAACUGAAGCACUAC

Cyclo	90	SEQ ID 0120	UCAAACUGAAGCACUACGG

DB	1	SEQ ID 0121	ACGGGCAAGGCCAAGUGGG

DB	2	SEQ ID 0122	CGGGCAAGGCCAAGUGGGA

DB	3	SEQ ID 0123	GGGCAAGGCCAAGUGGGAU

DB	4	SEQ ID 0124	GGCAAGGCCAAGUGGGAUG

DB	5	SEQ ID 0125	GCAAGGCCAAGUGGGAUGC

DB	6	SEQ ID 0126	CAAGGCCAAGUGGGAUGCC

DB	7	SEQ ID 0127	AAGGCCAAGUGGGAUGCCU

DB	8	SEQ ID 0128	AGGCCAAGUGGGAUGCCUG

DB	9	SEQ ID 0129	GGCCAAGUGGGAUGCCUGG

DB	10	SEQ ID 0130	GCCAAGUGGGAUGCCUGGA

DB	11	SEQ ID 0131	CCAAGUGGGAUGCCUGGAA

DB	12	SEQ ID 0132	CAAGUGGGAUGCCUGGAAU

DB	13	SEQ ID 0133	AAGUGGGAUGCCUGGAAUG

DB	14	SEQ ID 0134	AGUGGGAUGCCUGGAAUGA

DB	15	SEQ ID 0135	GUGGGAUGCCUGGAAUGAG

DB	16	SEQ ID 0136	UGGGAUGCCUGGAAUGAGC

DB	17	SEQ ID 0137	GGGAUGCCUGGAAUGAGCU

DB	18	SEQ ID 0138	GGAUGCCUGGAAUGAGCUG

DB	19	SEQ ID 0139	GAUGCCUGGAAUGAGCUGA

DB	20	SEQ ID 0140	AUGCCUGGAAUGAGCUGAA

DB	21	SEQ ID 0141	UGCCUGGAAUGAGCUGAAA

DB	22	SEQ ID 0142	GCCUGGAAUGAGCUGAAAG

DB	23	SEQ ID 0143	CCUGGAAUGAGCUGAAAGG

DB	24	SEQ ID 0144	CUGGAAUGAGCUGAAAGGG

DB	25	SEQ ID 0145	UGGAAUGAGCUGAAAGGGA

DB	26	SEQ ID 0146	GGAAUGAGCUGAAAGGGAC

DB	27	SEQ ID 0147	GAAUGAGCUGAAAGGGACU

DB	28	SEQ ID 0148	AAUGAGCUGAAAGGGACUU

DB	29	SEQ ID 0149	AUGAGCUGAAAGGGACUUC

DB	30	SEQ ID 0150	UGAGCUGAAAGGGACUUCC

DB	31	SEQ ID 0151	GAGCUGAAAGGGACUUCCA

DB	32	SEQ ID 0152	AGCUGAAAGGGACUUCCAA

DB	33	SEQ ID 0153	GCUGAAAGGGACUUCCAAG

DB	34	SEQ ID 0154	CUGAAAGGGACUUCCAAGG

DB	35	SEQ ID 0155	UGAAAGGGACUUCCAAGGA

DB	36	SEQ ID 0156	GAAAGGGACUUCCAAGGAA

DB	37	SEQ ID 0157	AAAGGGACUUCCAAGGAAG

DB	38	SEQ ID 0158	AAGGGACUUCCAAGGAAGA

DB	39	SEQ ID 0159	AGGGACUUCCAAGGAAGAU

DB	40	SEQ ID 0160	GGGACUUCCAAGGAAGAUG

DB	41	SEQ ID 0161	GGACUUCCAAGGAAGAUGC

DB	42	SEQ ID 0162	GACUUCCAAGGAAGAUGCC

DB	43	SEQ ID 0163	ACUUCCAAGGAAGAUGCCA

DB	44	SEQ ID 0164	CUUCCAAGGAAGAUGCCAU

DB	45	SEQ ID 0165	UUCCAAGGAAGAUGCCAUG

DB	46	SEQ ID 0166	UCCAAGGAAGAUGCCAUGA

DB	47	SEQ ID 0167	CCAAGGAAGAUGCCAUGAA

DB	48	SEQ ID 0168	CAAGGAAGAUGCCAUGAAA

DB	49	SEQ ID 0169	AAGGAAGAUGCCAUGAAAG

DB	50	SEQ ID 0170	AGGAAGAUGCCAUGAAAGC

DB	51	SEQ ID 0171	GGAAGAUGCCAUGAAAGCU

DB	52	SEQ ID 0172	GAAGAUGCCAUGAAAGCUU

DB	53	SEQ ID 0173	AAGAUGCCAUGAAAGCUUA

DB	54	SEQ ID 0174	AGAUGCCAUGAAAGCUUAC

DB	55	SEQ ID 0175	GAUGCCAUGAAAGCUUACA

DB	56	SEQ ID 0176	AUGCCAUGAAAGCUUACAU

DB	57	SEQ ID 0177	UGCCAUGAAAGCUUACAUC

DB	58	SEQ ID 0178	GCCAUGAAAGCUUACAUCA

DB	59	SEQ ID 0179	CCAUGAAAGCUUACAUCAA

DB	60	SEQ ID 0180	CAUGAAAGCUUACAUCAAC

DB	61	SEQ ID 0181	AUGAAAGCUUACAUCAACA

DB	62	SEQ ID 0182	UGAAAGCUUACAUCAACAA

DB	63	SEQ ID 0183	GAAAGCUUACAUCAACAAA

DB	64	SEQ ID 0184	AAAGCUUACAUCAACAAAG

DB	65	SEQ ID 0185	AAGCUUACAUCAACAAAGU

DB	66	SEQ ID 0186	AGCUUACAUCAACAAAGUA

DB	67	SEQ ID 0187	GCUUACAUCAACAAAGUAG

DB	68	SEQ ID 0188	CUUACAUCAACAAAGUAGA

DB	69	SEQ ID 0189	UUACAUCAACAAAGUAGAA

DB	70	SEQ ID 0190	UACAUCAACAAAGUAGAAG

DB	71	SEQ ID 0191	ACAUCAACAAAGUAGAAGA

DB	72	SEQ ID 0192	CAUCAACAAAGUAGAAGAG

DB	73	SEQ ID 0193	AUCAACAAAGUAGAAGAGC

DB	74	SEQ ID 0194	UCAACAAAGUAGAAGAGCU

DB	75	SEQ ID 0195	CAACAAAGUAGAAGAGCUA

DB	76	SEQ ID 0196	AACAAAGUAGAAGAGCUAA

DB	77	SEQ ID 0197	ACAAAGUAGAAGAGCUAAA

DB	78	SEQ ID 0198	CAAAGUAGAAGAGCUAAAG

DB	79	SEQ ID 0199	AAAGUAGAAGAGCUAAAGA

DB	80	SEQ ID 0200	AAGUAGAAGAGCUAAAGAA

DB	81	SEQ ID 0201	AGUAGAAGAGCUAAAGAAA

DB	82	SEQ ID 0202	GUAGAAGAGCUAAAGAAAA

DB	83	SEQ ID 0203	UAGAAGAGCUAAAGAAAAA

DB	84	SEQ ID 0204	AGAAGAGCUAAAGAAAAAA

DB	85	SEQ ID 0205	GAAGAGCUAAAGAAAAAAU

DB	86	SEQ ID 0206	AAGAGCUAAAGAAAAAAUA

DB	87	SEQ ID 0207	AGAGCUAAAGAAAAAAUAC

DB	88	SEQ ID 0208	GAGCUAAAGAAAAAAUACG

DB	89	SEQ ID 0209	AGCUAAAGAAAAAAUACGG

DB	90	SEQ ID 0210	GCUAAAGAAAAAAUACGGG

Luc	1	SEQ ID 0211	AUCCUCAUAAAGGCCAAGA

Luc	2	SEQ ID 0212	AGAUCCUCAUAAAGGCCAA

Luc	3	SEQ ID 0213	AGAGAUCCUCAUAAAGGCC

Luc	4	SEQ ID 0214	AGAGAGAUCCUCAUAAAGG

Luc	5	SEQ ID 0215	UCAGAGAGAUCCUCAUAAA

Luc	6	SEQ ID 0216	AAUCAGAGAGAUCCUCAUA

Luc	7	SEQ ID 0217	AAAAUCAGAGAGAUCCUCA

Luc	8	SEQ ID 0218	GAAAAAUCAGAGAGAUCCU

Luc	9	SEQ ID 0219	AAGAAAAAUCAGAGAGAUC

Luc	10	SEQ ID 0220	GCAAGAAAAAUCAGAGAGA

Luc	11	SEQ ID 0221	ACGCAAGAAAAAUCAGAGA

Luc	12	SEQ ID 0222	CGACGCAAGAAAAAUCAGA

Luc	13	SEQ ID 0223	CUCGACGCAAGAAAAAUCA

Luc	14	SEQ ID 0224	AACUCGACGCAAGAAAAAU

Luc	15	SEQ ID 0225	AAAACUCGACGCAAGAAAA

Luc	16	SEQ ID 0226	GGAAAACUCGACGCAAGAA

Luc	17	SEQ ID 0227	CCGGAAAACUCGACGCAAG

Luc	18	SEQ ID 0228	UACCGGAAAACUCGACGCA

Luc	19	SEQ ID 0229	CUUACCGGAAAACUCGACG

Luc	20	SEQ ID 0230	GUCUUACCGGAAAACUCGA

Luc	21	SEQ ID 0231	AGGUCUUACCGGAAAACUC

Luc	22	SEQ ID 0232	AAAGGUCUUACGGGAAAAC

Luc	23	SEQ ID 0233	CGAAAGGUCUUACCGGAAA

Luc	24	SEQ ID 0234	ACCGAAAGGUCUUACCGGA

Luc	25	SEQ ID 0235	GUACCGAAAGGUCUUACCG

Luc	26	SEQ ID 0236	AAGUACCGAAAGGUCUUAC

Luc	27	SEQ ID 0237	CGAAGUACCGAAAGGUCUU

Luc	28	SEQ ID 0238	GACGAAGUACCGAAAGGUC

Luc	29	SEQ ID 0239	UGGACGAAGUACCGAAAGG

Luc	30	SEQ ID 0240	UGUGGACGAAGUACCGAAA

Luc	31	SEQ ID 0241	UUUGUGGACGAAGUACCGA

Luc	32	SEQ ID 0242	UGUUUGUGGACGAAGUACC

Luc	33	SEQ ID 0243	UGUGUUUGUGGACGAAGUA

Luc	34	SEQ ID 0244	GUUGUGUUUGUGGACGAAG

Luc	35	SEQ ID 0245	GAGUUGUGUUUGUGGACGA

Luc	36	SEQ ID 0246	AGGAGUUGUGUUUGUGGAC

Luc	37	SEQ ID 0247	GGAGGAGUUGUGUUUGUGG

Luc	38	SEQ ID 0248	GCGGAGGAGUUGUGUUUGU

Luc	39	SEQ ID 0249	GCGCGGAGGAGUUGUGUUU

Luc	40	SEQ ID 0250	UUGCGCGGAGGAGUUGUGU

Luc	41	SEQ ID 0251	AGUUGCGCGGAGGAGUUGU

Luc	42	SEQ ID 0252	AAAGUUGCGCGGAGGAGUU

Luc	43	SEQ ID 0253	AAAAAGUUGCGCGGAGGAG

Luc	44	SEQ ID 0254	CGAAAAAGUUGCGCGGAGG

Luc	45	SEQ ID 0255	CGCGAAAAAGUUGCGCGGA

Luc	46	SEQ ID 0256	ACCGCGAAAAAGUUGCGCG

Luc	47	SEQ ID 0257	CAACCGCGAAAAAGUUGCG

Luc	48	SEQ ID 0258	AACAACCGCGAAAAAGUUG

Luc	49	SEQ ID 0259	GUAACAACCGCGAAAAAGU

Luc	50	SEQ ID 0260	AAGUAACAACCGCGAAAAA

Luc	51	SEQ ID 0261	UCAAGUAACAACCGCGAAA

Luc	52	SEQ ID 0262	AGUCAAGUAACAACCGCGA

Luc	53	SEQ ID 0263	CCAGUCAAGUAACAACCGC

Luc	54	SEQ ID 0264	CGCCAGUCAAGUAACAACC

Luc	55	SEQ ID 0265	GUCGCCAGUCAAGUAACAA

Luc	56	SEQ ID 0266	ACGUCGCCAGUCAAGUAAC

Luc	57	SEQ ID 0267	UUACGUCGCCAGUCAAGUA

Luc	58	SEQ ID 0268	GAUUACGUCGCCAGUCAAG

Luc	59	SEQ ID 0269	UGGAUUACGUCGCCAGUCA

Luc	60	SEQ ID 0270	CGUGGAUUACGUCGCCAGU

Luc	61	SEQ ID 0271	AUCGUGGAUUACGUCGCCA

Luc	62	SEQ ID 0272	AGAUCGUGGAUUACGUCGC

Luc	63	SEQ ID 0273	AGAGAUCGUGGAUUACGUC

Luc	64	SEQ ID 0274	AAAGAGAUCGUGGAUUACG

Luc	65	SEQ ID 0275	AAAAAGAGAUCGUGGAUUA

Luc	66	SEQ ID 0276	GGAAAAAGAGAUCGUGGAU

Luc	67	SEQ ID 0277	ACGGAAAAAGAGAUCGUGG

Luc	68	SEQ ID 0278	UGACGGAAAAAGAGAUCGU

Luc	69	SEQ ID 0279	GAUGACGGAAAAAGAGAUC

Luc	70	SEQ ID 0280	ACGAUGACGGAAAAAGAGA

Luc	71	SEQ ID 0281	AGACGAUGACGGAAAAAGA

Luc	72	SEQ ID 0282	AAAGACGAUGACGGAAAAA

Luc	73	SEQ ID 0283	GGAAAGACGAUGACGGAAA

Luc	74	SEQ ID 0284	ACGGAAAGACGAUGACGGA

Luc	75	SEQ ID 0285	GCACGGAAAGACGAUGACG

Luc	76	SEQ ID 0286	GAGCACGGAAAGACGAUGA

Luc	77	SEQ ID 0287	UGGAGCACGGAAAGACGAU

Luc	78	SEQ ID 0288	UUUGGAGCACGGAAAGACG

Luc	79	SEQ ID 0289	GUUUUGGAGCACGGAAAGA

Luc	80	SEQ ID 0290	UUGUUUUGGAGCACGGAAA

Luc	81	SEQ ID 0291	UGUUGUUUUGGAGCACGGA

Luc	82	SEQ ID 0292	GUUGUUGUUUUGGAGCACG

Luc	83	SEQ ID 0293	CCGUUGUUGUUUUGGAGCA

Luc	84	SEQ ID 0294	CGCCGUUGUUGUUUUGGAG

Luc	85	SEQ ID 0295	GCCGCCGUUGUUGUUUUGG

Luc	86	SEQ ID 0296	CCGCCGCCGUUGUUGUUUU

Luc	87	SEQ ID 0297	UCCCGCCGCCGUUGUUGUU

Luc	88	SEQ ID 0298	CUUCCCGCCGCCGUUGUUG

Luc	89	SEQ ID 0299	AACUUCCCGCCGCCGUUGU

Luc	90	SEQ ID 0300	UGAACUUCCCGCCGCCGUU

Example II

Validation of the Algorithm Using DBI, Luciferase, PLK, EGFR, and SEAP

[0378] The algorithm (Formula VIII) identified siRNAs for five genes, human DBI, firefly luciferase (fluc), renilla luciferase (rLuc), human PLK, and human secreted alkaline phosphatase (SEAP). Four individual siRNAs were selected on the basis of their SMARTSCORES™, or siRNA ranking derived by analysis of their sequence using Formula VIII (all of the siRNAs would be selected with Formula IX as well) and analyzed for their ability to silence their targets' expression. In addition to the scoring, a BLAST search was conducted for each siRNA. To minimize the potential for off-target silencing effects, only those target sequences with more than three mismatches against un-related sequences were selected. Semizarov, et al, Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6347. These duplexes were analyzed individually and in pools of 4 and compared with several siRNAs that were randomly selected. The functionality was measured as a percentage of targeted gene knockdown as compared to controls. All siRNAs were transfected as described by the methods above at 100 nM concentration into HEK293 using Lipofectamine 2000. The level of the targeted gene expression was evaluated by B-DNA as described above and normalized to the non-specific control. The siRNAs selected by the algorithm disclosed herein were significantly more potent than randomly selected siRNAs. The algorithm increased the chances of identifying an F50 siRNA from 48% to 91%, and an F80 siRNA from 13% to 57%. In addition, pools of SMART siRNA silence the selected target better than randomly selected pools.

Example III

Validation of the Algorithm Using Genes Involved in Clathrin-Dependent Endocytosis

[0379] Components of clathrin-mediated endocytosis pathway are key to modulating intracellular signaling and play important roles in disease. Chromosomal rearrangements that result in fusion transcripts between the Mixed-Lineage Leukemia gene (MLL) and CALM (clathrin assembly lymphoid myeloid leukemia gene) are believed to play a role in leukemogenesis. Similarly, disruptions in Rab7 and Rab9, as well as HIP1 (Huntingtin-interacting protein), genes that are believed to be involved in endocytosis, are potentially responsible for ailments resulting in lipid storage, and neuronal diseases, respectively. For these reasons, siRNA directed against clathrin and other genes involved in the clathrin-mediated endocytotic pathway are potentially important research and therapeutic tools.

[0380] siRNAs directed against genes involved in the clathrin-mediated endocytosis pathways were selected using Formula VIII. The targeted genes were clathrin heavy chain (CHC, accession # NM_—004859), clathrin light chain A (CLCa, NM_—001833), clathrin light chain B (CLCb, NM_—001834), CALM (U45976), β2 subunit of AP-2 (α2, NM_—001282), Eps15 (NM_—001981), Eps15R(NM_—021235), dynamin II (DYNII, NM_—004945), Rab5a (BC001267), Rab5b (NM_—002868), Rab5c (AF141304), and EEA.1 (XM_—018197).

[0381] For each gene, four siRNAs duplexes with the highest scores were selected and a BLAST search was conducted for each of them using the Human EST database. In order to minimize the potential for off-target silencing effects, only those sequences with more than three mismatches against un-related sequences were used. All duplexes were synthesized at Dharmacon, Inc. as 21-mers with 3′-UU overhangs using a modified method of 2′-ACE chemistry, Scaringe, Advanced 5′-silyl-2′-orthoester approach to RNA oligonucleotide synthesis, Methods Enzymol. 2000, 317:3, and the antisense strand was chemically phosphorylated to insure maximized activity.

[0382] HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, antibiotics and glutamine. siRNA duplexes were resuspended in 1×siRNA Universal buffer (Dharmacon, Inc.) to 20 μM prior to transfection. HeLa cells in 12-well plates were transfected twice with 4 μl of 20 μM siRNA duplex in 3 μl Lipofectamine 2000 reagent (Invitrogen, Carlsbad, Calif., USA) at 24-hour intervals. For the transfections in which 2 or 3 siRNA duplexes were included, the amount of each duplex was decreased, so that the total amount was the same as in transfections with single siRNAs. Cells were plated into normal culture medium 12 hours prior to experiments, and protein levels were measured 2 or 4 days after the first transfection.

[0383] Equal amounts of lysates were resolved by electrophoresis, blotted, and stained with the antibody specific to targeted protein, as well as antibodies specific to unrelated proteins, PP1 phosphatase and Tsg101 (not shown). The cells were lysed in Triton X-100/glycerol solubilization buffer as described previously. Tebar, Bohlander, & Sorkin, Clathrin Assembly Lymphoid Myeloid Leukemia (CALM) Protein: Localization in Endocytic-coated Pits, Interactions with Clathrin, and the Impact of Overexpression on Clathrin-mediated Traffic, Mol. Biol. Cell August 1999, 10:2687. Cell lysates were electrophoresed, transferred to nitrocellulose membranes, and Western blotting was performed with several antibodies followed by detection using enhanced chemiluminescence system (Pierce, Inc). Several x-ray films were analyzed to determine the linear range of the chemiluminescence signals, and the quantifications were performed using densitometry and AlphaImager v5.5 software (Alpha Innotech Corporation). In experiments with Eps15R-targeted siRNAs, cell lysates were subjected to immunoprecipitation with Ab860, and Eps 15R was detected in immunoprecipitates by Western blotting as described above.

[0384] The antibodies to assess the levels of each protein by Western blot were obtained from the following sources: monoclonal antibody to clathrin heavy chain (TD.1) was obtained from American Type Culture Collection (Rockville, Md., USA); polyclonal antibody to dynamin II was obtained from Affinity Bioreagents, Inc. (Golden, Colo., USA); monoclonal antibodies to EEA. 1 and Rab5a were purchased from BD Transduction Laboratories (Los Angeles, Calif., USA); the monoclonal antibody to Tsg101 was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif., USA); the monoclonal antibody to GFP was from ZYMED Laboratories Inc. (South San Francisco, Calif., USA); the rabbit polyclonal antibodies Ab32 specific to α-adaptins and Ab20 to CALM were described previously Sorkin, et al., Stoichiometric Interaction of the Epidermal Growth Factor Receptor with the Clathrin-associated Protein Complex AP-2, J. Biol. Chem. January 1995, 270:619, the polyclonal antibodies to clathrin light chains A and B were kindly provided by Dr. F. Brodsky (UCSF); monoclonal antibodies to PP1 (BD Transduction Laboratories) and α-Actinin (Chemicon) were kindly provided by Dr. M. Dell'Acqua (University of Colorado); Eps15 Ab577 and Eps 15R Ab860 were kindly provided by Dr. P. P. Di Fiore (European Cancer Institute).

[0385] The in vivo functionality of 48 individual siRNAs, selected using Formula VIII (most of them will meet the criteria incorporated by Formula IX as well) targeting 12 genes. Various cell lines were transfected with siRNA duplexes or pools of siRNA duplexes (Pool), and the cells were lysed 3 days after transfection with the exception of CALM (2 days) and β2 (4 days).

[0386] Note a β1-adaptin band (part of AP-1 Golgi adaptor complex) that runs slightly slower than β2 adaptin. CALM has two splice variants, 66 and 72 kD. The full-length Eps15R (a doublet of ˜130 kD) and several truncated spliced forms of ˜100 kD and ˜70 kD were detected in Eps15R immunoprecipitates (shown by arrows). The cells were lysed 3 days after transfection. Equal amounts of lysates were resolved by electrophoresis and blotted with the antibody specific to a targeted protein (GFP antibody for YFP fusion proteins) and the antibody specific to unrelated proteins PP1 phosphatase or α-actinin, and TSG101. The amount of protein in each specific band was normalized to the amount of non-specific proteins in each lane of the gel. Nearly all of them appear to be functional, which establishes that Formula VIII and IX can be used to predict siRNAs' functionality in general in a genome wide manner.

[0387] To generate the fusion of yellow fluorescent protein (YFP) with Rab5b or Rab5c (YFP-Rab5b or YFP-Rab5c), a DNA fragment encoding the full-length human Rab5b or Rab5c was obtained by PCR using Pfu polymerase (Stratagene) with a SacI restriction site introduced into the 5′ end and a KpnI site into the 3′ end and cloned into pEYFP-C1 vector (CLONTECH, Palo Alto, Calif., USA). GFP-CALM and YFP-Rab5a were described previously Tebar, Bohlander, & Sorkin, Clathrin Assembly Lymphoid Myeloid Leukemia (CALAM) Protein: Localization in Endocytic-coated Pits, Interactions with Clathrin, and the Impact of Overexpression on Clathrin-mediated Traffic, Mol. Biol. Cell August 1999, 10:2687.

Example IV

Validation of the Algorithm Using Eg5, GADPH, ATE1, MEK2, MEK1, QB, LaminA/C, c-myc, Human Cyclophilin, and Mouse Cyclophilin.

[0388] A number of genes have been identified as playing potentially important roles in disease etiology. Expression profiles of normal and diseased kidneys have implicated Edg5 in immunoglobulin A neuropathy, a common renal glomerular disease. Myc1, MEK1/2 and other related kinases have been associated with one or more cancers, while lamins have been implicated in muscular dystrophy and other diseases. For these reasons, siRNA directed against the genes encoding these classes of molecules would be important research and therapeutic tools.

Example V

Validation of the Algorithm Using BCL2

[0389] Bcl-2 is a ˜25 kD, 205-239 amino acid, anti-apoptotic protein that contains considerable homology with other members of the BCL family including BCLX, MCL1, BAX, BAD, and BIK. The protein exists in at least two forms (Bcl2a, which has a hydrophobic tail for membrane anchorage, and Bcl2b, which lacks the hydrophobic tail) and is predominantly localized to the mitochondrial membrane. While Bcl2 expression is widely distributed, particular interest has focused on the expression of this molecule in B and T cells. Bcl2 expression is down-regulated in normal germinal center B cells yet in a high percentage of follicular lymphomas, Bcl2 expression has been observed to be elevated. Cytological studies have identified a common translocation ((14; 18)(q32; q32)) amongst a high percentage (>70%) of these lymphomas. This genetic lesion places the Bcl2 gene in juxtaposition to immunoglobulin heavy chain gene (IgH) encoding sequences and is believed to enforce inappropriate levels of gene expression, and resistance to programmed cell death in the follicle center B cells. In other cases, hypomethylation of the Bcl2 promoter leads to enhanced expression and again, inhibition of apoptosis. In addition to cancer, dysregulated expression of Bcl-2 has been correlated with multiple sclerosis and various neurological diseases.

[0390] The correlation between Bcl-2 translocation and cancer makes this gene an attractive target for RNAi. Identification of siRNA directed against the bcl2 transcript (or Bcl2-IgH fusions) would further our understanding Bcl2 gene function and possibly provide a future therapeutic agent to battle diseases that result from altered expression or function of this gene.

[0391] In Silico Identification of Functional siRNA

[0392] To identify functional and hyperfunctional siRNA against the Bcl2 gene, the sequence for Bcl-2 was downloaded from the NCBI Unigene database and analyzed using the Formula VIII algorithm. As a result of these procedures, both the sequence and SMARTSCORES™, or siRNA rankings of the Bcl2 siRNA were obtained and ranked according to their functionality. Subsequently, these sequences were BLAST'ed (database) to insure that the selected sequences were specific and contained minimal overlap with unrealated genes.

[0393] In Vivo Testing of Bcl-2 SiRNA

[0394] Bcl-2 siRNAs having the top ten SMARTSCORES™, or siRNA rankings were selected and tested in a functional assay to determine silencing efficiency. To accomplish this, each of the ten duplexes were synthesized using 2′-O-ACE chemistry and transfected at 100 nM concentrations into cells. Twenty-four hours later assays were performed on cell extracts to assess the degree of target silencing. Controls used in these experiments included mock transfected cells, and cells that were transfected with a non-specific siRNA duplex.

[0395] The results of these experiments show that all ten of the selected siRNA induce 80% or better silencing of the Bcl2 message at 100 nM concentrations. These data verify that the algorithm successfully identified functional Bcl2 siRNA and provide a set of functional agents that can be used in experimental and therapeutic environments.

[0396]

siRNA 1	GGGAGAUAGUGAUGAAGUA	SEQ. ID NO. 301

siRNA 2	GAAGUACAUCCAUUAUAAG	SEQ. ID NO. 302

siRNA 3	GUACGACAACCGGGAGAUA	SEQ. ID NO. 303

siRNA 4	AGAUAGUGAUGAAGUACAU	SEQ. ID NO. 304

siRNA 5	UGAAGACUCUGCUCAGUUU	SEQ. ID NO. 305

siRNA 6	GCAUGCGGCCUCUGUUUGA	SEQ. ID NO. 306

siRNA 7	UGCGGCCUCUGUUUGAUUU	SEQ. ID NO. 307

siRNA 8	GAGAUAGUGAUGAAGUACA	SEQ. ID NO. 308

siRNA 9	GGAGAUAGUGAUGAAGUAC	SEQ. ID NO. 309

siRNA 10	GAAGACUCUGCUCAGUUUG	SEQ. ID NO. 310

Bcl2 siRNA: Sense Strand, 5′→3′

Example VI

Sequences Selected by the Algorithm

[0397] Sequences of the siRNAs selected using Formulas (Algorithms) VIII and IX with their corresponding ranking, which have been evaluated for the silencing activity in vivo in the present study (Formula VIII and IX, respectively) are shown in Table V. It should be noted that the “t” residues in Table V, and elsewhere, when referring to siRNA, should be replaced by “u” residues.

[0398]

TABLE V

	ACCESSION			FORMULA	FORMULA
GENE NAME	NUMBER	SEQ. ID NO	SEQUENCE	VIII	IX


CLTC	NM_004859	0428	GAAAGAATCTGTAGAGAAA	76	94.2

CLTC	NM_004859	0429	GCAATGAGCTGTTTGAAGA	65	39.9

CLTC	NM_004859	0430	TGACAAAGGTGGATAAATT	57	38.2

CLTC	NM_004859	0431	GGAAATGGATCTCTTTGAA	54	49.4

CLTA	NM_001833	0432	GGAAAGTAATGGTCCAACA	22	55.5

CLTA	NM_001833	0433	AGACAGTTATGCAGCTATT	4	22.9

CLTA	NM_001833	0434	CCAATTCTCGGAAGCAAGA	1	17

CLTA	NM_001833	0435	GAAAGTAATGGTCCAACAG	−1	−13

CLTB	NM_001834	0436	GCGCCAGAGTGAACAAGTA	17	57.5

CLTB	NM_001834	0437	GAAGGTGGCCCAGCTATGT	15	−8.6

CLTB	NM_001834	0311	GGAACCAGCGCCAGAGTGA	13	40.5

CLTB	NM_001834	0312	GAGCGAGATTGCAGGCATA	20	61.7

CALM	U45976	0313	GTTAGTATCTGATGACTTG	36	−34.6

CALM	U45976	0314	GAAATGGAACCACTAAGAA	33	46.1

CALM	U45976	0315	GGAAATGGAACCACTAAGA	30	61.2

CALM	U45976	0316	CAACTACACTTTCCAATGC	28	6.8

EPS15	NM_001981	0317	CCACCAAGATTTCATGATA	48	25.2

EPS15	NM_001981	0318	GATCGGAACTCCAACAAGA	43	49.3

EPS15	NM_001981	0319	AAACGGAGCTACAGATTAT	39	11.5

EPS15	NM_001981	0320	CCACACAGCATTCTTGTAA	33	−23.6

EPS15R	NM_021235	0321	GAAGTTACCTTGAGCAATC	48	33

EPS15R	NM_021235	0322	GGACTTGGCCGATCCAGAA	27	33

EPS15R	NM_021235	0323	GCACTTGGATCGAGATGAG	20	1.3

EPS15R	NM_021235	0324	CAAAGACCAATTCGCGTTA	17	27.7

DNM2	NM_004945	0325	CCGAATCAATCGCATCTTC	6	−29.6

DNM2	NM_004945	0326	GACATGATCCTGCAGTTCA	5	−14

DNM2	NM_004945	0327	GAGCGAATCGTCACCACTT	5	24

DNM2	NM_004945	0328	CCTCCGAGCTGGCGTCTAC	−4	−63.6

ARF6	AF93885	0329	TCACATGGTTAACCTCTAA	27	−21.1

ARF6	AF93885	0330	GATGAGGGACGCCATAATC	7	−38.4

ARF6	AF93885	0331	CCTCTAACTACAAATCTTA	4	16.9

ARF6	AF93885	0332	GGAAGGTGCTATCCAAAAT	4	11.5

RAB5A	BC001267	0333	GCAAGCAAGTCCTAACATT	40	25.1

RAB5A	BC001267	0334	GGAAGAGGAGTAGACCTTA	17	50.1

RAB5A	BC001267	0335	AGGAATCAGTGTTGTAGTA	16	11.5

RAB5A	BC001267	0336	GAAGAGGAGTAGACCTTAC	12	7

RAB5B	NM_002868	0337	GAAAGTCAAGCCTGGTATT	14	18.1

RAB5B	NM_002868	0338	AAAGTCAAGCCTGGTATTA	6	−17.8

RAB5B	NM_002868	0339	GCTATGAACGTGAATGATC	3	−21.1

RAB5B	NM_002868	0340	CAAGCCTGGTATTACGTTT	−7	−37.5

RAB5C	AF141304	0341	GGAACAAGATCTGTCAATT	38	51.9

RAB5C	AF141304	0342	GCAATGAACGTGAACGAAA	29	43.7

RAB5C	AF141304	0343	CAATGAACGTGAACGAAAT	18	43.3

RAB5C	AF141304	0344	GGACAGGAGCGGTATCACA	6	18.2

EEA1	XM_018197	0345	AGACAGAGCTTGAGAATAA	67	64.1

EEA1	XM_018197	0346	GAGAAGATCTTTATGCAAA	60	48.7

EEA1	XM_018197	0347	GAAGAGAAATCAGCAGATA	58	45.7

EEA1	XM_018197	0348	GCAAGTAACTCAACTAACA	56	72.3

AP2B1	NM_001282	0349	GAGCTAATCTGCCACATTG	49	−12.4

AP2B1	NM_001282	0350	GCAGATGAGTTACTAGAAA	44	48.9

AP2B1	NM_001282	0351	CAACTTAATTGTCCAGAAA	41	28.2

AP2B1	NM_001282	0352	CAACACAGGATTCTGATAA	33	−5.8

PLK	NM_005030	0353	AGATTGTGCCTAAGTCTCT	−35	−3.4

PLK	NM_005030	0354	ATGAAGATCTGGAGGTGAA	0	−4.3

PLK	NM_005030	0355	TTTGAGACTTCTTGCCTAA	−5	−27.7

PLK	NM_005030	0356	AGATCACCCTCCTTAAATA	15	72.3

GAPDH	NM_002046	0357	CAACGGATTTGGTCGTATT	27	−2.8

GAPDH	NM_002046	0358	GAAATCCCATCACCATCTT	24	3.9

GAPDH	NM_002046	0359	GACCTCAACTACATGGTTT	22	−22.9

GAPDH	NM_002046	0360	TGGTTTACATGTTCCAATA	9	9.8

c-Myc		0361	GAAGAAATCGATGTTGTTT	31	−11.7

c-Myc		0362	ACACAAACTTGAACAGCTA	22	51.3

c-Myc		0363	GGAAGAAATCGATGTTGTT	18	26

c-Myc		0364	GAAACGACGAGAACAGTTG	18	−8.9

MAP2K1	NM_002755	0365	GCACATGGATGGAGGTTCT	26	16

MAP2K1	NM_002755	0366	GCAGAGAGAGCAGATTTGA	16	0.4

MAP2K1	NM_002755	0367	GAGGTTCTCTGGATCAAGT	14	15.5

MAP2K1	NM_002755	0368	GAGCAGATTTGAAGCAACT	14	18.5

MAP2K2	NM_030662	0369	CAAAGACGATGACTTCGAA	37	26.4

MAP2K2	NM_030662	0370	GATCAGCATTTGCATGGAA	24	−0.7

MAP2K2	NM_030662	0371	TCCAGGAGTTTGTCAATAA	17	−4.5

MAP2K2	NM_030662	0372	GGAAGCTGATCCACCTTGA	16	59.2

KNSL1 (EG5)	NM_004523	0373	GCAGAAATCTAAGGATATA	53	35.8

KNSL1 (EG5)	NM_004523	0374	CAACAAGGATGAAGTCTAT	50	18.3

KNSL1 (EG5)	NM_004523	0375	CAGCAGAAATCTAAGGATA	41	32.7

KNSL1 (EG5)	NM_004523	0376	CTAGATGGCTTTCTCAGTA	39	3.9

CyclophilinA	NM_021130	0377	AGACAAGGTCCCAAAGACA	−16	58.1

CyclophilinA	NM_021130	0378	GGAATGGCAAGACCAGCAA	−6	36

CyclophilinA	NM_021130	0379	AGAATTATTCCAGGGTTTA	−3	16.1

CyclophilinA	NM_021130	0380	GCAGACAAGGTCCCAAAGA	8	8.9

LAMIN A/C	NM_170707	0381	AGAAGCAGCTTCAGGATGA	31	38.8

LAMIN A/C	NM_170707	0382	GAGCTTGACTTCCAGAAGA	33	22.4

LAMIN A/C	NM_170707	0383	CCACCGAAGTTCACCCTAA	21	27.5

LAMIN A/C	NM_170707	0384	GAGAAGAGCTCCTCCATCA	55	30.1

CyclophilinB	M60857	0385	GAAAGAGCATCTACGGTGA	41	83.9

CyclophilinB	M60857	0386	GAAAGGATTTGGCTACAAA	53	59.1

CyclophilinB	M60857	0387	ACAGCAAATTCCATCGTGT	−20	28.8

CyclophilinB	M60857	0388	GGAAAGACTGTTCCAAAAA	2	27

DBI1	NM_020548	0389	CAACACGCCTCATCCTCTA	27	−7.6

DBI2	NM_020548	0390	CATGAAAGCTTACATCAAC	25	−30.8

DBI3	NM_020548	0391	AAGATGCCATGAAAGCTTA	17	22

DBI4	NM_020548	0392	GCACATACCGCCTGAGTCT	15	3.9

rLUC1		0393	GATCAAATCTGAAGAAGGA	57	49.2

rLUC2		0394	GCCAAGAAGTTTCCTAATA	50	13.7

rLUC3		0395	CAGCATATCTTGAACCATT	41	−2.2

rLUC4		0396	GAACAAAGGAAACGGATGA	39	29.2

SeAP1	NM_031313	0397	CGGAAACGGTCCAGGCTAT	6	26.9

SeAP2	NM_031313	0398	GCTTCGAGCAGACATGATA	4	−11.2

SeAP3	NM_031313	0399	CCTACACGGTCCTCCTATA	4	4.9

SeAP4	NM_031313	0400	GCCAAGAACCTCATCATCT	1	−9.9

fLUC1		0401	GATATGGGCTGAATACAAA	54	40.4

fLUC2		0402	GCACTCTGATTGACAAATA	47	54.7

fLUC3		0403	TGAAGTCTCTGATTAAGTA	46	34.5

fLUC4		0404	TCAGAGAGATCCTCATAAA	40	11.4

mCyclo_1	NM_008907	0405	GCAAGAAGATCACCATTTC	52	46.4

mCyclo_2	NM_008907	0406	GAGAGAAATTTGAGGATGA	36	70.7

mCyclo_3	NM_008907	0407	GAAAGGATTTGGCTATAAG	35	−1.5

mCyclo_4	NM_008907	0408	GAAAGAAGGCATGAACATT	27	10.3

BCL2_1	NM_000633	0409	GGGAGATAGTGATGAAGTA	21	72

BCL2_2	NM_000633	0410	GAAGTACATCCATTATAAG	1	3.3

BCL2_3	NM_000633	0411	GTACGACAACCGGGAGATA	1	35.9

BCL2_4	NM_000633	0412	AGATAGTGATGAAGTACAT	−12	22.1

BCL2_5	NM_000633	0413	TGAAGACTCTGCTCAGTTT	36	19.1

BCL2_6	NM_000633	0414	GCATGCGGCCTCTGTTTGA	5	−9.7

QB1	NM_003365.1	0415	GCACACAGCUUACUACAUC	52	−4.8

QB2	NM_003365.1	0416	GAAAUGCCCUGGUAUCUCA	49	22.1

QB3	NM_003365.1	0417	GAAGGAACGUGAUGUGAUC	34	22.9

QB4	NM_003365.1	0418	GCACUACUCCUGUGUGUGA	28	20.4

ATE1-1	NM_007041	0419	GAACCCAGCUGGAGAACUU	45	15.5

ATE1-2	NM_007041	0420	GAUAUACAGUGUGAUCUUA	40	12.2

ATE1-3	NM_007041	0421	GUACUACGAUCCUGAUUAU	37	32.9

ATE1-4	NM_007041	0422	GUGCCGACCUUUACAAUUU	35	18.2

EGFR-1	NM_005228	0423	GAAGGAAACTGAATTCAAA	68	79.4

EGFR-1	NM_005228	0424	GGAAATATGTACTACGAAA	49	49.5

EGFR-1	NM_005228	0425	CCACAAAGCAGTGAATTTA	41	7.6

EGFR-1	NM_005228	0426	GTAACAAGCTCACGCAGTT	40	25.9

Example VII

Evidence for the Benefits of Pooling

[0399] Evidence for the benefits of pooling have been demonstrated using the reporter gene, luciferase. Ninety siRNA duplexes were synthesized using Dharmacon proprietary ACE® chemistry against one of the standard reporter genes: firefly luciferase. The duplexes were designed to start two base pairs apart and to cover approximately 180 base pairs of the luciferase gene (see sequences in Table IV). Subsequently, the siRNA duplexes were co-transfected with a luciferase expression reporter plasmid into HEK293 cells using standard transfection protocols and luciferase activity was assayed at 24 and 48 hours.

[0400] Transfection of individual siRNAs showed standard distribution of inhibitory effect. Some duplexes were active, while others were not. The functionality of the siRNA duplex is determined more by a particular sequence of the oligonucleotide than by the relative oligonucleotide position within a gene or excessively sensitive part of the mRNA, which is important for traditional anti-sense technology.

[0401] When two continuous oligonucleotides were pooled together, a significant increase in gene silencing activity was observed. A gradual increase in efficacy and the frequency of pools functionality was observed when the number of siRNAs increased to 3 and 4. Further, the relative positioning of the oligonucleotides within a pool did not determine whether a particular pool was functional.

[0402] However, relative positioning may nonetheless have an impact. An increased functionality may exist when the siRNA are positioned continuously head to toe (5′ end of one directly adjacent to the 3′ end of the others).

[0403] Additionally, experimental testing of siRNA pools that were tested performed at least as well as the best oligonucleotide in the pool. Moreover, when previously identified non-functional and marginally (semi) functional siRNA duplexes were pooled together in groups of five at a time, a significant functional cooperative action was observed. In fact, pools of semi-active oligonucleotides were 5 to 25 times more functional than the most potent oligonucleotide in the pool. Therefore, pooling several siRNA duplexes together does not interfere with the functionality of the most potent siRNAs within a pool, and pooling provides an unexpected significant increase in overall functionality

Example VIII

Highly Functional siRNA

[0404] Pools of five siRNAs in which each two siRNAs overlap to 10-90% resulted in 98% functional entities (>80% silencing). Pools of siRNAs distributed throughout the mRNA that were evenly spaced, covering an approximate 20-2000 base pair range, were also functional. When the pools of siRNA were positioned continuously head to tail relative to mRNA sequences and mimicked the natural products of Dicer cleaved long double stranded RNA, 98% of the pools evidenced highly functional activity (>95% silencing).

Example IX Human Cyclophilin B

[0405] Table IV above lists the siRNA sequences for the human cyclophilin B protein. A particularly functional siRNA may be selected by applying these sequences to any of Formula I to VII above.

[0406] Alternatively, one could pool 2, 3, 4, 5 or more of these sequences to create a kit for silencing a gene. Preferably, within the kit there would be at least one sequence that has a relatively high predicted functionality when any of Formulas I-VII is applied.

Example X

Sample Pools of siRNAs and Their Application to Human Disease

[0407] The genetic basis behind human disease is well documented and siRNA may be used as both research or diagnostic tools and therapeutic agents, either individually or in pools. Genes involved in signal transduction, the immune response, apoptosis, DNA repair, cell cycle control, and a variety of other physiological functions have clinical relevance and therapeutic agents that can modulate expression of these genes may alleviate some or all of the associated symptoms. In some instances, these genes can be described as a member of a family or class of genes and siRNA (randomly, conventionally, or rationally designed) can be directed against one or multiple members of the family to induce a desired result.

[0408] To identify rationally designed siRNA to each gene, the sequence was analyzed using Formula VIII or Formula X to identify rationally designed siRNA. To confirm the activity of these sequences, the siRNA are introduced into a cell type of choice (e.g., HeLa cells, HEK293 cells) and the levels of the appropriate message are analyzed using one of several art proven techniques. siRNA having heightened levels of potency can be identified by testing each of the before mentioned duplexes at increasingly limiting concentrations. Similarly, siRNA having increased levels of longevity can be identified by introducing each duplex into cells and testing functionality at 24, 48, 72, 96, 120, 144, 168, and 192 hours after transfection. Agents that induce >95% silencing at sub-nanomolar concentrations and/or induce functional levels of silencing for >96 hours are considered hyperfunctional.

[0409] Kinases

[0410] Protein Kinases (PKs) have been implicated in a number of biological processes. Kinase molecules play a central role in modulating cellular physiology and developmental decisions, and have been implicated in a large list of human maladies including cancer, diabetes, and others.

[0411] During the course of the last three decades, over a hundred distinct protein kinases have been identified, all with presumed specific cellular functions. A few of these enzymes have been isolated to sufficient purity to perform in vitro studies, but most remain intractable due to the low abundance of these molecules in the cell. To counter this technical difficulty, a number of protein kinases have been isolated by molecular cloning strategies that utilize the conserved sequences of the catalytic domain to isolate closely related homologs. Alternatively, some kinases have been purified (and subsequently studied) based on their interactions with other molecules.

[0412] p58 is a member of the p34cdc2-related supergene family and contains a large domain that is highly homologous to the cell division control kinase, cdc2. This new cell division control-related protein kinase was originally identified as a component of semipurified galactosyltransferase; thus, it has been denoted galactosyltransferase-associated protein kinase (GTA-kinase). GTA-kinase has been found to be expressed in both adult and embryonic tissues and is known to phosphorylate a number of substrates, including histone H1, and casein. Interestingly enough, over expression of this molecule in CHO cells has shown that elevated levels of p58 result in a prolonged late telophase and an early G1 phase, thus hinting of an important role for GTA-kinase in cell cycle regulation.

[0413] Cyclin Dependent Kinases

[0414] The cyclin-dependent kinases (Cdks) are a family of highly conserved serine/threonine kinases that mediate many of the cell cycle transitions that occur during duplication. Each of these Cdk catalytic subunits associates with a specific subset of regulatory subunits, termed cyclins, to produce a distinct Cdk-cyclin kinase complex that, in general, functions to execute a unique cell cycle event.

[0415] Activation of the Cdk-cyclin kinases during cellular transitions is controlled by a variety of regulatory mechanisms. For the Cdc2-cyclin B complex, inhibition of kinase activity during S phase and G₂is accomplished by phosphorylation of two Cdc2 residues, Thr¹⁴and Tyr¹⁵, which are positioned within the ATP-binding cleft. Phosphorylation of Thr¹⁴and/or Tyr¹⁵suppresses the catalytic activity of the molecule by disrupting the orientation of the ATP present within this cleft. In contrast, the abrupt dephosphorylation of these residues by the Cdc25 phosphatase results in the rapid activation of Cdc2-cyclin B kinase activity and subsequent downstream mitotic events. While the exact details of this pathway have yet to be elucidated, it has been proposed that Thr¹⁴/Tyr¹⁵phosphorylation functions to permit a cell to attain a critical concentration of inactive Cdk-cyclin complexes, which, upon activation, induces a rapid and complete cell cycle transition. Furthermore, there is evidence in mammalian cells that Thr¹⁴/Tyr¹⁵phosphorylation also functions to delay Cdk activation after DNA damage.

[0416] The Schizosaccharomyces pombe wee1 gene product was the first kinase identified that is capable of phosphorylating Tyr¹⁵in Cdc2. Homologs of the Wee1 kinase have been subsequently identified and biochemically characterized from a wide range of species including human, mouse, frog, Saccharomyces cerevisiae, and Drosophila. In vertebrate systems, where Thr¹⁴in Cdc2 is also phosphorylated, the Wee1 kinase was capable of phosphorylating Cdc2 on Tyr¹⁵, but not Thr¹⁴, indicating that another kinase was responsible for Thr¹⁴phosphorylation. This gene, Myt1 kinase, was recently isolated from the membrane fractions of Xenopus egg extracts and has been shown to be capable of phosphorylating Thr¹⁴and, to a lesser extent, Tyr¹⁵in Cdc2. A human Myt1 homolog displaying similar properties has been isolated, as well as a non-membrane-associated molecule with Thr¹⁴kinase activity.

[0417] In the past decade it has been shown that cancer can originate from overexpression of positive regulators, such as cyclins, or from underexpression of negative regulators (e.g., p16 (INK4a), p15 (INK4b), p21 (Cip1)). Inhibitors such as Myt1 are the focus of much cancer research because they are capable of controlling cell cycle proliferation, now considered the Holy Grail for cancer treatment. For these reasons, siRNA directed against kinases and kinase inhibitors including but not limited to ABL1, ABL2, ACK1, ALK, AXL, BLK, BMX, BTK, C20orf64, CSF1R, SCK, DDR1, DDR2, DKFZp761P1010, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FER, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1, FLT3, FLT4, FRK, FYN, HCK, IGF1R, INSR, ITK, JAK1, JAK2, JAK3, KDR, KIAA1079, KIT, LCK, LTK, LYN, MATK, MERTK, MET, MST1R, MUSK, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PTK2, PTK2B, PTK6, PTK7, PTK9, PTK9L, RET, ROR1, ROR2, ROS1, RYK, SRC, SYK, TEC, TEK, TIE, TNK1, TXK, TYK2, TYRO3, YES 1, and related proteins, may be useful for research and therapeutic purposes.

Example XII

Validation of Multigene Knockout Using RAB5 and EPS

[0418] Two or more genes having similar, overlapping functions often leads to genetic redundancy. Mutations that knockout only one of, e.g., a pair of such genes (also referred to as homologs) results in little or no phenotype due to the fact that the remaining intact gene is capable of fulfilling the role of the disrupted counterpart. To fully understand the function of such genes in cellular physiology, it is often necessary to knockout or knockdown both homologs simultaneously. Unfortunately, concomitant knockdown of two or more genes is frequently difficult to achieve in higher organisms (e.g., mice) thus it is necessary to introduce new technologies dissect gene function. One such approach to knocking down multiple genes simultaneously is by using siRNA. To determine the effects of gene knockdown on clathrin-related endocytosis, internalization assays were performed using epidermal growth factor and transferrin. Specifically, mouse receptor-grade EGF (Collaborative Research Inc.) and iron-saturated human transferrin (Sigma) were iodinated as described previously (Jiang, X., Huang, F., Marusyk, A. & Sorkin, A. (2003) Mol Biol Cell 14, 858-70). HeLa cells grown in 12-well dishes were incubated with ¹²⁵I-EGF (1 ng/ml) or ¹²⁵I-transferrin (1 μg/ml) in binding medium (DMEM, 0.1% bovine serum albumin) at 37° C., and the ratio of internalized and surface radioactivity was determined during 5-min time course to calculate specific internalization rate constant k_eas described previously (Jiang, X et al.). The measurements of the uptakes of radiolabeled transferrin and EGF were performed using short time-course assays to avoid influence of the recycling on the uptake kinetics, and using low ligand concentration to avoid saturation of the clathrin-dependent pathway (for EGF Lund, K. A., Opresko, L. K., Strarbuck, C., Walsh, B. J. & Wiley, H. S. (1990) J. Biol. Chem. 265, 15713-13723).

[0419] The effects of knocking down Rab5a, 5b, 5c, Eps, or Eps 15R (individually) and demonstrate that disruption of single genes has little or no effect on EGF or Tfn internalization. In contrast, simultaneous knock down of Rab5a, 5b, and 5c, or Eps and Eps 15R, leads to a distinct phenotype (note: total concentration of siRNA in these experiments remained constant with that in experiments in which a single siRNA was introduced. These experiments demonstrate the effectiveness of using rationally designed siRNA to knockdown multiple genes and validates the utility of these reagents to override genetic redundancy.

Example XIII

Validation OF Multigene Knockouts As Demonstrated by Gene Expression Profiling, a Prophetic Example

[0420] To further demonstrate the ability to concomitantly knockdown the expression of multiple gene targets, single siRNA or siRNA pools directed against a collection of genes (e.g., 4, 8, 16, or 23 different targets) are simultaneously transfected into cells and cultured for twenty-four hours. Subsequently, mRNA is harvested from treated (and untreated) cells and labeled with one of two fluorescent probes dyes (e.g., a red fluorescent probe for the treated cells, a green fluorescent probe for the control cells.). Equivalent amounts of labeled RNA from each sample is then mixed together and hybridized to sequences that have been linked to a solid support (e.g., a slide, “DNA CHIP”). Following hybridization, the slides are washed and analyzed to assess changes in the levels of target genes induced by siRNA.

Example XIV

Gene Silencing: Prophetic Example

[0421] Below is an example of how one might transfect a cell.

[0422] Select a cell line. The selection of a cell line is usually determined by the desired application. The most important feature to RNAi is the level of expression of the gene of interest. It is highly recommended to use cell lines for which siRNA transfection conditions have been specified and validated.

[0423] Plate the cells. Approximately 24 hours prior to transfection, plate the cells at the appropriate density so that they will be approximately 70-90% confluent, or approximately 1×10⁵cells/ml at the time of transfection. Cell densities that are too low may lead to toxicity due to excess exposure and uptake of transfection reagent-siRNA complexes. Cell densities that are too high may lead to low transfection efficiencies and little or no silencing. Incubate the cells overnight. Standard incubation conditions for mammalian cells are 37° C. in 5% CO₂. Other cell types, such as insect cells, require different temperatures and CO₂concentrations that are readily ascertainable by persons skilled in the art. Use conditions appropriate for the cell type of interest.

[0424] siRNA re-suspension. Add 20 μl siRNA universal buffer to each siRNA to generate a final concentration of 50 μM.

[0425] siRNA-lipid complex formation. Use RNase-free solutions and tubes. Using the following table, Table VI:

[0426]

	TABLE VI

	96-WELL	24-WELL

MIXTURE 1
(TRANSIT-TKO-PLASMID DILUTION MIXTURE)
	Opti-MEM	9.3	μl	46.5	μl
	TransIT-TKO (1 μg/μl)	0.5	μl	2.5	μl
	MIXTURE 1 FINAL VOLUME	10.0	μl	50.0	μl
MIXTURE 2
(SIRNA DILUTION MIXTURE)
	Opti-MEM	9.0	μl	45.0	μl
	siRNA (1 μM)	1.0	μl	5.0	μl
	MIXTURE 2 FINAL VOLUME	10.0	μl	50.0	μl
MIXTURE 3
(SIRNA-TRANSFECTION REAGENT MIXTURE)
	Mixture 1	10	μl	50	μl
	Mixture 2	10	μl	50	μl
	MIXTURE 3 FINAL VOLUME	20	μl	100	μl
Incubate 20 minutes at room temperature
MIXTURE 4
(MEDIA-SIRNA/TRANSFECTION REAGENT MIXTURE)
	Mixture 3	20	μl	100	μl
	Complete media	80	μl	400	μl
	MIXTURE 4 FINAL VOLUME	100	μl	500	μl

Incubate 48 hours at 37° C.

[0427] Transfection. Create a Mixture 1 by combining the specified amounts of OPTI-MEM serum free media and transfection reagent in a sterile polystyrene tube. Create a Mixture 2 by combining specified amounts of each siRNA with OPTI-MEM media in sterile 1 ml tubes. Create a Mixture 3 by combining specified amounts of Mixture 1 and Mixture 2. Mix gently (do not vortex) and incubate at room temperature for 20 minutes. Create a Mixture 4 by combining specified amounts of Mixture 3 to complete media. Add appropriate volume to each cell culture well. Incubate cells with transfection reagent mixture for 24-72 hours at 37° C. This incubation time is flexible. The ratio of silencing will remain consistent at any point in the time period. Assay for gene silencing using an appropriate detection method such as RT-PCR, Western blot analysis, immunohistochemistry, phenotypic analysis, mass spectrometry, fluorescence, radioactive decay, or any other method that is now known or that comes to be known to persons skilled in the art and that from reading this disclosure would useful with the present invention. The optimal window for observing a knockdown phenotype is related to the mRNA turnover of the gene of interest, although 24-72 hours is standard. Final Volume reflects amount needed in each well for the desired cell culture format. When adjusting volumes for a Stock Mix, an additional 10% should be used to accommodate variability in pipetting, etc. Duplicate or triplicate assays should be carried out when possible.

Example XVII

siRNAs that Target P53 Generated by Algorithms

[0428] siRNAs that target p53 (gene accession number NM_—000546), having sequences generated in silico by the algorithms herein, are provided. In various embodiments, the siRNAs are rationally designed. In various embodiments, the siRNAs are functional or hyperfunctional.

[0429] In another embodiment, an siRNA that target p53 are provided, wherein the siRNA is selected from the group consisting of the following sequences:

[0430]


SEQ ID NO:	SEQUENCE

438	AAACCUACCAGGGCAGCUA

439	AAAUUUGCGUGUGGAGUAU

440	AAGCACAUCUGCAUUUUCA

441	AAGGGUUAGUUUACAAUCA

442	ACAAUCAGCCACAUUCUAG

443	ACAGUUGGGCAGCUGGUUA

444	ACCACUGGAUGGAGAAUAU

445	AGAAACCACUGGAUGGAGA

446	AGACUCCAGUGGUAAUCUA

447	AGACUGACAUUCUCCACUU

448	AGAGGGAGUUGUCAAGUCU

449	AGAUGAAGCUCCCAGAAUG

450	AGCAAUGGAUGAUUUGAUG

451	AGCGAGCACUGCCCAACAA

452	AGGAUUUCAUCUCUUGUAU

453	AGUAGGACAUACCAGCUUA

454	AGUAUUUGGAUGACAGAAA

455	CAACAUCUUUUACAUUCUG

456	CAAGAUGUUUUGCCAACUG

457	CAAGGCCCAUAUCUGUGAA

458	CAAUAGGUGUGCGUCAGAA

459	CAGAUGAAGCUCCCAGAAU

460	CAGUCUACCUCCCGCCAUA

461	CAUACCAGCUUAGAUUUUA

462	CAUGGCGACUGUCCAGCUU

463	CCAAGCAAUGGAUGAUUUG

464	CCACCAUCCACUACAACUA

465	CCACUACAACUACAUGUGU

466	CCAGAUGAAGCUCCCAGAA

467	CCAGCCACCUGAAGUCCAA

468	CCAUGGCCAUCUACAAGCA

469	CCCAAGCAAUGGAUGAUUU

470	CCCACACCCUGGAGGAUUU

471	CCGAGUGGAAGGAAAUUUG

472	CCUGGAGGAUUUCAUCUCU

473	CGCCUGAGGUUGGCUCUGA

474	CGUCUGGGCUUCUUGCAUU

475	CGUGAGCGCUUCGAGAUGU

476	CUGGAAGGGUCAACAUCUU

477	CUUCAAGGCCCAUAUCUGU

478	CUUCUUGCAUUCUGGGACA

479	GAAACCACCUUUUAUUACA

480	GAAACCACUGGAUGGAGAA

481	GAAACUACUUCCUGAAAAC

482	GAAAUGUUCUUGCAGUUAA

483	GAAAUUUGCGUGUGGAGUA

484	GAAGAAACCACUGGAUGGA

485	GAAGACUCCAGUGGUAAUC

486	GAAGCUGUCCCUCAUGUUG

487	GAAGGGUCAACAUCUUUUA

488	GAAUAUUUCACCCUUCAGA

489	GAAUGAGGCCUUGGAACUC

490	GACAGAAGGGCCUGACUCA

491	GACAUACCAGCUUAGAUUU

492	GACAUUCUCCACUUCUUGU

493	GACUGGGUCUCGCUUUGUU

494	GAGAAUAUUUCACCCUUCA

495	GAGCCGCAGUCAGAUCCUA

496	GAGGAUUUCAUCUCUUGUA

497	GAGGGUUAAUGAAAUAAUG

498	GAGGUUGGCUCUGACUGUA

499	GAGUAGGACAUACCAGCUU

500	GAGUGCAUUGUGAGGGUUA

501	GAUGAAGCUCCCAGAAUGC

502	GCAAGAAAGGGGAGCCUCA

503	GCAAGCACAUCUGCAUUUU

504	GCAAUAGGUGUGCGUCAGA

505	GCACAGAGGAAGAGAAUCU

506	GCACCCAGGACUUCCAUUU

507	GCACUGGUGUUUUGUUGUG

508	GCAGUUAAGGGUUAGUUUA

509	GCAUCUUAUCCGAGUGGAA

510	GCCCAUAUCUGUGAAAUGC

511	GCGCACAGAGGAAGAGAAU

512	GCUCAAGACUGGCGCUAAA

513	GCUCAGGGUCAAUUUCUUU

514	GCUGAAUGAGGCCUUGGAA

515	GCUGGGAUUACAAUUGUGA

516	GCUUCGAGAUGUUCCGAGA

517	GCUUUGAGGUGCGUGUUUG

518	GGAAGACUCCAGUGGUAAU

519	GGAAGCUGUCCCUCAUGUU

520	GGACAUACCAGCUUAGAUU

521	GGACUUCCAUUUGCUUUGU

522	GGAGAUGUAAGAAAUGUUC

523	GGAGUGGAGUGGCGUGAUC

524	GGAUUUCAUCUCUUGUAUA

525	GGGCUCCACUGAACAAGUU

526	GUACCACCAUCCACUACAA

527	GUAUUUGGAUGACAGAAAC

528	GUCAACAUCUUUUACAUUC

529	GUGACACGCUUCCCUGGAU

530	GUGCAGCUGUGGGUUGAUU

531	GUGCUGGGAUUACAAUUGU

532	GUGGCGUGAUCUUGGCUUA

533	GUGUGGAGUAUUUGGAUGA

534	GUGUGGUGGUGCCCUAUGA

535	GUUAAGGGUUAGUUUACAA

536	GUUCAAGACAGAAGGGCCU

537	UACAAUCAGCCACAUUCUA

538	UAGAGGGAGUUGUCAAGUC

539	UAUCCGAGUGGAAGGAAAU

540	UCAAGGCCCAUAUCUGUGA

541	UCAGACCUAUGGAAACUAC

542	UGAAUGAGGCCUUGGAACU

543	UGACACGCUUCCCUGGAUU

544	UGACAUUCUCCACUUCUUG

545	UGAGGGAUGUUUGGGAGAU

546	UGGAAGGGUCAACAUCUUU

547	UGGAGGAGCCGCAGUCAGA

548	UGGAGGAUUUCAUCUCUUG

549	UGGAUGACAGAAACACUUU

550	UGGGAGAUGUAAGAAAUGU

551	UGUAUAUGAUGAUCUGGAU

552	UGUGAGGGUUAAUGAAAUA

553	UUAUCCGAGUGGAAGGAAA

554	UUGGGCAGCUGGUUAGGUA

555	UUUGGGAGAUGUAAGAAAU

[0431] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least 90% complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs, and said sense region comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of SEQ ID NO: 438-555.

[0432] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least 90% complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs, and said sense region comprises a sequence that is selected from the group consisting of SEQ ID NO: 438-555.

[0433] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least 90% complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs, and said sense region comprises a sequence that is identical to a contiguous stretch of at least 18 bases of a sequence selected from the group consisting of SEQ ID NO: 438-555.

[0434] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least 90% complementary, said sense region and said antisense region together form a duplex region comprising 18-30 base pairs, and said sense region comprises a sequence that is identical to a contiguous stretch of at least 18 bases of a sequence selected from the group consisting of SEQ ID NO: 438-555.

[0435] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least 90% complementary, said sense region and said antisense region together form a duplex region that is 19-30 base pairs, and said sense region comprises a sequence that is identical to a sequence selected from the group consisting of SEQ ID NO: 438-555.

[0436] In another embodiment, an siRNA is provided, said siRNA comprising a sense region and an antisense region, wherein said sense region and said antisense region are at least 90% complementary, said sense region and said antisense region together form a duplex region that is 19-30 base pairs, and said sense region comprises a sequence that is identical to a sequence selected from the group consisting of SEQ ID NO: 438-555.

[0437] In another embodiment, a pool of at least two siRNAs is provided, wherein said pool comprises a first siRNA and a second siRNA, said first siRNA comprises a duplex region of length 18-30 base pairs that has a first sense region that is at least 90% similar to 18 bases of a first sequence selected from the group consisting of SEQ ID NO: 438-555, and said second siRNA comprises a duplex region of length 18-30 base pairs that has a second sense region that is at least 90% similar to 18 bases of a second sequence selected from the group consisting of SEQ ID NO: 438-555, wherein said first sense region and said second sense region are not identical.

[0438] In another embodiment, the pool of at least two siRNA is provided wherein said first sense region comprises a sequence that is identical to at least 18 bases of a sequence selected from the group consisting of SEQ ID NO: 438-555, and said second sense region comprises a sequence that is identical to at least 18 bases of a sequence selected from the group consisting of SEQ ID NO: 438-555.

[0439] In another embodiment, the pool of at least two siRNA is provided wherein said duplex of said first siRNA is 19-30 base pairs and said first sense region comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of SEQ ID NO: 438-555 and said duplex of said second siRNA is 19-30 base pairs and comprises a sequence that is at least 90% similar to a sequence selected from the group consisting of SEQ ID NO: 438-555.

[0440] In another embodiment, the pool of at least two siRNA is provided, wherein said duplex of said first siRNA is 19-30 base pairs and said first sense region comprises a sequence that is identical to at least 18 bases of a sequence selected the group consisting of SEQ ID NO: 438-555 and said duplex of said second siRNA is 19-30 base pairs and said second sense region comprises a sequences that is identical to a sequence selected from the group consisting of SEQ ID NO: 438-555.

[0441] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departure from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.

Claims

The invention claimed is:

1. An siRNA molecule, wherein said siRNA molecule consists of: (a) a duplex region; and (b) either no overhang regions or at least one overhang region, wherein each overhang region contains six or fewer nucleotides, wherein the duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region together form said duplex region and said duplex region is 19-30 base pairs in length and said antisense region comprises a sequence that is the complement of SEQ ID NO: 494.

2. The siRNA molecule of claim 1, wherein said antisense region and said sense region are each 19-25 bases in length.

3. The siRNA molecule of claim 2, wherein said antisense region and said sense region are each 19 bases in length.

4. The siRNA molecule of claim 1, wherein said siRNA molecule has at least one overhang region.

5. The siRNA molecule of claim 1, wherein said siRNA molecule has no overhang regions.

6. The siRNA molecule of claim 2, wherein said siRNA molecule has at least one overhang region.

7. The siRNA molecule of claim 2, wherein said siRNA molecule has no overhang regions.

8. The siRNA molecule of claim 3, wherein said siRNA molecule has at least one overhang region.

9. The siRNA molecule of claim 3, wherein said siRNA molecule has no overhang regions.

10. A chemically synthesized double stranded siRNA molecule which comprises a duplex region comprising a sense region and an antisense region, wherein:

(a) each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length; and

(b) the antisense region of said duplex region of said siRNA molecule comprises a sequence that is the complement of the sequence of SEQ ID NO: 494.

11. The chemically synthesized double stranded siRNA molecule of claim 10, wherein each strand of said siRNA molecule is 19 nucleotides in length.

12. A pool of at least two siRNAs, wherein said pool comprises a first siRNA and a second siRNA, wherein said first siRNA is the siRNA molecule of claim 1, wherein the duplex region of said first siRNA is a first duplex region and said second siRNA consists of a second duplex region and either no overhang regions or at least one overhang region, wherein each overhang region contains six or fewer nucleotides, wherein the second duplex region of said second siRNA comprises a sense region and an antisense region, wherein said sense region and said antisense region of said second siRNA together form said second duplex region and said second duplex region is 19-30 base pairs in length and said antisense region of said second duplex region comprises a sequence that is the complement of a sequence selected from the group consisting of a sequence selected from SEQ ID NO: 438-493 and 495-555.

13. The pool of claim 12, wherein said first siRNA and said second siRNA each have no overhang regions.

14. The pool of claim 12, wherein said first duplex region and said second duplex region are each 19-25 base pairs in length.

15. The pool of claim 14, wherein said first duplex region and said second duplex region are each 19 base pairs in length.

16. The pool of claim 15, wherein said first siRNA contains no overhang regions.

17. The pool of claim 15, wherein the second siRNA contains no overhang regions.

18. The pool of claim 15, wherein the first siRNA contains at least one overhang region.

19. The pool of claim 15, wherein the second siRNA contains at least one overhang region.

20. The chemically synthesized double stranded siRNA molecule of claim 10 wherein each strand of said siRNA molecule is 19-25 nucleotides in length.

21. An siRNA molecule, wherein said siRNA molecule consists of: (a) a duplex region; and (b) no overhang regions or at least one overhang region containing six or fewer nucleotides, wherein the duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region together form said duplex region and said duplex region is 19-30 base pairs in length and said sense region comprises the sequence 5′ GAGAAUAUUUCACCCUUCA 3′ set forth in SEQ ID NO: 494.

22. The siRNA molecule of claim 21, wherein said antisense region comprises a sequence that is the complement of SEQ ID NO: 494.

23. The siRNA molecule of claim 22, wherein said siRNA molecule has at least one overhang region.

24. The siRNA molecule of claim 22, wherein said siRNA molecule has no overhang regions.

25. The siRNA molecule of claim 24, wherein the sense region consists of the sequence set forth in SEQ ID NO: 494 and wherein the antisense region consists of a sequence that is the complement of the sequence set forth in SEQ ID NO: 494.

Patent Citations (154)

Patent	Date	Inventor	Cited By
US5958773(A)	1999-09-01	Monia	Applicant
US6001992(A)	1999-12-01	Ackerman	Applicant
US6111086(A)	2000-08-01	Scaringe	Applicant
US6172216(B1)	2001-01-01	Bennett et al.	Applicant
US6291642(B1)	2001-09-01	Weinstein	Applicant
US6506559(B1)	2003-01-01	Fire et al.	Applicant
US6566127(B1)	2003-05-01	Pavco	Applicant
US6590093(B1)	2003-07-01	Scaringe	Applicant
US6965025(B2)	2005-11-01	Gaarde et al.	Applicant
US6994979(B2)	2006-02-01	Reed	Applicant
US7022831(B1)	2006-04-01	Reed	Applicant
US7022837(B2)	2006-04-01	Harding	Applicant
US7033830(B2)	2006-04-01	Karras	Applicant
US7157570(B2)	2007-01-01	Yun	Applicant
US7250496(B2)	2007-07-01	Bentwich	Applicant
US7371735(B2)	2008-05-01	Harel-Bellan et al.	Examiner
US7399853(B2)	2008-07-01	Freier	Applicant
US7459547(B2)	2008-12-01	Zamore et al.	Applicant
US7507811(B2)	2009-03-01	Khvorova	Applicant
US7511132(B2)	2009-03-01	Khvorova	Applicant
US7514550(B2)	2009-04-01	Khvorova	Applicant
US7521191(B2)	2009-04-01	Khvorova	Applicant
US7541453(B2)	2009-06-01	Khvorova	Applicant
US7550572(B2)	2009-06-01	Khvorova	Applicant
US7569684(B2)	2009-08-01	Khvorova	Applicant
US7576196(B2)	2009-08-01	Khvorova	Applicant
US7576197(B2)	2009-08-01	Khvorova	Applicant
US7579457(B2)	2009-08-01	Khvorova	Applicant
US7579458(B2)	2009-08-01	Khvorova	Applicant
US7582746(B2)	2009-09-01	Khvorova	Applicant
US7582747(B2)	2009-09-01	Khvorova	Applicant
US7589191(B2)	2009-09-01	Khvorova	Applicant
US7592442(B2)	2009-09-01	Khvorova	Applicant
US7592443(B2)	2009-09-01	Khvorova	Applicant
US7592444(B2)	2009-09-01	Khvorova	Applicant
US7595370(B2)	2009-09-01	Khvorova	Applicant
US7595387(B2)	2009-09-01	Khovorova	Applicant
US7595388(B2)	2009-09-01	Khvorova	Applicant
US7595389(B2)	2009-09-01	Khvorova	Applicant
US7598369(B2)	2009-10-01	Khvorova	Applicant
US7605250(B2)	2009-10-01	Khvorova	Applicant
US7605252(B2)	2009-10-01	Khvorova	Applicant
US7608706(B2)	2009-10-01	Khvorova	Applicant
US7608707(B2)	2009-10-01	Khvorova	Applicant
US7612196(B2)	2009-11-01	Khvorova	Applicant
US7615541(B2)	2009-11-01	Khvorova	Applicant
US7619081(B2)	2009-11-01	Khvorova	Applicant
US7632938(B2)	2009-12-01	Khvorova	Applicant
US7632939(B2)	2009-12-01	Khvorova	Applicant
US7635770(B2)	2009-12-01	Khvorova	Applicant
US7635771(B2)	2009-12-01	Khvorova	Applicant
US7638621(B2)	2009-12-01	Khvorova	Applicant
US7638622(B2)	2009-12-01	Khvorova	Applicant
US7642349(B2)	2010-01-01	Khvorova	Applicant
US7645869(B2)	2010-01-01	Khvorova	Applicant
US7645870(B2)	2010-01-01	Khvorova	Applicant
US2002/0081578(A1)	2002-06-01	Plowman et al.	Applicant
US2002/0086321(A1)	2002-07-01	Craig	Applicant
US2002/0086356(A1)	2002-07-01	Tuschl et al.	Applicant
US2002/0150945(A1)	2002-10-01	Finney	Applicant
US2003/0087259(A1)	2003-05-01	Clancy et al.	Applicant
US2003/0105051(A1)	2003-06-01	McSwiggen	Applicant
US2003/0143732(A1)	2003-07-01	Fosnaugh	Applicant
US2003/0157030(A1)	2003-08-01	Davis et al.	Applicant
US2003/0224512(A1)	2003-12-01	Dobie	Applicant
US2003/0228597(A1)	2003-12-01	Cowsert	Applicant
US2004/0006365(A1)	2004-01-01	Brady	Applicant
US2004/0014956(A1)	2004-01-01	Woolf et al.	Applicant
US2004/0029275(A1)	2004-02-01	Brown et al.	Applicant
US2004/0054155(A1)	2004-03-01	Woolf	Applicant
US2004/0063654(A1)	2004-04-01	Davis et al.	Applicant
US2004/0077574(A1)	2004-04-01	Klinghoffer	Applicant
US2004/0101857(A1)	2004-05-01	Ward	Applicant
US2004/0101915(A1)	2004-05-01	Deveraux	Applicant
US2004/0102391(A1)	2004-05-01	Dean	Applicant
US2004/0180357(A1)	2004-09-01	Reich	Applicant
US2004/0191818(A1)	2004-09-01	O'Toole	Applicant
US2004/0192629(A1)	2004-09-01	Xu et al.	Applicant
US2004/0204380(A1)	2004-10-01	Ackerman	Applicant
US2004/0219671(A1)	2004-11-01	McSwiggen	Applicant
US2004/0248296(A1)	2004-12-01	Beresford	Applicant
US2004/0248299(A1)	2004-12-01	Jayasena	Applicant
US2004/0259247(A1)	2004-12-01	Tuschl et al.	Applicant
US2005/0048529(A1)	2005-03-01	McSwiggen	Applicant
US2005/0107328(A1)	2005-05-01	Wyatt	Applicant
US2005/0130181(A1)	2005-06-01	McSwiggen	Applicant
US2005/0176025(A1)	2005-08-01	McSwiggen	Applicant
US2005/0181382(A1)	2005-08-01	Zamore	Applicant
US2005/0186586(A1)	2005-08-01	Zamore	Applicant
US2005/0227935(A1)	2005-10-01	McSwiggen	Applicant
US2005/0239731(A1)	2005-10-01	McSwiggen	Applicant
US2005/0245475(A1)	2005-11-01	Khvorova	Applicant
US2005/0272680(A1)	2005-12-01	Bhanot	Applicant
US2006/0025372(A1)	2006-02-01	Bhanot	Applicant
US2006/0069056(A1)	2006-03-01	Feinstein et al.	Applicant
US2006/0286575(A1)	2006-12-01	Farrell	Applicant
US2007/0031844(A1)	2007-02-01	Khvorova	Applicant
US2007/0254850(A1)	2007-11-01	Lieberman	Applicant
US2007/0269395(A1)	2007-11-01	Christiano	Applicant
US2007/0275465(A1)	2007-11-01	Woppman	Applicant
US2007/0281901(A1)	2007-12-01	Yanni	Applicant
US2008/0108583(A1)	2008-05-01	Feinstein	Applicant
US2008/0113351(A1)	2008-05-01	Naito	Applicant
US2008/0124370(A1)	2008-05-01	Marx	Applicant
US2008/0287382(A1)	2008-11-01	Feinstein et al.	Applicant
US2009/0082291(A1)	2009-03-01	Feinstein et al.	Applicant
US2009/0105173(A1)	2009-04-01	Feinstein	Applicant
US2010/0029746(A1)	2010-02-01	Feinstein	Applicant
WO9800532	1998-01-01		Applicant
WO9938965	1999-08-01		Applicant
WO99/55910	1999-11-01		Applicant
WO199954459	2000-02-01		Applicant
WO20645	2000-04-01		Applicant
WO/044895	2000-08-01		Applicant
WO/44914	2000-08-01		Applicant
WO21559	2000-12-01		Applicant
WO76497	2000-12-01		Applicant
WO1/36646	2001-05-01		Applicant
WO2001/068836	2001-09-01		Applicant
WO244321	2002-06-01		Applicant
WO2002/055693	2002-08-01		Applicant
WO2002/059300	2002-08-01		Applicant
WO2000032765	2002-08-01		Applicant
WO3035869	2003-05-01		Applicant
WO3035870	2003-05-01		Applicant
WO3046176	2003-06-01		Applicant
WO2003/062394	2003-07-01		Applicant
WO2003/064625	2003-08-01		Applicant
WO2003/064626	2003-08-01		Applicant
WO2003/070918	2003-08-01		Applicant
WO3070897	2003-08-01		Applicant
WO3070969	2003-08-01		Applicant
WO3646625	2003-08-01		Applicant
WO2003/074654	2003-09-01		Applicant
WO3072704	2003-09-01		Applicant
WO2003/046176	2003-11-01		Applicant
WO2004031237	2004-04-01		Applicant
WO2004046324	2004-06-01		Applicant
WO2004048511	2004-06-01		Applicant
WO2004090105	2004-10-01		Applicant
WO2004/094636	2004-11-01		Applicant
WO2004094636	2004-11-01		Applicant
WO2004/111191	2004-12-01		Applicant
WO2005001043	2005-01-01		Applicant
WO20030070910	2005-02-01		Applicant
WO2005/062937	2005-07-01		Applicant
WO2005078095	2005-08-01		Applicant
WO2005089224(A2)	2005-09-01		Applicant
WO2004080406	2005-10-01		Applicant
WO2005117991	2005-12-01		Applicant
WO2006015389	2006-02-01		Applicant
WO2006110813	2006-10-01		Applicant
WO2007/087451	2007-08-01		Applicant
WO2009/001359	2008-12-01		Applicant

Non-Patent Literature (115)

Skalecki et al., Arch. Biochem. Biophys. vol. 365, No. 1 pp. 1-9 (1999).Applicant
Tsuruga et al., HsMCM6: a new member of the human MCM/P1 family encodes a protein homologous to fission yeast mis5, 1997 Genes to Cells, vol. 2, pp. 381-399.Applicant
Abeliovich, et al. (2000) Mice Lacking Alph-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System. Neuron v.25:239-52.Applicant
Amarzguioui, Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes (2000) vol. 29, No. 21, 4113-4124.Applicant
Amarzguioui M et al, Tolerance for mutations and chemical modifications in a siRNA Nucleic Acids Research vol. 31, No. 2, Jan. 15, 2003 pp. 589-595 , XP002270887 ISSN: 0305-1048.Applicant
Bass, B.L., (2001) The Short Answer, Nature V.411:428-29.Applicant
Betrand (2002) Comparison of Antisense Oligonucleotides and siRNAs in cell culture and in vivo, Biotechnical and Biophysicial Research Communication 296:1000-1004.Applicant
Boutla, Shot 5′-phosphorylated double-stranded RNAs induce RNA interference in Drosophila, 1776-1780 (Brief Communication) (2001).Applicant
Brown et al. (1997) Identification and cDNA Cloning of a Novel Mammalian C2 Domain-Containing Phosphoinositide 3-kinase, HsC2-PI3K. Biochemical and Biophysical Research Communications. 233, 537-544.Applicant
Brummelkarna et al. A System for Stable Expression of Short Intereferring RNAs in Mammalian Cells, Science vol. 296 pp. 550-553 (2002).Applicant
Cahill et al. (1999) Characterization of MAD2B and Other Mitotic Spindle Checkpoint Genes. Genomics. 58:181-187.Applicant
Caplen et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate systems, Proc. Natl. Acad. Sci USA vol. 98, pp. 9742-9747 (2001).Applicant
Caplen, dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for analysis of RNA interference, Jul. 11, 2001; Gene; 252(1-2):95-105.Applicant
Caplen, RNAi as a gene therapy approach. Expert Opin. Ther. 3(4):575-586. (2003).Applicant
Chalk, siRNA db: a database of siRNA sequences. Nucleic Acids Research. vol. 33 pp. D131-D134 (2004).Applicant
Chen et al. (2005) TSSK5, A Novel Member of the Testis-Specific Serine/Threonin Kinase Family, Phosphorylates CREB at Ser-122, and Stimulates the CRE-CREB Responsive Pathway. Biochemical and Biophysical Research Communications. 333: 742-749.Applicant
Cherry, Michael J. (1995) Computer Manipulation of DNA and Protein Sequences. Current Protocols in Molecular Biology. 7.7.1-7.7.23.Applicant
Chi, Genomewide view of gene silencing by small interfering RNAs (2003).Applicant
Chinault, Overlap Hybridization Screening: Isolation and Characterization of Overlapping DNA Framgments Surroungin the leu2 Gene on Yeast Chromosome III (1979), 5(2):111-26.Applicant
Daniel et al., Specific association of Type I with Ran GTPase in lipopolysacchardie-mediated differentiation, Oncogene 2001, vol. 20: 2618-2625.Applicant
Dodelet et al. (2000) Eph Receptors and Ephrin Ligands: embryogenesis to tumorigenesis. Oncogene 19:5614-5619.Applicant
Domin et al.(1997) Cloning of Human Phosphoinositide 3-Kinase with a C2 Domain that Displays Reduced Sensitivity to the Inhibitor Wortmannin. Biochem. J., v.325:139-47.Applicant
Dottori, et al. (1998) EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract, Proc. Natl. Acad. Sci. vol. 95, pp. 13248-13253, Neurobiology.Applicant
Ekholm, et al.(2004) Deregulation of Cyclin E in Human Cells Interferes with Prereplication Complex Assembly. The Journal of Cell Biology. vol. 165, pp. 789-800.Applicant
Elbashir et al. (2001) Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells. Nature vol. 411, pp. 494-498.Applicant
Elbashir et al. (2002) Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs. Methods. 26:199-213.Applicant
Elbashir, Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melaongaster, The EMBO Journal v. 20(23): 6877-6888 (2001).Applicant
El Touny, et al. (2006) Identification of Both Myt-I and Wee-I as Necessary Mediators of the P2I-Independent Inactivation of the Cdc-2/Cyclin BI complex and Growth Inhibition of TRAMP Cancer Cells by Genistein. The Prostate, vol. 66:1542-1555.Applicant
European Patent Office, European Patent Application No. 03786798.3 Office Action dated Nov. 15, 2007.Applicant
Far, R-K, The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides (2003) Nucleic Acids Research. vol. 31, No. 15, pp. 4417-4424.Applicant
Feng, et al. (2003) Inhibiting the Expression of DNA Replication-Initiation Proteins Induces Apoptosis in Human Cancer Cells. Cancer Research, vol. 63, pp. 7356-7364.Applicant
Fox, et al. (1995) cDNA Cloning and Tissue Distribution of Five Human EPH-like Receptor Protein-tyrosine kinases, Oncogene; 10(5): 897-905.Applicant
Futami et al. (2002) Induction of Apoptosis in Hela Cells with siRNA Expression Vector Targeted Against BLC-2. Nucleic Acids Research Supplement No. 2:251-2.Applicant
Genbank Accession NM 001790 Oct. 10, 2008.Applicant
GenBank Accession No. NM—00345, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=6806896. Accessed on Aug. 1, 2008.Applicant
Genbank Accession No. NM—002645.2, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=157671928. Accessed on Jul. 31, 2008.Applicant
Genbank Accession No. NM—138578, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=20336334. Accessed on Aug. 11, 2008.Applicant
Genbank Accession Z15005.1 (1993).Applicant
Hammond et al., Post-transcriptional gene silencing by double-stranded RNA, Nature Reviews, 2001, vol. 2, 110-119 ) MacMilan Magazines Ltd.Applicant
Hao, et al. (2004) Expression Analysis of the Human Testis-specific Serine/Threonine Kinase (TSSK) Homologues. A TSSK Member is Present in the Equatorial Segment of Human Sperm. Molecular Human Reproduction, vol. 10, No. 6 pp. 433-444.Applicant
Harborth et al. Identification of Essential Genes in Cultured Mammalian Cells Using Small Interfering RNAs. (2001) J. Cell. Sci. 114:4557-4565).Applicant
Ho, Potent Antisense Oligunucleotides to the Human Multidrug Resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with Oligonucleotides Libraries. Nucleic Acids Research, vol. 24: 1901-1907 (1996).Applicant
Holen, et al. (2002) Positional Effects of Shorts Interfering RNAs Targeting the Human Coagulation Trigger Tissue Factor. Nucleic Acids Research, vol. 30, No. 8, pp. 1757-1766.Applicant
Human Neuropeptide Y Blast results, http://www.ncbi.nlm.nih.gov/blast, accessed on Mar. 18, 2008.Applicant
International Search Report for PCT/US04, Sep. 24, 2007 (Brusca).Applicant
International Search Report for PCT/US03/36787, Feb. 25, 2005 (Epps-Ford).Applicant
Iliakis et al. (1990) Induction and Repair of DNA Strand Breaks in Radiation-resistant Cells Obtained by Transformation of Primary Rat Embryo Cells with the Oncogenes H-ras and v-myc. Cancer Research, 50, pp. 6575-6579.Applicant
Jackson, et al., Expression profiling reveals off-target gene regulation by RNAi, Nature Biotechnology, vol. 21, pp. 635-637 (2003).Applicant
Kalra, Central administration of antisense oligodeoxynucleotides to neuropeptide Y (NPY) mRNA reveals the critical role of newly synthesized NPY in regulation of LHRH release, Regulatory Peptides (1995) 215-220.Applicant
Kasif (2002), A computational framework for optimal masking in the synthesis of oligonucleoitde microarrays, University Press, Nucleic Acids Research 2002, No. 30, No. 20 e106.Applicant
Khvorova, Functional siRNAs and miRNAs Exhibit Strand Bias vol. 115, pp. 209-216 (2003).Applicant
Kretscmer-Kazemei, The Activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleoitdes (2003) Nucleic Acids Research. vol. 31, No. 15, 4417-4424.Applicant
Kumar, High-Throughput Selection of Effective RNAi Probes for Gene Silencing (2003).Applicant
Laitala et al., Inhibition of Bone Resorption in Vitro by Antisense RNA and DNA Molecules Targeted against Carbonic Anhydrase II or Two Subuntis of Vacuolar H + ATPase, Journal of Clinical Investigation 1994, vol. 93, pp. 2311-2318.Applicant
Lapidot-Lifson, et al. (1992) Cloning and Antisense Oligodeoxynucleotide Inhibition of a Human Homolog of cdc2 required in Hematopoiesis, Proc. Natl. Acad. Sci. vol. 89, pp. 579-583.Applicant
Levenkova, Gene specific siRNA selector, Bioinofrmatics vol. 20, pp. 430-432 (2004).Applicant
Lindgren, et al. (2002) Contribution of Known and Unknown Susceptibility Genes to Early-Onset Diabetes in Scandinavia, Diabetes vol. 51, 1609-1617.Applicant
Lu, et al., The Human AQP4 gene: Definition of the locus encoding two water channel polypeptides in brain, Proc. Natl Acad. Sci vol. 93, pp. 10908-10912 (Oct. 1996).Applicant
Marathi, RAD1, a Human Structural Homolog of the Schizosaccharomyces pombe RAD1 Cell Cycle Checkpoint Gene, Genomcs 54, 344-347 (1998).Applicant
Miller, V M et al., “Allele-specific silencing of dominant disease genes” Proceedings of the National Acadamy of Sciences of USA, vol. 100, No. 12, Jun. 10, 2003, pp. 7195-7200 , XP002276730.Applicant
Miyagashi et al. (2003) Comparison of the Suppressive Effects of Antisense Oligonucleotides and siRNAs Directed Against the Same Targets in Mammalian Cells. Antisense and Nucleic Acid Drug Development 13:1-7.Applicant
Murphy, et al. (2000) Synucleins are Developmentally Expressed, and Alpha-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons. The Journal of Neuroscience, vol. 20(9):3214-20.Applicant
Naito, siDirect: highly effective, target specific siRNA design software for mammalian RNA interference, Nucleic Acids Research vol. 32, W124-129 (2004).Applicant
NCBI Nucleotide Result for NM-002609, http://www.ncbi.nlm.nih.gov/sites/entrez, accessed on Jul. 14, 2008.Applicant
NCBI Sequence Viewer v2.0 for NM-004438, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=45439363, accessed on Jul. 3, 2008.Applicant
Oishi, et al., Identification and Characterization of PKN Beta, a Novel Isoform of Protein Kinase PKN: Expression and Arachiodonic Acid Dependency Are Different from those of PKN alpha, 1999 Biochemical and Biophysical Research Communcation, 261, pp. 808-814.Applicant
Olie et al, A Novel Antisense Oligonucleotide Targeting Survivin Expression Induces Apoptosis and Sensitizes Lung Cancer Cells to Chemotherapy, Cancer Research 2000, vol. 60: pp. 2805-2809.Applicant
Pan, et al. (2005) Calmodulin-dependent protein kinase IV regulates nuclear export of Cabin 1 during T-cell activation, The EMBO Journal, 24, 2104-2113.Applicant
Promega siRNA Target Designer-Version 1.51, http:///www.promega.com/siRNADesigner/program/default.asp. Accessed Jun. 24, 2008.Applicant
Promega siRNA Target Designer-Version 1.1, http:///www.promega.com/siRNADesigner/program/default.asp. (2003).Applicant
Rabert et al. (1998) A Tetrodextrin-Resistant Voltage-gated Sodium Channel from Human Dorsal Root Ganglia, hPN3/SCN10A. Pain, 78, pp. 107-114.Applicant
Reynolds, Rational siRNA design for RNA interference, Nature Biotechnology vol. 22, No. 3, pp. 326-330 (2004).Applicant
Ross, et al. (2001) Inhibition of Kirsten-ras Expression in Human Colorectal Cancer Using Rationally Selected Kirsten-ras Antisense Oligonucleotides, Molecular Cancer Therapeutics vol. 1, 29-41.Applicant
Shi et al. (2001) Gremlin negatively Modulates BMP-4 Induction of Embryonic Mouse Lung Branching Morphogenesis. Am J Physiol Lung Cell Mol Physiol, 280, pp. L1030-L1039.Applicant
Semizarov, Specificity of short interfereing RNA determined through gene expression signatures, Proceedings of the National Acadamy of Sciences USA vol. 100, pp. 6347-6352 (2003).Applicant
siRNA Design for RNA Interference (RNAi) Experiments, http://web.archive.org/web/20010101000000-20021231235959/http://www.ambion.com/techlib/misc/siRNA—design.html. Accessed on Mar. 6, 2008.Applicant
siDesign Center for “gene name: src,” http://www.dharmacon.com/DesignCenter/DesignCenterPage.aspx, accessed on May 13, 2008.Applicant
siRNA Converter, http://web.archive.org/web/20020101-20021231re—/http://www.ambion.com/techlib/misc/siRNA—finder.html. Accessed Mar. 6, 2008. (siRNA Target Finder).Applicant
Sorensen, et al. (2003) Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice, J. Mol. Biol. 327, 761-766.Applicant
Tan et al. (2006) Functional Cooperation Between FACT and MCM Helicase Facilitates Initiation of Chromatin DNA Replication. The EMBO Journal, vol. 25, pp. 3975-3985.Applicant
Truss, HuSide—The Human siRNA database: an open access database for published functional siRNA sequences and technical details of efficient transfer into recipient cells, Nucleic Acids Research vol. 33, pp. D108-D111 (2005).Applicant
Tsuji, et al. (2006) Essential Role of Phosphoorylation of MCM2 by Cdc7/Dbf4 in the Initiation of DNA Replication in Mammalian Cells. Molecular Biology of the Cell, vol. 17, pp. 4459-4472.Applicant
Tuschl, Expanding small RNA interference (May 2002), Nature Biotechnology, vol. 20, pp. 446-448.Applicant
Tuschl, et al. (2001) The siRNA User Guide. Max Planck Institute for Biophysical Chemistry, pp. 1, 3 and 5, http://www.mpibpc.gwdg.de/abteilungen/100/105/siRNAuserguide.pdf.Applicant
Tijsterman, Dicers at RISC, The Mechanism of RNAi, Cell, Apr. 2004, vol. 117, pp. 1-4.Applicant
Tuschl et al. (2003) The siRNA User Guide. 6 pages.Applicant
Ui-Tei, Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference, Nucleic Acids Research, Feb. 2004, vol. 32, No. 3 pp. 936-948.Applicant
Vankayalapati, et al. (2003) Targeting Aurora2 Kinase in Oncogenesis: A Structural Bioinformatics Approach to Target Validation and Rational Drug Design. Molecular Cancer Therapeutics, v.2:283:94.Applicant
Walton, et al. (1999) Prediction of Antisense Oligonucleotide Binding Affinity to a Structured RNA Target Biotechnol. Bioengineering, v.65(1):1-9. (Abstract Only).Applicant
Vickers, Efficient Reduction of Target RNAs by Small Interfereing RNA and Rnase H-dependent Antisense Agents, J. Biol. Chem. vol. 278, No. 9, 7108-7118 (2003).Applicant
Wang, et al., (2006) Dexamethasone Represses Signaling through the Mammalian Target of Rapamycin in Muscle Cells by Enhancing Expression of REDD1. The Joumal of Biological Chemistry vol. 281, No. 51, pp. 39128-39134.Applicant
Yao et al. (2000) Nature Cell Biology 2:484-491.Applicant
Yuan, siRNA Selection Server: an automated siRNA oligonucleotide prediction server (2004).Applicant
Zender et al., siRNA based strategies for inhibition of apoptotic pathways in vivo—analytical and therapeutic implications, Jan. 2004, vol. 9, pp. 51-54.Applicant
Zhang, Physical and Functional Interationc between Myeloid Cell Leukemia 1 Protein (MCL1) ad Fortilin, J. Biol. Chem. 37430-37438 (2002).Applicant
Abifadel et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, 2003, Nature Genetics, vol. 34, pp. 154-156.Applicant
Ishibashi et al., A Novel Dual Specificity Phosphatase Induced by Setum Stimulation and Heat Shock, (1994) J. Biol. Chem. 47: 29897-2902).Applicant
Rashid et al. Decreased plasma cholesterol and hypersensitivity to statins inmice lacking PCSK9, 2005 PNAS, vol. 102, pp. 5374-5379.Applicant
Ishimi et al., Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix, 2003, European Journal of Biochemistry, vol. 270, pp. 1089-1101.Applicant
Wang et al. Connective Tissue Growth Factor siRNA modulates mRNA levels for a subet of molecules in normaland TFG-Beta1 stimulated porcine skin fibroblasts, 2004, Wound Rep. Reg.12, pp. 205-206.Applicant
Nguyen T. el Current Opin. Molec Ther. vol. 10, No. 2, pp. 158-167 (2008).Applicant
Shuai, K., Modulation of STAT signaling by STAT interacting proteins, 2000, Oncogene vol. 19, pp. 2638-2644.Applicant
Notice of Allowance and Allowed Claims in U.S. Appl. No. 11/237,598.Applicant
Pending claims in U.S. Appl. No. 11/827,199 (US 2009/0082291).Applicant
Chalk, et al., (2004) Improved and automated predictionof effective siRNA. Biochem Biophys Res comm 319:264-274.Applicant
Fire et al., (1998) Potent andspecific genetic interference by double stranded RNA in Caenorhabitis elegans. Nature 391:806-811.Applicant
McManus and Sharp (2002) Gene silencing in mammals by small interfering siRNAs. Nature Reviews Genetics 3:737-747.Applicant
Scherer and Rossi. (2003) “Approaches for the sequence-specific knockdown of mRNA”. Nat. Biotechnol., 21 (12):1457-1465.Applicant
Scherer and Rossi (2004) Therapeutic Applications RNA Interferences: Recent Advances in siRNA Design. Advances in Genetics 22:1-21.Applicant
Human Neuropeptide Y Blast results, http://www.ncbi.nlm.nih.gov/blast, accessed on Mar. 18, 2008.Applicant
Gautarn et al. Heparin-binding protein (Hbp/CAP37): A missing link in neutrophil-evoked alteration of vascular permeability, Nature Medicine 2001, vol. 7, pp. 1123-1127.Applicant
iHOP [online] [retrieved on Sep. 9, 2008]. Retrieved from the Internet. <http://www.ihop-net.org/UniPub/iHOP/bng/119248.html?list=0>.Applicant
Shi et al. (1995), Abl-interactor -1 a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity, Genes & Dev. 9:2583-2597.Applicant
siRNA Target Finder, Ambion, http://ambion.com/techlib/misc/siRNA—finder.html, (from DHARMA 2100-US46 U.S. Appl. No. 11/811,950).Applicant
White et al., The nuclear Receptor Co-Repressor Nrip1 (RIP 140) is essential for female fertility. Nature Medicine, 2000, vol. 6, No. 12: 1368-1374.Applicant